

# CITATION REPORT

List of articles citing

## Drug combination studies and their synergy quantification using the Chou-Talalay method

DOI: 10.1158/0008-5472.can-09-1947  
Cancer Research, 2010, 70, 440-6.

**Source:** <https://exaly.com/paper-pdf/49585856/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2275	Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles.		
2274	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.		
2273	Sulfonimide and Amide Derivatives as Novel PPAR Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.		
2272	Enzymatic Self-Assembly Confers Exceptionally Strong Synergism with NF-B Targeting for Selective Necroptosis of Cancer Cells.		
2271	Nucleoside Analogue-Based Supramolecular Nanodrugs Driven by Molecular Recognition for Synergistic Cancer Therapy.		
2270	Polymer Prodrug-Based Nanoreactors Activated by Tumor Acidity for Orchestrated Oxidation/Chemotherapy.		
2269	Inhibiting Mycobacterium tuberculosis DosRST Signaling by Targeting Response Regulator DNA Binding and Sensor Kinase Heme.		
2268	.		
2267	Arsenoplatin1 Is a Dual Pharmacophore Anticancer Agent.		
2266	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1.		
2265	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. <b>2010</b> , 115, 4497-506		152
2264	A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFKappaB pathway. <b>2010</b> , 4, 50		47
2263	Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. <b>2010</b> , 89, 1115-24		26
2262	Tramadol and caffeine produce synergistic interactions on antinociception measured in a formalin model. <b>2010</b> , 97, 357-62		19
2261	A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. <b>2010</b> , 6, 33		51
2260	Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. <b>2010</b> , 5, e14124		116
2259	Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. <i>Cancer Research</i> , <b>2010</b> , 70, 9309-18	10.1	69

2258	Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?. <b>2010</b> , 6, 619-34	46
2257	An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. <b>2010</b> , 285, 33747-55	90
2256	Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. <b>2010</b> , 21, 97-103	6
2255	Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. <b>2010</b> , 9, 2068-78	42
2254	Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. <b>2010</b> , 10, 918-29	28
2253	A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. <b>2010</b> , 294, 245-53	13
2252	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. <b>2010</b> , 298, 195-203	19
2251	Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells. <b>2010</b> , 12, 376-87	31
2250	Synthesis and selective anticancer activity of organochalcogen based redox catalysts. <b>2010</b> , 53, 6954-63	107
2249	The mass-action law based algorithms for quantitative econo-green bio-research. <b>2011</b> , 3, 548-59	31
2248	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. <b>2011</b> , 10, 3119-28	44
2247	Cancer Cell Culture. <b>2011</b> ,	17
2246	Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. <b>2011</b> , 306, 161-170	42
2245	Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. <b>2011</b> , 47, 1432-41	36
2244	Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer. <b>2011</b> , 13, R120	20
2243	Analysis of drug interactions. <b>2011</b> , 731, 421-34	141
2242	Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies. <b>2011</b> ,	3
2241	KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. <b>2011</b> , 25, 1021-9	15

2240	Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. <b>2011</b> , 17, 103-12	143
2239	Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. <b>2011</b> , 102, 591-6	28
2238	Knocking down cyclin D1b inhibits breast cancer cell growth and suppresses tumor development in a breast cancer model. <b>2011</b> , 102, 1537-44	16
2237	Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. <b>2011</b> , 257, 59-66	14
2236	Induction of apoptosis in pediatric acute lymphoblastic leukemia (ALL) cells by the therapeutic opioid methadone and effective synergy with Bcl-2 inhibition. <b>2011</b> , 35, 1649-57	22
2235	Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. <b>2011</b> , 18, 1390-400	149
2234	Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. <b>2011</b> , 29, 627-36	21
2233	The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. <b>2011</b> , 29, 1224-9	20
2232	S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. <b>2011</b> , 127, 109-19	86
2231	Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. <b>2011</b> , 101, 379-90	37
2230	Cryptotanshinone enhances TNF- $\alpha$ -induced apoptosis in chronic myeloid leukemia KBM-5 cells. <b>2011</b> , 16, 696-707	47
2229	Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. <b>2011</b> , 90, 173-83	32
2228	Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. <b>2011</b> , 11, 483	41
2227	Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. <b>2011</b> , 11, 44	21
2226	Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. <b>2011</b> , 9, 71	60
2225	Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. <b>2011</b> , 32, 289-300	83
2224	ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2 <sup>high</sup> /Mcl-1 <sup>low</sup> profile and synergizes with other antineoplastic agents. <b>2011</b> , 17, 5973-81	47
2223	Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. <b>2011</b> , 10, 2094-103	29

2222	Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. <b>2011</b> , 10, 1481-9		55
2221	Rebuttal to the Response of Lee and Kong. <i>Cancer Research</i> , <b>2011</b> , 71, 2796-2797	10.1	1
2220	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity Response. <i>Cancer Research</i> , <b>2011</b> , 71, 2794-2795	10.1	3
2219	Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. <b>2011</b> , 10, 313-24		8
2218	Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. <b>2011</b> , 2, e156		43
2217	High-throughput RNAi screening reveals novel regulators of telomerase. <i>Cancer Research</i> , <b>2011</b> , 71, 3328-34	10.1	35
2216	Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. <b>2011</b> , 11, 524-34		76
2215	EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. <b>2011</b> , 17, 6522-30		44
2214	Prediction of drug combinations by integrating molecular and pharmacological data. <b>2011</b> , 7, e1002323		145
2213	Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. <b>2011</b> , 1, e44		58
2212	Combined treatment of pancreatic cancer with mithramycin a and tolfenamic Acid promotes sp1 degradation and synergistic antitumor activity--letter. <i>Cancer Research</i> , <b>2011</b> , 71, 2793; discussion 2794-800	10.1	5
2211	Autophagy inhibition synergistically enhances anticancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells, and tumor xenografts. <b>2012</b> , 11, 898-908		17
2210	Synergistic Apoptosis-Inducing Antileukemic Effects of Arsenic Trioxide and Mucuna macrocarpa Stem Extract in Human Leukemic Cells via a Reactive Oxygen Species-Dependent Mechanism. <b>2012</b> , 2012, 921430		10
2209	p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. <b>2012</b> , 132, 356-64		55
2208	In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines. <b>2012</b> , 12, 988-93		2
2207	Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. <b>2012</b> , 33, 1782-90		25
2206	Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy. <b>2012</b> , 23, 711-21		9
2205	Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. <b>2012</b> , 2, e60		52

2204	The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. <b>2012</b> , 2, e69	64
2203	Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. <b>2012</b> , 18, 4633-45	40
2202	HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. <b>2012</b> , 86, 3393-7	60
2201	Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo. <b>2012</b> , 146, 938-45	56
2200	Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. <b>2012</b> , 7, e45063	46
2199	Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. <b>2012</b> , 142, 1487-94	25
2198	Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. <b>2012</b> , 11, 1320-31	20
2197	Peptidomimetic Src/pre-tubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. <b>2012</b> , 11, 1936-47	27
2196	Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: structure-activity relationships and pharmacophore modeling. <b>2012</b> , 12, 1015-24	21
2195	Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system. <b>2012</b> , 23, 272-9	14
2194	Silibinin and Paclitaxel Cotreatment Significantly Suppress the Activity and Lung Metastasis of Triple Negative 4T1 Mammary Tumor Cell in Mice. <b>2012</b> , 2, 301-11	23
2193	Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. <b>2012</b> , 17, 1044-52	386
2192	Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response. <b>2012</b> , 109, 20071-6	70
2191	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. <b>2012</b> , 19, 977-87	71
2190	Synergism of three-drug combinations of sanguinarine and other plant secondary metabolites with digitonin and doxorubicin in multi-drug resistant cancer cells. <b>2012</b> , 19, 1288-97	61
2189	Synthesis of bisethyl norspermine lipid prodrug as gene delivery vector targeting polyamine metabolism in breast cancer. <b>2012</b> , 9, 1654-64	13
2188	Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. <b>2012</b> , 18, 3552-61	74
2187	How valid are claims for synergy in published clinical studies?. <b>2012</b> , 23, 2161-2166	24

2186	Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups. <b>2012</b> , 13, 2352-62	13
2185	Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production. <b>2012</b> , 35, 1706-14	7
2184	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. <b>2012</b> , 119, 5201-10	111
2183	A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule. <b>2012</b> , 33, 261-70	25
2182	Oroxilin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway. <b>2012</b> , 90, 521-31	20
2181	Penta-O-galloyl-β-glucose attenuates cisplatin-induced nephrotoxicity via reactive oxygen species reduction in renal epithelial cells and enhances antitumor activity in Caki-2 renal cancer cells. <b>2012</b> , 26, 206-14	14
2180	Pharmacodynamics of ginsenosides: antioxidant activities, activation of Nrf2, and potential synergistic effects of combinations. <b>2012</b> , 25, 1574-80	66
2179	Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. <b>2012</b> , 26, 910-7	70
2178	Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma. <b>2012</b> , 420, 516-22	
2177	Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells. <b>2012</b> , 60, 9882-9	54
2176	Multicompartment intracellular self-expanding nanogel for targeted delivery of drug cocktail. <b>2012</b> , 24, 6479-83	72
2175	Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. <b>2012</b> , 12, 200	35
2174	Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. <b>2012</b> , 12, 556	56
2173	Effect of combinations of marketed human anthelmintic drugs against <i>Trichuris muris</i> in vitro and in vivo. <b>2012</b> , 5, 292	30
2172	Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures. <b>2012</b> , 5, 19	44
2171	Polymer nanoparticulate drug delivery and combination cancer therapy. <b>2012</b> , 8, 1471-80	16
2170	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. <b>2012</b> , 8, 646-54	57
2169	The roots of <i>Salvia miltiorrhiza</i> (Danshen) and <i>Pueraria lobata</i> (Gegen) inhibit atherogenic events: a study of the combination effects of the 2-herb formula. <b>2012</b> , 143, 859-66	38

2168	The DNA damage response to monofunctional anticancer DNA binders. <b>2012</b> , 9, e59-e67	5
2167	Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. <b>2012</b> , 65, 312-9	22
2166	Blockade of NF- $\kappa$ B activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. <b>2012</b> , 6, 530-41	24
2165	Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis. <b>2012</b> , 19, 711-23	20
2164	Digitonin synergistically enhances the cytotoxicity of plant secondary metabolites in cancer cells. <b>2012</b> , 19, 1307-14	35
2163	Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. <b>2012</b> , 55, 7230-44	134
2162	P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines. <b>2012</b> , 11, 77	25
2161	Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. <b>2012</b> , 7, e37222	44
2160	Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies. <b>2012</b> , 7, e38583	18
2159	Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. <b>2012</b> , 7, e40439	56
2158	Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF- $\kappa$ B in R-HepG2 cell line. <b>2012</b> , 7, e40720	49
2157	Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. <b>2012</b> , 7, e43826	47
2156	The combined action of phytolavicides for the control of dengue fever vector, <i>Aedes aegypti</i> . <b>2012</b> , 22, 549-557	10
2155	Drug Synergy [Mechanisms and Methods of Analysis. <b>2012</b> ,	18
2154	Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. <b>2012</b> , 53, 4205-12	48
2153	Classifying compound mechanism of action for linking whole cell phenotypes to molecular targets. <b>2012</b> , 25, 216-23	4
2152	Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells. <b>2012</b> , 131, 2134-42	17
2151	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. <b>2012</b> , 4, 139ra84	76

2150	Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. <b>2012</b> , 30, 1743-9	19
2149	Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study. <b>2012</b> , 20, 2227-34	41
2148	Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. <b>2012</b> , 350, 99-106	18
2147	Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion. <b>2012</b> , 258, 351-66	8
2146	Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. <b>2012</b> , 38, 1086-94	28
2145	Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. <b>2012</b> , 30, 25-36	23
2144	Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. <b>2012</b> , 39, 1683-9	22
2143	Alpha-tomatine synergises with paclitaxel to enhance apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in vivo. <b>2013</b> , 20, 1297-305	23
2142	Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway. <b>2013</b> , 382, 243-52	28
2141	Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles. <b>2013</b> , 3, 14671	16
2140	LHRH-PE40 fusion protein tethered silica nanorattles for imaging-guided tumor-specific drug delivery and bimodal therapy. <b>2013</b> , 25, 5508-13	22
2139	Silibinin reverses drug resistance in human small-cell lung carcinoma cells. <b>2013</b> , 339, 102-6	32
2138	Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. <b>2013</b> , 13, 86	31
2137	Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. <b>2013</b> , 85, 452-62	67
2136	Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival. <b>2013</b> , 30, 638	6
2135	Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. <b>2013</b> , 133, 2065-76	62
2134	Detection of synergistic combinations of Baccharis extracts with terbinafine against Trichophyton rubrum with high throughput screening synergy assay (HTSS) followed by 3D graphs. Behavior of some of their components. <b>2013</b> , 20, 1230-9	18
2133	Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest. <b>2013</b> , 92, 1207-20	21

2132	Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells. <b>2013</b> , 72, 35-44	8
2131	A golden approach to ion channel inhibition. <b>2013</b> , 34, 481-8	8
2130	The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. <b>2013</b> , 37, 1200-7	46
2129	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. <b>2013</b> , 105, 1485-95	121
2128	β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. <b>2013</b> , 108, 2485-94	112
2127	A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML. <b>2013</b> , 10, 4358-66	23
2126	Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. <b>2013</b> , 4, e890	11
2125	Potential of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines. <b>2013</b> , 82, 214-21	14
2124	Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. <b>2013</b> , 62, 869-75	94
2123	Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. <b>2013</b> , 12, 1958-67	54
2122	Activity of tribendimidine and praziquantel combination therapy against the liver fluke <i>Opisthorchis viverrini</i> in vitro and in vivo. <b>2013</b> , 87, 252-6	12
2121	Development and validation of a general approach to predict and quantify the synergism of anti-cancer drugs using experimental design and artificial neural networks. <b>2013</b> , 115, 84-93	24
2120	A screen for apoptotic synergism between clinical relevant nephrotoxicant and the cytokine TNF-β. <b>2013</b> , 27, 2264-72	5
2119	c-Jun N-terminal kinase in synergistic neurite outgrowth in PC12 cells mediated through P90RSK. <b>2013</b> , 14, 153	6
2118	Preclinical models for drug selection in myeloproliferative neoplasms. <b>2013</b> , 8, 317-24	2
2117	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <b>2013</b> , 49, 3936-44	63
2116	A high-throughput yeast assay identifies synergistic drug combinations. <b>2013</b> , 11, 299-307	16
2115	Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. <b>2013</b> , 65, 263-72	74

2114 Principles of Cytotoxic Chemotherapy. **2013**, 167-185

2113 Network-based drug discovery by integrating systems biology and computational technologies. **2013**, 14, 491-505 80

2112 Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. **2013**, 16, 159-70 16

2111 The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. **2013**, 344, 378-87 33

2110 Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. **2013**, 56, 427-36 116

2109 Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. **2013**, 139, 315-25 26

2108 Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. **2013**, 57, 235-48 51

2107 Application of fractional factorial designs to study drug combinations. **2013**, 32, 307-18 36

2106 One-pot construction of functional mesoporous silica nanoparticles for the tumor-acidity-activated synergistic chemotherapy of glioblastoma. **2013**, 5, 7995-8001 67

2105 Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. **2013**, 7, 497-512 30

2104 Carrier-free functionalized multidrug nanorods for synergistic cancer therapy. **2013**, 34, 8960-7 88

2103 Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection. **2013**, 100, 321-7 8

2102 The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. **2013**, 34, 2277-88 66

2101 Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. **2013**, 41, 253-60.e2 23

2100 Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2'-deoxycytidine on ovarian cancer. **2013**, 108, 579-86 46

2099 Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. **2013**, 154, 1247-59 42

2098 Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. **2013**, 12, 768-76 75

2097 The blockage of Ras/ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells. **2013**, 434, 35-41 18

2096	Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. <b>2013</b> , 21, 1212-23	126
2095	Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. <b>2013</b> , 108, 2021-32	198
2094	Selective cytotoxic activity of new lipophilic hydroxytyrosol alkyl ether derivatives. <b>2013</b> , 61, 5046-53	32
2093	Analyses of the combination of 6-MP and dasatinib in cell culture. <b>2013</b> , 43, 13-22	3
2092	Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. <b>2013</b> , 29, 1851-8	73
2091	Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. <b>2013</b> , 171, 339-48	88
2090	Antihyperglycemic activity of trigonelline and sitagliptin in nicotinamide-streptozotocin induced diabetes in Wistar rats. <b>2013</b> , 3, 125-130	8
2089	Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. <b>2013</b> , 98, 319-24	36
2088	Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites. <b>2013</b> , 134, 235-43	16
2087	[( $\eta^6$ -Praziquantel)Cr(CO) <sub>3</sub> ] derivatives with remarkable in vitro anti-schistosomal activity. <b>2013</b> , 19, 2232-5	26
2086	Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. <b>2013</b> , 72, 329-40	12
2085	Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK-CHOP-death receptor pathway. <b>2013</b> , 222, 22242-22254	46
2084	Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. <b>2013</b> , 6, 78	15
2083	Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. <b>2013</b> , 12, 2121-34	42
2082	Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down?. <b>2013</b> , 21, 1-14	61
2081	Enhancing macrocyclic diterpenes as multidrug-resistance reversers: structure-activity studies on jolkinol D derivatives. <b>2013</b> , 56, 748-60	49
2080	Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. <b>2013</b> , 87, 37-51	93
2079	MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. <b>2013</b> , 14, 932-6	24

2078	Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. <b>2013</b> , 2, 129-42	23
2077	Tacrolimus enhances the potency of posaconazole against <i>Rhizopus oryzae</i> in vitro and in an experimental model of mucormycosis. <b>2013</b> , 207, 834-41	43
2076	Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. <b>2013</b> , 14, 14800-32	28
2075	A hydroalcoholic extract from the leaves of <i>Nerium oleander</i> inhibits glycolysis and induces selective killing of lung cancer cells. <b>2013</b> , 79, 1017-23	28
2074	Activity of oxantel pamoate monotherapy and combination chemotherapy against <i>Trichuris muris</i> and hookworms: revival of an old drug. <b>2013</b> , 7, e2119	29
2073	Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. <b>2013</b> , 57, 1291-303	33
2072	Synergistic Action of Flavonoids, Baicalein, and Daidzein in Estrogenic and Neuroprotective Effects: A Development of Potential Health Products and Therapeutic Drugs against Alzheimer's Disease. <b>2013</b> , 2013, 635694	31
2071	Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells. <b>2013</b> , 2013, 805639	29
2070	Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. <i>Cancer Research</i> , <b>2013</b> , 73, 776-84	10.1 92
2069	The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. <b>2013</b> , 288, 25593-25602	20
2068	Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. <b>2013</b> , 3, 324-37	49
2067	Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. <b>2013</b> , 11, 714-23	38
2066	Synergistic bactericidal activity between hyperosmotic stress and membrane-disrupting nanoemulsions. <b>2013</b> , 62, 69-77	12
2065	Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. <b>2013</b> , 3, 52-67	88
2064	Targeting SRC and tubulin in mucinous ovarian carcinoma. <b>2013</b> , 19, 6532-43	29
2063	Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. <b>2013</b> , 19, 4383-91	26
2062	A combined omics study on activated macrophages--enhanced role of STATs in apoptosis, immunity and lipid metabolism. <b>2013</b> , 29, 2735-43	23
2061	Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. <b>2013</b> , 161, 104-16	35

2060	The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. <i>Cancer Research</i> , <b>2013</b> , 73, 7022-33	10.1	43
2059	Anticancer effects of niclosamide in human glioblastoma. <b>2013</b> , 19, 4124-36		107
2058	Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. <b>2013</b> , 12, 1763-73		44
2057	Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways. <b>2013</b> , 2013, 723780		24
2056	Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms. <b>2013</b> , 17, 1385-96		68
2055	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. <b>2013</b> , 17, 1397-409		43
2054	Synergistic cytotoxicity of red beetroot ( <i>Beta vulgaris</i> L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines. <b>2013</b> , 10,		51
2053	Synergy between enzastaurin doxorubicin in inducing melanoma apoptosis. <b>2013</b> , 26, 900-11		8
2052	Combined Eotocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration. <b>2013</b> , 46, 538-53		14
2051	Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways. <b>2013</b> , 133, 1982-93		24
2050	Combination drug scheduling defines a "window of opportunity" for chemopotential of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. <b>2013</b> , 12, 1968-80		30
2049	CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. <b>2013</b> , 12, 1171-9		48
2048	Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. <b>2013</b> , 110, 18226-31		168
2047	Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. <b>2013</b> , 4, e505		88
2046	Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. <b>2013</b> , 4, e798		29
2045	RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance. <b>2013</b> , 32, 3944-53		17
2044	Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. <b>2013</b> , 32, 4331-42		40
2043	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. <b>2013</b> , 4, e810		59

2042	The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. <b>2013</b> , 4, e956	19
2041	The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. <b>2013</b> , 19, 1717-28	72
2040	The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. <b>2013</b> , 161, 57-67	22
2039	Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. <b>2013</b> , 14, 127-34	32
2038	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. <b>2013</b> , 122, 1222-32	252
2037	Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. <b>2013</b> , 29, 51-7	18
2036	Combined effects of green tea extracts, green tea polyphenols or epigallocatechin gallate with acarbose on inhibition against $\alpha$ -amylase and $\alpha$ -glucosidase in vitro. <b>2013</b> , 18, 11614-23	70
2035	Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. <b>2013</b> , 8, 270-8	39
2034	Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. <b>2013</b> , 43, 495-502	22
2033	Ciprofloxacin inhibits proliferation and synergistic effect against hepatocellular carcinoma cancer lines with cisplatin. <b>2013</b> , 7, 17893-1801	1
2032	Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells. <b>2013</b> , 6, 1-13	14
2031	Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. <b>2013</b> , 8, e55183	72
2030	Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors. <b>2013</b> , 8, e65164	34
2029	Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. <b>2013</b> , 8, e66755	47
2028	Comparative gene expression profiling identifies common molecular signatures of NF- $\kappa$ B activation in canine and human diffuse large B cell lymphoma (DLBCL). <b>2013</b> , 8, e72591	63
2027	Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. <b>2013</b> , 8, e75414	34
2026	DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs. <b>2013</b> , 8, e81489	17
2025	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. <b>2013</b> , 3, 58	17

2024	A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against <i>Trypanosoma cruzi</i> . <b>2014</b> , 9, e85706	34
2023	Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. <b>2014</b> , 9, e88754	17
2022	In-depth analysis shows synergy between erlotinib and miR-34a. <b>2014</b> , 9, e89105	53
2021	Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma. <b>2014</b> , 9, e98557	10
2020	Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines. <b>2014</b> , 9, e105792	17
2019	Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. <b>2014</b> , 9, e107154	35
2018	A hadoop-based method to predict potential effective drug combination. <b>2014</b> , 2014, 196858	20
2017	Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. <b>2014</b> , 5, 5624-36	39
2016	Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. <b>2014</b> , 5, 9227-38	66
2015	Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells. <b>2014</b> , 5, 4180-94	63
2014	Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. <b>2014</b> , 13, 2537-46	43
2013	Data Analytics for Traditional Chinese Medicine Research. <b>2014</b> ,	4
2012	Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs. <b>2014</b> , 11, 41	23
2011	Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo. <b>2014</b> , 5, e1138	11
2010	Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. <b>2014</b> , 110, 2472-8	15
2009	SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide. <b>2014</b> , 22, 1643-52	29
2008	IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival. <b>2014</b> , 5, e1300	26
2007	Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. <b>2014</b> , 28, 894-903	18

2006	A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. <b>2014</b> , 13, 2542-53	13
2005	Fabrication of doxorubicin and heparin co-loaded microcapsules for synergistic cancer therapy. <b>2014</b> , 69, 554-60	11
2004	Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia. <b>2014</b> , 9, 1665-79	11
2003	Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <b>2014</b> , 3, 1579-94	58
2002	Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme. <b>2014</b> , 3, e150	5
2001	DCDB 2.0: a major update of the drug combination database. <b>2014</b> , 2014, bau124	68
2000	Diterpenes from Euphorbia piscatoria: synergistic interaction of Lathyranes with doxorubicin on resistant cancer cells. <b>2014</b> , 80, 1739-45	26
1999	The phosphoinositide 3-kinase $\beta$ -selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. <b>2014</b> , 13, 1044-53	41
1998	FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors. <b>2014</b> , 12, 514-26	17
1997	Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. <b>2014</b> , 20, 3507-20	83
1996	Probing of the combined effect of bisquaternary ammonium antimicrobial agents and acetylsalicylic acid on model phospholipid membranes: differential scanning calorimetry and mass spectrometry studies. <b>2014</b> , 10, 3155-62	9
1995	Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. <i>Cancer Research</i> , <b>2014</b> , 74, 7217-7228	10.1 39
1994	Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. <b>2014</b> , 196, 113-21	38
1993	The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody. <b>2014</b> , 55, 2141-50	12
1992	Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. <b>2014</b> , 3, 1322-35	22
1991	Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. <b>2014</b> , 33, 4724-34	131
1990	Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. <b>2014</b> , 3, e78	22
1989	Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation. <b>2014</b> , 41, 57-62	6

1988	HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer. <b>2014</b> , 135, 2462-74	16
1987	Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice. <b>2014</b> , 122, 380-91	6
1986	Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways. <b>2014</b> , 13, 1625-35	37
1985	Enhancement of doxorubicin cytotoxicity by tanshinone IIA in HepG2 human hepatoma cells. <b>2014</b> , 80, 70-6	25
1984	Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. <b>2014</b> , 13, 1429-38	49
1983	In vitro synergistic action of geldanamycin- and docetaxel-containing HEMA copolymer-RGDfK conjugates against ovarian cancer. <b>2014</b> , 14, 1735-47	5
1982	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 $\alpha$ and oxidative phosphorylation in melanoma. <i>Cancer Research</i> , <b>2014</b> , 74, 7037-47	10.1 126
1981	Abstracts from Purines 2014, an International Conference on Nucleotides, Nucleosides and Nucleobases, held in Bonn, Germany, from July 23-27, 2014. <b>2014</b> , 10, 657-854	4
1980	Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells. <b>2014</b> , 7, 812	9
1979	Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. <b>2014</b> , 10, 1120-36	74
1978	Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. <b>2014</b> , 9, 1101-10	20
1977	Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. <b>2014</b> , 6, 234ra59	165
1976	Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. <b>2014</b> , 13, 2276-87	25
1975	Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. <b>2014</b> , 9, e101286	35
1974	Multifunctional polymeric nanoplexes for anticancer co-delivery of p53 and mitoxantrone. <b>2014</b> , 2, 8005-8016	10
1973	Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. <b>2014</b> , 13, 2559-71	18
1972	Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. <b>2014</b> , 2014, 424239	60
1971	High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers. <b>2014</b> , 19, 1391-401	3

1970	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. <i>Cancer Research</i> , <b>2014</b> , 74, 6968-79	10.1	110
1969	EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells. <b>2014</b> , 25, 624-32		12
1968	Emetine dihydrochloride: a novel therapy for bladder cancer. <b>2014</b> , 191, 502-9		16
1967	Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. <b>2014</b> , 342, 159-66		26
1966	An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. <b>2014</b> , 134, 331-7		31
1965	TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. <b>2014</b> , 8, 261-72		19
1964	Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro. <b>2014</b> , 38, 411-7		6
1963	Inhibition of autophagy augments the anticancer activity of E-mangostin in chronic myeloid leukemia cells. <b>2014</b> , 55, 628-38		28
1962	Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. <b>2014</b> , 33, 3422-31		74
1961	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. <b>2014</b> , 33, 295-307		3
1960	Nitazoxanide: nematicidal mode of action and drug combination studies. <b>2014</b> , 193, 1-8		26
1959	Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. <b>2014</b> , 35, 2905-14		49
1958	Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy. <b>2014</b> , 343, 74-9		13
1957	Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. <b>2014</b> , 140, 443-52		68
1956	Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors. <b>2014</b> , 118, 83-92		12
1955	Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach. <b>2014</b> , 76, 155-69		3
1954	Nanoparticles containing insoluble drug for cancer therapy. <b>2014</b> , 32, 778-88		100
1953	Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. <b>2014</b> , 28, 1993-2004		17

1952	Improved neuroprotective effects by combining <i>Bacopa monnieri</i> and <i>Rosmarinus officinalis</i> supercritical CO <sub>2</sub> extracts. <b>2014</b> , 19, 119-27	9
1951	Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. <b>2014</b> , 38, 236-42	22
1950	Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. <b>2014</b> , 134, 988-96	27
1949	Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. <b>2014</b> , 99, 498-509	19
1948	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. <b>2014</b> , 349, 408-16	179
1947	Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. <i>Cancer Research</i> , <b>2014</b> , 74, 896-907	10.1 92
1946	Potential by caffeine of cytogenetic damage induced by steroidal derivatives in human lymphocytes in vitro. <b>2014</b> , 766, 42-5	3
1945	Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer. <b>2014</b> , 11, 2623-30	78
1944	Combination studies of platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, cisplatin or carboplatin. <b>2014</b> , 6, 126-31	16
1943	The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. <b>2014</b> , 35, 3044-51	63
1942	Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. <b>2014</b> , 34, 1198-207	50
1941	A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. <b>2014</b> , 116, 41-8	28
1940	Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells. <b>2014</b> , 29, 995-1007	11
1939	Dual drug loaded vitamin D3 nanoparticle to target drug resistance in cancer. <b>2014</b> , 4, 57271-57281	11
1938	Space-Filling Fractional Factorial Designs. <b>2014</b> , 109, 1134-1144	44
1937	Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. <b>2014</b> , 8, 1508-20	71
1936	Improving the MDR reversal activity of 6,17-epoxylathyrane diterpenes. <b>2014</b> , 22, 6392-400	27
1935	Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. <b>2014</b> , 28, 2197-205	47

1934	Delivering curcumin and gemcitabine in one nanoparticle platform for colon cancer therapy. <b>2014</b> , 4, 61948-61959	10
1933	Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ER $\beta$ in breast cancer. <b>2014</b> , 33, 4985-96	26
1932	Diversity matters: how bees benefit from different resin sources. <b>2014</b> , 176, 943-53	40
1931	The combination of cannabidiol and $\Delta^9$ -tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. <b>2014</b> , 13, 2955-67	83
1930	Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity. <b>2014</b> , 20, 176-86	24
1929	Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells. <b>2014</b> , 147, 539-50	71
1928	Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer. <b>2014</b> , 35, 9759-67	13
1927	Combination screening of synthetic drugs and plant derived natural productsPotential and challenges for drug development. <b>2014</b> , 1, 59-69	24
1926	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. <b>2014</b> , 12, 750-64	202
1925	Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine. <b>2014</b> , 50, 3243-61	12
1924	Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. <b>2014</b> , 20, 6479-94	22
1923	XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer. <b>2014</b> , 19, 1594-602	8
1922	Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. <b>2014</b> , 4, 35242-35250	55
1921	Environmental side effects of pharmaceutical cocktails: what we know and what we should know. <b>2014</b> , 279, 169-89	186
1920	The berry constituents quercetin, kaempferol, and pterostilbene synergistically attenuate reactive oxygen species: involvement of the Nrf2-ARE signaling pathway. <b>2014</b> , 72, 303-11	158
1919	Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF- $\kappa$ B, and cell-cycle progression in non-small cell lung cancer. <b>2014</b> , 13, 2203-14	48
1918	SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. <b>2014</b> , 16, 595-605	33
1917	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. <b>2014</b> , 28, 1216-26	45

1916	Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. <b>2014</b> , 167, 87-99	50
1915	Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. <b>2014</b> , 13, 16-26	20
1914	Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment. <b>2014</b> , 88, 1086-93	81
1913	Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim. <b>2014</b> , 14, 431	36
1912	HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. <b>2014</b> , 33, 4867-76	35
1911	Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. <b>2014</b> , 20, 5423-34	45
1910	Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. <b>2014</b> , 354, 355-64	24
1909	Frequently asked questions in drug combinations and the mass-action law-based answers. <b>2014</b> , 1, 3-21	25
1908	Mechanisms underlying the exquisite sensitivity of <i>Candida albicans</i> to combinatorial cationic and oxidative stress that enhances the potent fungicidal activity of phagocytes. <b>2014</b> , 5, e01334-14	57
1907	Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors. <b>2014</b> , 1840, 1051-62	13
1906	Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity. <b>2014</b> , 136, 1312-9	25
1905	Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. <b>2014</b> , 13, 1848-59	29
1904	A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. <b>2014</b> , 10, 298-304	155
1903	Genome-wide transcriptome profiling of homologous recombination DNA repair. <b>2014</b> , 5, 3361	137
1902	Synergistic inhibition on acetylcholinesterase by the combination of berberine and palmatine originally isolated from Chinese medicinal herbs. <b>2014</b> , 53, 511-6	29
1901	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. <b>2014</b> , 99, 726-36	11
1900	Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. <b>2014</b> , 14, 151	50
1899	Enhancement of gefitinib-induced growth inhibition by <i>Marsdenia tenacissima</i> extract in non-small cell lung cancer cells expressing wild or mutant EGFR. <b>2014</b> , 14, 165	19

1898	Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPAR $\alpha$ and RXR $\alpha$ . <b>2014</b> , 134, 1195-206		22
1897	Definition of PKC- $\zeta$ /CDK6, and MET as therapeutic targets in triple-negative breast cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 4822-35	10.1	48
1896	Rapamycin rescues ABT-737 efficacy in small cell lung cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 2846-56	10.1	39
1895	PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. <b>2014</b> , 167, 69-79		42
1894	Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells. <b>2014</b> , 66, 492-9		14
1893	Searching for synergy in silico, in vitro and in vivo. <b>2014</b> , 1, 30-43		22
1892	Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. <b>2014</b> , 60, 1551-62		60
1891	The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. <b>2014</b> , 21, 247-57		83
1890	The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. <b>2014</b> , 32, 317-26		21
1889	Novel insights into the antiproliferative effects and synergism of quercetin and menadione in human leukemia Jurkat T cells. <b>2014</b> , 38, 836-49		27
1888	The additive damage model: a mathematical model for cellular responses to drug combinations. <b>2014</b> , 357, 10-20		8
1887	PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[ $\beta$ ]indene Derivative in Lung Cancer Cells. <b>2014</b> , 7, 256-266.e5		0
1886	Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic[ $\alpha$ ]octapeptide modified liposomes for targeting integrin $\beta$ in triple-negative breast cancer. <b>2014</b> , 35, 5347-5358		69
1885	Combination therapy: a new strategy to manage diabetes and its complications. <b>2014</b> , 21, 123-30		54
1884	Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. <b>2014</b> , 8, 323-36		37
1883	Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. <b>2014</b> , 14, 305-18		24
1882	A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo. <b>2014</b> , 88, 158-68		14
1881	Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. <b>2014</b> , 8, 4996-5009		138

1880	NADPH oxidases as therapeutic targets in chronic myelogenous leukemia. <b>2014</b> , 20, 4014-25	37
1879	Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. <b>2014</b> , 103, 2315-22	63
1878	Targeted polytherapy in small cell sarcoma and its association with doxorubicin. <b>2014</b> , 8, 1458-68	7
1877	VN/14-1 induces ER stress and autophagy in HP-LTLC human breast cancer cells and has excellent oral pharmacokinetic profile in female Sprague Dawley rats. <b>2014</b> , 734, 98-104	5
1876	Cationic membrane-active peptides - anticancer and antifungal activity as well as penetration into human skin. <b>2014</b> , 23, 326-31	61
1875	Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. <b>2014</b> , 187, 145-57	86
1874	AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. <b>2014</b> , 85, 141-6	16
1873	Synergistic effects of 5-fluorouracil and gambogenic acid on A549 cells: activation of cell death caused by apoptotic and necroptotic mechanisms via the ROS-mitochondria pathway. <b>2014</b> , 37, 1259-68	17
1872	FOXN1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs. <b>2015</b> , 47, 1230-40	15
1871	Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. <b>2015</b> , 46, 963-72	51
1870	Systematic synergy modeling: understanding drug synergy from a systems biology perspective. <b>2015</b> , 9, 56	26
1869	Reconceptualizing synergism and antagonism among multiple stressors. <b>2015</b> , 5, 1538-47	308
1868	Id3 induces an Elk-1-caspase-8-dependent apoptotic pathway in squamous carcinoma cells. <b>2015</b> , 4, 914-24	12
1867	Analysis of drug combinations: current methodological landscape. <b>2015</b> , 3, e00149	528
1866	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. <b>2015</b> , 136, 2055-64	79
1865	Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins. <b>2015</b> , 5, 140156	36
1864	Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells. <b>2015</b> , 5, 17523	45
1863	Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. <b>2015</b> , 5, 18789	50

1862	Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis. <b>2015</b> , 1, 15061	38
1861	Sulfoquinovosyl diacylglyceride selectively targets acute lymphoblastic leukemia cells and exerts potent anti-leukemic effects in vivo. <b>2015</b> , 5, 12082	5
1860	A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines. <b>2015</b> , 5, 12361	57
1859	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. <b>2015</b> , 5, 13891	69
1858	Overview: General Principles. <b>2015</b> , 34-47	
1857	Control of Pim2 kinase stability and expression in transformed human haematopoietic cells. <b>2015</b> , 35,	13
1856	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <b>2015</b> , 125, 2689-92	37
1855	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <b>2015</b> , 125, 3447-54	80
1854	Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. <b>2015</b> , 1, 15059	22
1853	Systematic prediction of drug combinations based on clinical side-effects. <b>2014</b> , 4, 7160	34
1852	Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells. <b>2015</b> , 129, 210-5	10
1851	The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription. <b>2015</b> , 12, 108	9
1850	Combinatorial microRNAs suppress hypoxia-induced cardiomyocytes apoptosis. <b>2015</b> , 37, 921-32	21
1849	Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells. <b>2015</b> , 46, 299-307	7
1848	Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. <b>2015</b> , 15, 817	20
1847	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. <b>2015</b> , 17, 33	110
1846	A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds. <b>2015</b> , 16, 2513-21	6
1845	Recent Advances in Upconversion Nanoparticles-Based Multifunctional Nanocomposites for Combined Cancer Therapy. <b>2015</b> , 27, 7692-712	199

1844	A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma. <b>2015</b> , 137, 2243-52	17
1843	Synthetic antimicrobial Peptide in dual-treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm <i>Candida albicans</i> . <b>2015</b> , 21, 853-61	13
1842	Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study. <b>2015</b> , 14, 216-25	2
1841	Rational Design of Polymeric Hybrid Micelles with Highly Tunable Properties to Co-Deliver MicroRNA-34a and Vismodegib for Melanoma Therapy. <b>2015</b> , 25, 7457-7469	35
1840	Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control. <b>2015</b> , 10, 2485-502	9
1839	Coadministration of doxorubicin and etoposide loaded in camel milk phospholipids liposomes showed increased antitumor activity in a murine model. <b>2015</b> , 10, 2847-55	8
1838	Lovastatin overcomes gefitinib resistance through TNF- $\beta$ signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo. <b>2015</b> , 6, 23857-73	19
1837	Nanoshell-mediated photothermal therapy can enhance chemotherapy in inflammatory breast cancer cells. <b>2015</b> , 10, 6931-41	44
1836	The Influence of Sesquiterpenes from <i>Myrica rubra</i> on the Antiproliferative and Pro-Oxidative Effects of Doxorubicin and Its Accumulation in Cancer Cells. <b>2015</b> , 20, 15343-58	39
1835	Curcumin and emodin down-regulate TGF- $\beta$ signaling pathway in human cervical cancer cells. <b>2015</b> , 10, e0120045	67
1834	The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells. <b>2015</b> , 10, e0127058	33
1833	What is synergy? The Saariseik Agreement revisited. <b>2015</b> , 6, 181	88
1832	A Novel Pharmacological Method to Study the Chinese Medicinal Formula Hua-Zheng-Hui-Sheng-Dan. <b>2015</b> , 2015, 436807	5
1831	Preclinical evaluation on the tumor suppression efficiency and combination drug effects of fermented wheat germ extract in human ovarian carcinoma cells. <b>2015</b> , 2015, 570785	6
1830	Cripto-1 Promotes the Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma Cells. <b>2015</b> , 2015, 421285	6
1829	Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo. <b>2015</b> , 6, 32930-43	68
1828	Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells. <b>2015</b> , 6, 21557-71	22
1827	Polyphenol-rich extract of <i>Pimenta dioica</i> berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice. <b>2015</b> , 6, 16379-95	26

1826	Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. <b>2015</b> , 6, 28296-311	65
1825	MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. <b>2015</b> , 6, 35202-17	21
1824	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. <b>2015</b> , 6, 2088-100	25
1823	Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. <b>2015</b> , 58, 5053-74	8
1822	Self-assembled targeted folate-conjugated eight-arm-polyethylene glycol-betulinic acid nanoparticles for co-delivery of anticancer drugs. <b>2015</b> , 3, 3754-3766	41
1821	Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer. <b>2015</b> , 1853, 2261-72	39
1820	General Reagent Free Route to pH Responsive Polyacryloyl Hydrazide Capped Metal Nanogels for Synergistic Anticancer Therapeutics. <b>2015</b> , 7, 11497-507	17
1819	Toxicological interactions between the mycotoxins deoxynivalenol, nivalenol and their acetylated derivatives in intestinal epithelial cells. <b>2015</b> , 89, 1337-46	100
1818	Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer. <b>2015</b> , 61, 10-25	134
1817	Selective induction of oxidative stress in cancer cells via synergistic combinations of agents targeting redox homeostasis. <b>2015</b> , 23, 3097-104	15
1816	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. <b>2015</b> , 14, 100	59
1815	Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. <b>2015</b> , 388, 1029-38	9
1814	Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics. <b>2015</b> , 19, 1319-37	25
1813	Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. <b>2015</b> , 59, 2143-54	20
1812	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). <b>2015</b> , 21, 5563-77	42
1811	Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. <i>Cancer Research</i> , <b>2015</b> , 75, 5318-28	10.1 19
1810	Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer. <b>2015</b> , 220, 438-446	40
1809	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer. <b>2016</b> , 108, djv394	36

1808	Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263. <b>2015</b> , 6, e2034	40
1807	Response surface models in the field of anesthesia: A crash course. <b>2015</b> , 53, 139-45	12
1806	Paclitaxel Enhances Carboplatin-DNA Adduct Formation and Cytotoxicity. <b>2015</b> , 28, 2250-2	11
1805	The Eltrombopag antitumor effect on hepatocellular carcinoma. <b>2015</b> , 47, 1696-702	18
1804	Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF- $\kappa$ B-mediated survival signaling pathways in human gallbladder cancer cells. <b>2015</b> , 33, 1683-90	10
1803	ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells. <b>2015</b> , 34, 1239-48	4
1802	Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. <b>2015</b> , 13, 659-69	21
1801	Application of the combination index integrated with confidence intervals to study the toxicological interactions of antibiotics and pesticides in <i>Vibrio qinghaiensis</i> sp.-Q67. <b>2015</b> , 39, 447-56	22
1800	Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. <b>2015</b> , 201, 90-9	103
1799	Large-scale exploration and analysis of drug combinations. <b>2015</b> , 31, 2007-16	79
1798	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. <b>2015</b> , 36, 355-67	157
1797	Effect of sun ginseng potentiation on epirubicin and paclitaxel-induced apoptosis in human cervical cancer cells. <b>2015</b> , 39, 22-8	19
1796	Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. <b>2015</b> , 25, 1223-7	22
1795	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. <b>2015</b> , 520, 239-42	166
1794	Dual drug-loaded paclitaxel/hydroquinone nanoparticles for effective breast cancer therapy. <b>2015</b> , 17, 1	50
1793	Combination effects of SMAC mimetic birinapant with TNF $\alpha$ /TRAIL, and docetaxel in preclinical models of HNSCC. <b>2015</b> , 125, E118-24	20
1792	Synergistic anti-tumour effects of tetrandrine and chloroquine combination therapy in human cancer: a potential antagonistic role for p21. <b>2015</b> , 172, 2232-45	43
1791	The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. <b>2015</b> , 25, 856-63	11

1790	Effect of citral on the cytotoxicity of doxorubicin in human B-lymphoma cells. <b>2015</b> , 53, 262-8	20
1789	In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. <b>2015</b> , 17, 1086-94	26
1788	Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). <b>2015</b> , 10, 365-73	19
1787	HPLC/DAD analysis and in vitro enzyme inhibition: An integrated approach to predict herbal binary mixture behaviour employing median effect equation. <b>2015</b> , 119, 176-182	14
1786	A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/ $\beta$ -catenin signaling. <b>2015</b> , 36, 318-26	17
1785	Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. <b>2015</b> , 26, 408-15	53
1784	Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling. <b>2015</b> , 14, 23-30	19
1783	Environmentally oriented models and methods for the evaluation of drug-drug interaction effects. <b>2015</b> , 45, 131-55	14
1782	Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. <b>2015</b> , 7, 5859-68	110
1781	Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. <b>2015</b> , 58, 2764-78	33
1780	Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. <b>2015</b> , 51, 11587-90	66
1779	Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. <b>2015</b> , 107,	25
1778	Recent Advances in Retinoblastoma Treatment. <b>2015</b> ,	4
1777	Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling. <b>2015</b> , 7, 298ra119	56
1776	Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase. <b>2015</b> , 36, 9347-56	10
1775	Glialin-mediated production of polyamines by RAW264.7 macrophages modulates intestinal epithelial permeability in vitro. <b>2015</b> , 1852, 1779-86	11
1774	Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival. <b>2015</b> , 196, 339-49	15
1773	Polymeric Nanostructures for Imaging and Therapy. <b>2015</b> , 115, 10967-1011	351

1772	Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. <b>2015</b> , 5, 8477	83
1771	Basic and clinical pharmacology contribution to extend anthelmintic molecules lifespan. <b>2015</b> , 212, 35-46	17
1770	Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines. <b>2015</b> , 28, 1574-83	36
1769	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <b>2015</b> , 138, 323-31	16
1768	A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy. <b>2015</b> , 17, 155-66	59
1767	Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy. <b>2015</b> , 3, 6310-6326	49
1766	Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. <b>2015</b> , 366, 160-72	24
1765	Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies. <b>2015</b> , 11, e1004119	4
1764	APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma. <b>2015</b> , 64, 1506-16	60
1763	A novel self-assembled targeted nanoparticle platform based on carboxymethylcellulose co-delivery of anticancer drugs. <b>2015</b> , 3, 6605-6617	34
1762	Aceroside VIII is a new natural selective HDAC6 inhibitor that synergistically enhances the anticancer activity of HDAC inhibitor in HT29 cells. <b>2015</b> , 81, 222-7	14
1761	The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. <b>2015</b> , 5, 9054	33
1760	Prioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic data. <b>2015</b> , 11, e1004068	27
1759	Co-delivery of protein and small molecule therapeutics using nanoparticle-stabilized nanocapsules. <b>2015</b> , 26, 950-4	65
1758	Inhibition of Multidrug Resistance of Cancer Cells by Co-Delivery of DNA Nanostructures and Drugs Using Porous Silicon Nanoparticles@Giant Liposomes. <b>2015</b> , 25, 3330-3340	97
1757	Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia. <b>2015</b> , 1, e1400203	24
1756	Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. <b>2015</b> , 1851, 919-28	20
1755	Combined diazepam and MK-801 therapy provides synergistic protection from tetramethylenedisulfotetramine-induced tonic-clonic seizures and lethality in mice. <b>2015</b> , 48, 100-8	16

1754	Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective. <b>2015</b> , 405, 53-61	13
1753	The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation. <b>2015</b> , 102, 12-24	8
1752	SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. <b>2015</b> , 27, 384-98	10
1751	Optimizing the compatibility of paired-herb in an ancient Chinese herbal decoction Kai-Xin-San in activating neurofilament expression in cultured PC12 cells. <b>2015</b> , 162, 155-62	23
1750	ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. <b>2015</b> , 13, 74	22
1749	The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. <b>2015</b> , 34, 31	30
1748	Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. <b>2015</b> , 8, 431-43	75
1747	Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. <b>2015</b> , 10, e0119614	15
1746	Blood-brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate. <b>2015</b> , 10, 1703-13	52
1745	Drug combination studies and their synergy quantification using the Chou-Talalay method--letter. <i>Cancer Research</i> , <b>2015</b> , 75, 2400	10.1 87
1744	Design and activity of AP endonuclease-1 inhibitors. <b>2015</b> , 8, 79-93	22
1743	Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer. <b>2015</b> , 7, 6661-73	48
1742	The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. <b>2015</b> , 14, 232-42	5
1741	Non-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cells. <b>2015</b> , 5, 8726	48
1740	Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. <b>2015</b> , 151, 281-94	49
1739	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. <b>2015</b> , 468, 125-32	103
1738	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. <b>2015</b> , 21, 2601-12	71
1737	Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. <b>2015</b> , 95, 28-37	22

1736	Micelle-assisted combination therapies for effective glioblastoma treatment: an in-vitro assessment. <b>2015</b> , 26, 312-22	5
1735	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <b>2015</b> , 7, 282ra50	40
1734	Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. <b>2015</b> , 59, 250-61	43
1733	Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. <b>2015</b> , 7, 7584-98	92
1732	Multi-drug delivery nanocarriers for combination therapy. <b>2015</b> , 6, 1916-1929	67
1731	On-demand combinational delivery of curcumin and doxorubicin via a pH-labile micellar nanocarrier. <b>2015</b> , 495, 572-578	37
1730	Inhibition of Human Pancreatic Cancer Cell Proliferation by Devil's Club <i>Oplopanax horridus</i> and Its Polyacetylene Bioactive Compound. <b>2015</b> , 67, 954-64	7
1729	Combinations of alkaloids affecting different molecular targets with the saponin digitonin can synergistically enhance trypanocidal activity against <i>Trypanosoma brucei brucei</i> . <b>2015</b> , 59, 7011-7	19
1728	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <b>2015</b> , 21, 1163-71	275
1727	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <b>2015</b> , 21, 1182-9	139
1726	The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells. <b>2015</b> , 464, 292-8	15
1725	Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. <b>2015</b> , 98, 602-13	49
1724	Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. <b>2015</b> , 15, 462	37
1723	Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. <b>2015</b> , 15, 422	15
1722	Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer. <b>2015</b> , 220, 107-118	41
1721	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <b>2015</b> , 7, 312ra176	86
1720	Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate. <b>2015</b> , 26, 2497-506	73
1719	Concentration addition prediction for a multiple-component mixture containing no effect chemicals. <b>2015</b> , 7, 9912-9917	19

1718	Synergistic effects of anethole and ibuprofen in acute inflammatory response. <b>2015</b> , 242, 247-53	18
1717	Self-delivery nanoparticles from an amphiphilic covalent drug couple of irinotecan and bendamustine for cancer combination chemotherapy. <b>2015</b> , 5, 86254-86264	31
1716	Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. <b>2015</b> , 220, 160-168	12
1715	The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts. <b>2015</b> , 15, 474	25
1714	Chemical profile and in vivo hypoglycemic effects of Syzygium jambos, Costus speciosus and Tapeinochilos ananassae plant extracts used as diabetes adjuvants in Puerto Rico. <b>2015</b> , 15, 244	21
1713	Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/ $\beta$ -catenin signaling. <b>2015</b> , 467, 14-20	43
1712	Effective Boolean dynamics analysis to identify functionally important genes in large-scale signaling networks. <b>2015</b> , 137, 64-72	6
1711	Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. <b>2015</b> , 15, 477	17
1710	Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers. <b>2015</b> , 12, 4085-98	58
1709	Polypharmacology Shakes Hands with Complex Aetiopathology. <b>2015</b> , 36, 802-821	24
1708	Novel 3-Substituted 7-Phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as Single Entities with Multitarget Antiproliferative Activity. <b>2015</b> , 58, 7991-8010	20
1707	An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. <b>2015</b> , 28, 472-485	55
1706	Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. <b>2015</b> , 6, e1595	33
1705	Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. <b>2015</b> , 98, 51-68	94
1704	Synthesis of silver nanoparticles for the dual delivery of doxorubicin and alendronate to cancer cells. <b>2015</b> , 3, 7237-7245	92
1703	Platelet-Derived Growth Factor Receptor $\beta$ Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1. <b>2015</b> , 149, 420-32.e16	48
1702	Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin. <b>2015</b> , 14, 1907-15	24
1701	Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine. <b>2015</b> , 1, e1500439	141

1700	pH-Sensitive pullulan-DOX conjugate nanoparticles for co-loading PDTC to suppress growth and chemoresistance of hepatocellular carcinoma. <b>2015</b> , 3, 8070-8078		26
1699	A self-assembled nanoparticle platform based on poly(ethylene glycol)βiosgenin conjugates for co-delivery of anticancer drugs. <b>2015</b> , 5, 74828-74834		11
1698	Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. <i>Cancer Research</i> , <b>2015</b> , 75, 4398-406	10.1	45
1697	Erosion of the chronic myeloid leukaemia stem cell pool by PPARβagonists. <b>2015</b> , 525, 380-3		193
1696	Epoxythyrol Derivatives: Modulation of ABCB1-Mediated Multidrug Resistance in Human Colon Adenocarcinoma and Mouse T-Lymphoma Cells. <b>2015</b> , 78, 2215-28		23
1695	Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance. <b>2015</b> , 153, 247-252		13
1694	The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. <b>2015</b> , 14, 3418-29		74
1693	ANOVA and the analysis of drug combination experiments. <b>2015</b> , 12, 1108		6
1692	Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. <b>2015</b> , 212, 2189-201		112
1691	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. <i>Cancer Research</i> , <b>2015</b> , 75, 5106-5119	10.1	155
1690	A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. <b>2015</b> , 220, 189-200		44
1689	YM155 suppresses cell proliferation and induces cell death in human adult T-cell leukemia/lymphoma cells. <b>2015</b> , 39, 1473-9		8
1688	Co-delivery of docetaxel and chloroquine via PEO-PPO-PCL/TPGS micelles for overcoming multidrug resistance. <b>2015</b> , 495, 932-9		59
1687	Catanionic drug-derivative nano-objects constructed by chlorambucil and its derivative for efficient leukaemia therapy. <b>2015</b> , 136, 1081-8		5
1686	Bioinert Anodic Alumina Nanotubes for Targeting of Endoplasmic Reticulum Stress and Autophagic Signaling: A Combinatorial Nanotube-Based Drug Delivery System for Enhancing Cancer Therapy. <b>2015</b> , 7, 27140-51		23
1685	Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. <b>2015</b> , 13, 504-13		232
1684	Wnt/βcatenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. <b>2015</b> , 6, 8904		130
1683	ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. <b>2015</b> , 56, 2146-52		49

1682	Multifunctional nanoparticles for prostate cancer therapy. <b>2015</b> , 16, 98-107	13
1681	Synergistic antibacterial activity of the combination of the alkaloid sanguinarine with EDTA and the antibiotic streptomycin against multidrug resistant bacteria. <b>2015</b> , 67, 264-73	28
1680	Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. <b>2015</b> , 59, 1061-9	61
1679	Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. <b>2015</b> , 356, 862-71	35
1678	Synergistic anticancer activity of fluorescent copper nanoclusters and cisplatin delivered through a hydrogel nanocarrier. <b>2015</b> , 7, 209-22	75
1677	Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells. <b>2015</b> , 39, 65-71	14
1676	Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. <b>2015</b> , 75, 235-46	40
1675	Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. <b>2015</b> , 17, 822-31	13
1674	Chemical inhibitor targeting the replication protein A-DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer. <b>2015</b> , 93, 25-33	32
1673	Computational systems biology approaches to anti-angiogenic cancer therapeutics. <b>2015</b> , 20, 187-97	36
1672	Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. <b>2015</b> , 37, 405-14	119
1671	Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation. <b>2015</b> , 193, 1023-9	14
1670	AB0035 Bactericidal/permeability-Increasing Protein Levels in Human Synovial Fluid and Its Effects in Experimental Crystal-Induced Inflammation. <b>2016</b> , 75, 908.3-909	
1669	Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. <b>2016</b> , 7, 40348-40361	17
1668	Combination Therapy of Antiepileptic Drugs (AEDS) With Safe Natural Anticonvulsant Agent. <b>2016</b> , 04,	
1667	MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. <b>2016</b> , 9, 4387-96	8
1666	A novel temperature-responsive micelle for enhancing combination therapy. <b>2016</b> , 11, 3357-69	14
1665	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. <b>2016</b> , 7, 50302-50314	22

1664	In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. <b>2016</b> , 10, 1299-306	9
1663	The combined effects of proteasome inhibitor bortezomib with topoisomerase I and II inhibitors on topoisomerase enzymes. <b>2016</b> , 46, 1882-1888	
1662	Desferal regulates hCt1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. <b>2016</b> , 7, 49310-49321	14
1661	Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. <b>2016</b> , 7, 60535-60554	49
1660	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. <b>2016</b> , 7, 29131-42	16
1659	Synergic Effect of -Mangostin on the Cytotoxicity of Cisplatin in a Cervical Cancer Model. <b>2016</b> , 2016, 7981397	20
1658	Biomolecular Network-Based Synergistic Drug Combination Discovery. <b>2016</b> , 2016, 8518945	18
1657	Quantitative Characterization of the Toxicities of Cd-Ni and Cd-Cr Binary Mixtures Using Combination Index Method. <b>2016</b> , 2016, 4158451	2
1656	HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. <b>2016</b> , 6, 1324-35	51
1655	Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy. <b>2016</b> , 5, 27-34	15
1654	The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. <b>2016</b> , 36, 356-64	16
1653	Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells. <b>2016</b> , 9, 107	26
1652	Synergistic Enhancement of Newcastle Disease Virus to 5-Fluorouracil Cytotoxicity against Tumor Cells. <b>2016</b> , 4,	18
1651	Tocotrienol Nanoemulsion Platform of Curcumin Elicit Elevated Apoptosis and Augmentation of Anticancer Efficacy against Breast and Ovarian Carcinomas. <b>2016</b> , 17,	14
1650	Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin- $\alpha$ In Vitro Synergy Quantification of Pifithrin- $\alpha$ Combined with Pt Drugs in Prostate and Colorectal Cancer Cells. <b>2016</b> , 21,	27
1649	Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. <b>2016</b> , 8,	51
1648	Investigating the Synergistic Effects of Combined Modified Alginates on Macrophage Phenotype. <b>2016</b> , 8,	10
1647	Combination Therapy in Cancer. <b>2016</b> , 1-6	

1646	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. <b>2016</b> , 11, e0150567	27
1645	Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. <b>2016</b> , 7, 201	172
1644	Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform. <b>2016</b> , 33, 401-432	18
1643	Oncogenic regulation of tumor metabolic reprogramming. <b>2016</b> , 7, 62726-62753	82
1642	Phytochemical concentrations and biological activities of Sorghum bicolor alcoholic extracts. <b>2016</b> , 7, 3410-20	27
1641	Investigation of the cytotoxic implications of metal chelators against melanoma and approaches to improve the cytotoxicity profiles of metal coordinating agents. <b>2016</b> , 29, 789-805	3
1640	Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment. <b>2016</b> , 132, 262-7	14
1639	Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. <b>2016</b> , 8, 208-22	28
1638	Chemo/Photoacoustic Dual Therapy with mRNA-Triggered DOX Release and Photoinduced Shockwave Based on a DNA-Gold Nanoplatfrom. <b>2016</b> , 12, 756-69	33
1637	Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma. <b>2016</b> , 291, 14146-14159	32
1636	Multifunctional Carbon/Silica Nanocapsules with Gold Core for Synergistic Photothermal and Chemo-Cancer Therapy under the Guidance of Bimodal Imaging. <b>2016</b> , 26, 4252-4261	100
1635	A probabilistic approach for collective similarity-based drug-drug interaction prediction. <b>2016</b> , 32, 3175-3182	61
1634	XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II $\beta$ to the Nucleus. <b>2016</b> , 22, 6142-6152	53
1633	Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells. <b>2016</b> , 45, 269-80	7
1632	Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy. <b>2016</b> , 57, 638-47	18
1631	Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27. <b>2016</b> , 78, 657-68	4
1630	Effects and synergy of feed ingredients on canine neoplastic cell proliferation. <b>2016</b> , 12, 159	8
1629	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. <b>2016</b> ,	1

1628	Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy. <b>2016</b> , 6, 38787	20
1627	BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. <b>2016</b> , 6, 25523	40
1626	Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. <b>2016</b> , 6, 22622	54
1625	Data on quantification of signaling pathways activated by KIT and PDGFRA mutants. <b>2016</b> , 9, 828-838	2
1624	A Pipeline for Drug Target Identification and Validation. <b>2016</b> , 81, 257-267	11
1623	Idelalisib induces G1 <sub>0</sub> arrest and apoptosis in chronic myeloid leukemia K562 cells. <b>2016</b> , 36, 3643-3650	7
1622	Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification. <b>2016</b> , 4, 25	18
1621	A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. <b>2016</b> , 9, 76	64
1620	Pharmacodynamic Issues in Antibiotic Combinations. <b>2016</b> , 89-108	
1619	Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic. <b>2016</b> , 14, 1477-1487	55
1618	Augmenting the potency of third-line antibiotics with Berberis aristata: In vitro synergistic activity against carbapenem-resistant Escherichia coli. <b>2016</b> , 6, 10-16	10
1617	Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. <b>2016</b> , 15, 890-8	14
1616	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. <b>2016</b> , 24, 3174-83	11
1615	Cost-effectiveness of Screening for Abdominal Aortic Aneurysm in Combination with Medical Intervention in Patients with Small Aneurysms. <b>2016</b> , 51, 766-73	19
1614	PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. <b>2016</b> , 39, 94-105	102
1613	Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. <b>2016</b> , 46, 325-339	61
1612	Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin. <b>2016</b> , 507, 50-60	25
1611	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <b>2016</b> , 6, 838-851	176

1610	Nanoparticles Encapsulated with LL37 and Serpin A1 Promotes Wound Healing and Synergistically Enhances Antibacterial Activity. <b>2016</b> , 13, 2318-31	66
1609	PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. <b>2016</b> , 15, 1669-81	17
1608	Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines. <b>2016</b> , 11, 655-665	10
1607	A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy. <b>2016</b> , 6, 73-86	45
1606	The evolution of drug discovery: from phenotypes to targets, and back. <b>2016</b> , 7, 788-798	21
1605	Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer. <b>2016</b> , 107, 29-40	11
1604	Novel sesquiterpene lactone analogues as potent anti-breast cancer agents. <b>2016</b> , 10, 921-37	21
1603	Targeting I $\kappa$ B Kinase $\gamma$ NF- $\kappa$ B Signaling in Human Prostate Cancer by a Novel I $\kappa$ B Kinase $\gamma$ Inhibitor CmpdA. <b>2016</b> , 15, 1504-14	25
1602	Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells. <b>2016</b> , 44, 17-24	9
1601	Design, synthesis, and biological evaluation of novel asiatic acid derivatives as potential anticancer agents. <b>2016</b> , 6, 39296-39309	3
1600	Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function. <b>2016</b> , 110, 193-204	22
1599	Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease. <b>2016</b> , 60, 3700-8	19
1598	Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs. <b>2016</b> , 105, 205-227	146
1597	A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice. <b>2016</b> , 15, 1163-76	14
1596	Temozolomide in combination with metformin act synergistically to inhibit proliferation and expansion of glioma stem-like cells. <b>2016</b> , 11, 2792-2800	37
1595	Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell. <b>2016</b> , 35, 58	15
1594	Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma. <b>2016</b> , 377, 117-25	51
1593	Comparative Analysis of the Antimicrobial Activities of Plant Defensin-Like and Ultrashort Peptides against Food-Spoiling Bacteria. <b>2016</b> , 82, 4288-4298	20

1592	Bifurcation-based approach reveals synergism and optimal combinatorial perturbation. <b>2016</b> , 42, 399-414	3
1591	Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. <b>2016</b> , 22, 4391-404	47
1590	Combenefit: an interactive platform for the analysis and visualization of drug combinations. <b>2016</b> , 32, 2866-8	286
1589	Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia. <b>2016</b> , 30, 1691-700	24
1588	Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing. <b>2016</b> , 43, 38-47	18
1587	Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy. <b>2016</b> , 12, 435-49	55
1586	Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells. <b>2016</b> , 54, 2629-2635	31
1585	Carrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor Therapy. <b>2016</b> , 8, 13262-9	229
1584	Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation. <b>2016</b> , 37, 14259-14269	22
1583	The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect. <b>2016</b> , 11, 740-749	6
1582	A Comparative Evaluation of Hydroxycamptothecin Drug Nanorods With and Without Methotrexate Prodrug Functionalization for Drug Delivery. <b>2016</b> , 11, 384	10
1581	Tailoring Soft Nanoparticles for Potential Application as Drug Carriers in Bladder Cancer Chemotherapy. <b>2016</b> , 167-195	1
1580	Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance. <b>2016</b> , 8, 25060-8	54
1579	Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition. <b>2016</b> , 513, 8-16	55
1578	Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway. <b>2016</b> , 21, 1398-1407	39
1577	Cancer network activity associated with therapeutic response and synergism. <b>2016</b> , 8, 88	5
1576	Synthetic lethality in lung cancer and translation to clinical therapies. <b>2016</b> , 15, 61	23
1575	Inhibition of $\beta$ -secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5. <b>2016</b> , 12, 2900-2905	4

1574	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement. <b>2016</b> , 22, 4341-9	29
1573	Evaluation of synergistic effects of sulforaphene with photodynamic therapy in human cervical cancer cell line. <b>2016</b> , 31, 1675-1682	4
1572	Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. <b>2016</b> , 29, 643-655	23
1571	Comments on "The synergistic toxicity of the multi chemical mixtures: Implications for risk assessment in the terrestrial environment". <b>2016</b> , 94, 396-398	19
1570	Combination treatment with Rhizoma Paridis and Rhizoma Curcuma longa extracts and 10-hydroxycamptothecin enhances the antitumor effect in H22 tumor model by increasing the plasma concentration. <b>2016</b> , 83, 627-634	14
1569	Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. <b>2016</b> , 381, 96-103	138
1568	Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha. <b>2016</b> , 111, 849-858	18
1567	Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. <b>2016</b> , 238, 10-21	53
1566	Antioxidant properties of atypical antipsychotic drugs used in the treatment of schizophrenia. <b>2016</b> , 176, 245-251	25
1565	Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatin by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299. <b>2016</b> , 12, 41-51	4
1564	Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase. <b>2016</b> , 173, 191-211	29
1563	Triterpenoids from Momordica balsamina: Reversal of ABCB1-mediated multidrug resistance. <b>2016</b> , 24, 5061-5067	18
1562	Prediction of multidimensional drug dose responses based on measurements of drug pairs. <b>2016</b> , 113, 10442-7	91
1561	Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. <b>2016</b> , 108, 54-67	70
1560	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. <b>2016</b> , 3, 15-30	28
1559	Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. <b>2016</b> , 21, 1265-1278	37
1558	A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition. <b>2016</b> , 15, 2620-2629	21
1557	Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs. <b>2016</b> , 381, 287-95	13

1556	Dual-acting, function-responsive, and high drug payload nanospheres for combining simplicity and efficacy in both self-targeted multi-drug co-delivery and synergistic anticancer effect. <b>2016</b> , 512, 194-203	12
1555	Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers. <b>2016</b> , 99, 99-109	11
1554	Plumbagin Enhances Tamoxifen Sensitivity and Inhibits Tumor Invasion in Endocrine Resistant Breast Cancer through EMT Regulation. <b>2016</b> , 30, 1968-1977	17
1553	Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. <b>2016</b> , 15, 2609-2619	47
1552	Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. <b>2016</b> , 49, 1609-19	17
1551	Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage. <b>2016</b> , 84, 1906-1914	68
1550	Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. <b>2015</b> , 5, 18144	32
1549	Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1. <b>2016</b> , 6, 33358	9
1548	Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. <b>2016</b> , 241, 68-80	90
1547	Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. <b>2016</b> , 17, 1168-1176	9
1546	Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment. <b>2016</b> , 15, 2508-2520	8
1545	P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy. <b>2016</b> , 48, 397-411	7
1544	Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <b>2016</b> , 142, 548-56	58
1543	Gaining Insights Into the Pharmacology of Anthelmintics Using Haemonchus contortus as a Model Nematode. <b>2016</b> , 93, 465-518	13
1542	Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. <b>2016</b> , 6, 31009	26
1541	Isoeugenol is a selective potentiator of camptothecin cytotoxicity in vertebrate cells lacking TDP1. <b>2016</b> , 6, 26626	14
1540	Assessment of different 3D culture systems to study tumor phenotype and chemosensitivity in pancreatic ductal adenocarcinoma. <b>2016</b> , 49, 243-52	10
1539	Rationale and strategies for formulation development of oral fixed dose combination drug products. <b>2016</b> , 46, 615-631	14

1538	CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. <b>2016</b> , 6, 19004	8
1537	A chemical family-based strategy for uncovering hidden bioactive molecules and multicomponent interactions in herbal medicines. <b>2016</b> , 6, 23840	20
1536	PI3K p110 $\alpha$ isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. <b>2016</b> , 35, 78	26
1535	Engineering a Brain Cancer Chip for High-throughput Drug Screening. <b>2016</b> , 6, 25062	117
1534	BG-4, a novel anticancer peptide from bitter melon ( <i>Momordica charantia</i> ), promotes apoptosis in human colon cancer cells. <b>2016</b> , 6, 33532	43
1533	Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. <b>2016</b> , 791, 751-762	34
1532	An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. <b>2016</b> , 6, 22120	11
1531	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 6320-6330	10.1 85
1530	Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells. <b>2016</b> , 84, 1393-1405	21
1529	Changes in the in vitro activity of platinum drugs when administered in two aliquots. <b>2016</b> , 16, 688	5
1528	AB0036 Soluble CD83 Plasma Levels Are Associated with Disease Activity and Course of Disease in Early Rheumatoid Arthritis. <b>2016</b> , 75, 909.1-909	
1527	MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. <b>2016</b> , 16, 550	12
1526	Effect of oxaliplatin combined with polyene phosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells. <b>2016</b> , 12, 4538-4546	4
1525	Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53. <b>2016</b> , 39, 2088-2098	13
1524	Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. <b>2016</b> , 10, 5823-34	52
1523	Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. <b>2016</b> , 14, 61	35
1522	Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. <b>2016</b> , 9, 25	12
1521	Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway. <b>2016</b> , 38, 83-94	59

1520	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. <b>2016</b> , 534, 341-6	141
1519	Combining the uniform design-based ray procedure with combination index to investigate synergistic lethal toxicities of ternary mixtures on <i>Caenorhabditis elegans</i> . <b>2016</b> , 8, 4466-4472	14
1518	Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. <b>2016</b> , 240, 489-503	185
1517	Synergism of the IGRs Methoprene and Pyriproxyfen Against Larval Cat Fleas (Siphonaptera: Pulicidae). <b>2016</b> , 53, 629-633	14
1516	A combinatorial strategy for treating KRAS-mutant lung cancer. <b>2016</b> , 534, 647-51	249
1515	Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. <b>2016</b> , 7, 774-9	24
1514	Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. <b>2016</b> , 6, 87-95	75
1513	Synergetic effects of aqueous extracts of Fuzi ( <i>Radix Aconiti Lateralis Preparata</i> ) and Tubeimu ( <i>Rhizoma Bolbostemmatidis</i> ) on MDA-MB-231 and SKBR3 cells. <b>2016</b> , 36, 113-24	6
1512	Clinical development of new drug-radiotherapy combinations. <b>2016</b> , 13, 627-42	162
1511	Jatrophone diterpenes and cancer multidrug resistance - ABCB1 efflux modulation and selective cell death induction. <b>2016</b> , 23, 968-78	33
1510	Facile Approach To Construct Ternary Cocktail Nanoparticles for Cancer Combination Therapy. <b>2016</b> , 27, 1564-8	32
1509	PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. <b>2016</b> , 14, 67	28
1508	Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. <b>2016</b> , 35, 70	12
1507	Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma. <b>2016</b> , 22, 5839-5850	20
1506	Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. <b>2016</b> , 29, 859-873	124
1505	Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis. <b>2016</b> , 37, 12347-12358	21
1504	Phase II enzyme induction and anti-inflammatory effects of crude extracts and secondary fractions obtained from bran from five black glutinous rice cultivars. <b>2016</b> , 51, 333-341	1
1503	In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71. <b>2016</b> , 60, 5357-67	24

1502	Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death. <b>2016</b> , 23, 64-75	22
1501	Synthetic Hydroxytropolones Inhibit Replication of Wild-Type and Acyclovir-Resistant Herpes Simplex Viruses. <b>2016</b> , 60, 2140-9	30
1500	Sonic Hedgehog Pathway Activation Is Associated With Resistance to Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Carcinoma. <b>2016</b> , 17, 301-8	34
1499	Polymer nanoparticle delivery of dichloroacetate and DACH-Pt to enhance antitumor efficacy and lower systemic toxicity. <b>2016</b> , 4, 661-9	11
1498	Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight. <b>2016</b> , 23, 233-42	89
1497	Essential Oil from Myrica rubra Leaves Potentiated Antiproliferative and Prooxidative Effect of Doxorubicin and its Accumulation in Intestinal Cancer Cells. <b>2016</b> , 82, 89-96	7
1496	Real-time self-tracking of an anticancer small molecule nanodrug based on colorful fluorescence variations. <b>2016</b> , 6, 12472-12478	24
1495	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1. <b>2016</b> , 59, 1140-1148	30
1494	ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells. <b>2016</b> , 245, 100-9	79
1493	Optimization of drug combinations using Feedback System Control. <b>2016</b> , 11, 302-15	67
1492	Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein. <b>2016</b> , 103, 118-28	26
1491	Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. <b>2016</b> , 14, 298-309	72
1490	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. <b>2016</b> , 22, 194-201	141
1489	Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination. <b>2016</b> , 12, 614-23	36
1488	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. <b>2016</b> , 22, 2020-31	44
1487	Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. <b>2016</b> , 371, 20-9	48
1486	Cellular determinants involving mitochondrial dysfunction, oxidative stress and apoptosis correlate with the synergic cytotoxicity of epigallocatechin-3-gallate and menadione in human leukemia Jurkat T cells. <b>2016</b> , 103, 300-17	22
1485	Dual drug loaded nanoliposomal chemotherapy: A promising strategy for treatment of head and neck squamous cell carcinoma. <b>2016</b> , 99, 73-83	43

1484	New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B. <b>2016</b> , 151, 86-92	11
1483	Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice. <b>2016</b> , 5, e296	86
1482	A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. <b>2016</b> , 371, 205-13	25
1481	Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. <b>2016</b> , 35, 4663-74	22
1480	Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. <b>2016</b> , 159, 284-94	23
1479	Discussion. <b>2016</b> , 159, 294-5	
1478	Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. <i>Cancer Research</i> , <b>2016</b> , 76, 902-11	10.1 46
1477	Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. <b>2016</b> , 15, 842-53	11
1476	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <b>2016</b> , 15, 593-607	39
1475	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. <b>2016</b> , 15, 830-41	29
1474	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. <b>2016</b> , 29, 311-323	146
1473	Near Infrared-Guided Smart Nanocarriers for MicroRNA-Controlled Release of Doxorubicin/siRNA with Intracellular ATP as Fuel. <b>2016</b> , 10, 3637-47	121
1472	The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells. <b>2016</b> , 103, 572-83	5
1471	Lupeol enhances inhibitory effect of 5-fluorouracil on human gastric carcinoma cells. <b>2016</b> , 389, 477-84	18
1470	Metformin attenuates transforming growth factor beta (TGF- $\beta$ ) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. <b>2016</b> , 15, 1046-59	50
1469	Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. <b>2016</b> , 84, 103-15	22
1468	Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. <i>Cancer Research</i> , <b>2016</b> , 76, 2432-42	10.1 45
1467	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. <b>2015</b> , 60, 1492-9	16

1466	Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. <b>2016</b> , 90, 3112-22	41
1465	Low doses of PEG-coated gold nanoparticles sensitize solid tumors to cold plasma by blocking the PI3K/AKT-driven signaling axis to suppress cellular transformation by inhibiting growth and EMT. <b>2016</b> , 87, 118-130	64
1464	CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling. <i>Cancer Research</i> , <b>2016</b> , 76, 2687-97	10.1 21
1463	Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. <b>2016</b> , 22, 1978-88	12
1462	Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes. <b>2016</b> , 21, 407-19	8
1461	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. <b>2016</b> , 18, 26	16
1460	In vitro evaluation of antitumoral efficacy of catalase in combination with traditional chemotherapeutic drugs against human lung adenocarcinoma cells. <b>2016</b> , 37, 10775-84	8
1459	Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. <b>2016</b> , 18, 1109-19	25
1458	FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. <b>2016</b> , 22, 3884-93	60
1457	Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia. <b>2016</b> , 95, 425-35	6
1456	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. <b>2016</b> , 22, 1138-49	56
1455	Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. <b>2016</b> , 37, 7589-97	22
1454	Synergistic effect of radon and sodium arsenite on DNA damage in HBE cells. <b>2016</b> , 41, 127-31	11
1453	Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. <b>2016</b> , 57, 1938-41	15
1452	Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. <b>2016</b> , 22, 122-33	62
1451	Targeting acid ceramidase sensitises head and neck cancer to cisplatin. <b>2016</b> , 52, 163-72	33
1450	Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells. <b>2016</b> , 499, 101-109	18
1449	Actively targeting D- $\alpha$ -tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer. <b>2016</b> , 8, 3100-18	38

1448	"Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. <b>2016</b> , 98, 3-18	317
1447	Pharmacological effects of berberine and its derivatives: a patent update. <b>2016</b> , 26, 229-43	93
1446	Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. <b>2016</b> , 22, 383-94	16
1445	XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. <b>2016</b> , 22, 1663-73	24
1444	Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. <b>2016</b> , 22, 405-14	54
1443	CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1. <b>2016</b> , 195, 771-9	29
1442	Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. <b>2016</b> , 81, 172-80	10
1441	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. <b>2016</b> , 22, 935-47	32
1440	mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition. <b>2016</b> , 10, 101-12	16
1439	Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing. <b>2016</b> , 21, 125-32	14
1438	Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors. <b>2017</b> , 35, 1833-1848	22
1437	Downregulation of STAT3/NF- $\kappa$ B potentiates gemcitabine activity in pancreatic cancer cells. <b>2017</b> , 56, 402-411	23
1436	Targeting oncogenic protein kinase C $\alpha$ for treatment of mutant KRAS LADC. <b>2017</b> , 8, 58-64	5
1435	In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. <b>2017</b> , 257, 118-131	39
1434	Epithelial-to-Mesenchymal Transition in Paclitaxel-Resistant Ovarian Cancer Cells Is Downregulated by Luteolin. <b>2017</b> , 232, 391-401	34
1433	BH3 mimetic ABT-737 induces apoptosis in CD34 acute myeloid leukemia cells and shows synergistic effect with conventional chemotherapeutic drugs. <b>2017</b> , 13, e144-e152	1
1432	Evaluation of methylene blue, pyrimethamine and its combination on an in vitro Neospora caninum model. <b>2017</b> , 144, 827-833	5
1431	RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. <i>Cancer Research</i> , <b>2017</b> , 77, 1345-1356	10.1 24

1430	P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. <b>2017</b> , 56, 1515-1525	23
1429	Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. <b>2017</b> , 104, 1-9	37
1428	A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. <b>2017</b> , 7, 41615	47
1427	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. <b>2017</b> , 16, 566-577	74
1426	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1. <b>2017</b> , 60, 2148-2154	12
1425	Gambogic acid potentiates the chemosensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting proliferation and inducing apoptosis. <b>2017</b> , 13, 662-668	7
1424	Synergistic antitumor activity of a self-assembling camptothecin and capecitabine hybrid prodrug for improved efficacy. <b>2017</b> , 263, 102-111	45
1423	Self-assembled PEG-carboxymethylcellulose nanoparticles/ $\beta$ -cyclodextrin hydrogels for injectable and thermosensitive drug delivery. <b>2017</b> , 7, 2905-2912	21
1422	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. <b>2017</b> , 36, 3334-3345	52
1421	Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway. <b>2017</b> , 177, 456-469	12
1420	Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines. <b>2017</b> , 17, 49	13
1419	Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549) cells. <b>2017</b> , 103, 28-40	44
1418	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. <b>2017</b> , 8, 14294	73
1417	Effects of U0126 and MK2206 on cell growth and re-growth of endometriotic stromal cells grown on substrates of varying stiffness. <b>2017</b> , 7, 42939	8
1416	Individual and combined effects of Aflatoxin B, Deoxynivalenol and Zearalenone on HepG2 and RAW 264.7 cell lines. <b>2017</b> , 103, 18-27	46
1415	Combination of ruthenium(II)-arene complex [Ru( $\eta$ -cymene)Cl(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity. <b>2017</b> , 7, 43005	78
1414	Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells. <b>2017</b> , 213, 848-853	20
1413	Enhanced anticancer effect of Combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma. <b>2017</b> , 89, 36-46	12

1412	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. <b>2017</b> , 102, 168-175	7
1411	Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. <b>2017</b> , 116, 1027-1036	17
1410	Multilayer photodynamic therapy for highly effective and safe cancer treatment. <b>2017</b> , 54, 271-280	16
1409	The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/III-Tubulin Axis. <b>2017</b> , 15, 953-964	11
1408	(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3. <b>2017</b> , 56, 2003-2013	7
1407	Selective elimination of neuroblastoma cells by synergistic effect of Akt kinase inhibitor and tetrathiomolybdate. <b>2017</b> , 21, 1859-1869	11
1406	Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. <b>2017</b> , 11, 2227-2238	299
1405	Cytotoxic and apoptotic effects of the combination of palladium (II) 5,5-diethylbarbiturate complex with bis(2-pyridylmethyl)amine and curcumin on non small lung cancer cell lines. <b>2017</b> , 25, 1717-1723	17
1404	Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells. <b>2017</b> , 128, 247-257	24
1403	Synergistic antileukemic therapies in -induced T-ALL. <b>2017</b> , 114, 2006-2011	37
1402	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <b>2017</b> , 129, e26-e37	107
1401	Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer. <b>2017</b> , 7, 41977	10
1400	Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production. <b>2017</b> , 17, 129-140	34
1399	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. <b>2017</b> , 15, 250-258	39
1398	A new parameter to simultaneously assess antioxidant activity for multiple phenolic compounds present in food products. <b>2017</b> , 229, 215-222	3
1397	Capsaicin synergizes with camptothecin to induce increased apoptosis in human small cell lung cancers via the calpain pathway. <b>2017</b> , 129, 54-66	31
1396	Biotic and abiotic factors investigated in two Drosophila species - evidence of both negative and positive effects of interactions on performance. <b>2017</b> , 7, 40132	6
1395	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. <b>2017</b> , 7, 682	16

1394	Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. <i>Cancer Research</i> , <b>2017</b> , 77, 3293-3305	10.1	33
1393	RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro. <b>2017</b> , 28, 514-521		12
1392	4-Acetylanthroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. <b>2017</b> , 325, 48-60		29
1391	Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells. <b>2017</b> , 5, 3531-3540		21
1390	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. <b>2017</b> , 19, 413-424		53
1389	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. <b>2017</b> , 16, 1290-1298		27
1388	Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression. <b>2017</b> , 622, 1-12		19
1387	Exploring Jolkinol D Derivatives To Overcome Multidrug Resistance in Cancer. <b>2017</b> , 80, 1411-1420		16
1386	Coordinating Biointeraction and Bioreaction of a Nanocarrier Material and an Anticancer Drug to Overcome Membrane Rigidity and Target Mitochondria in Multidrug-Resistant Cancer Cells. <b>2017</b> , 27, 1700804		23
1385	Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy. <b>2017</b> , 258, 95-107		153
1384	Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. <b>2017</b> , 35, 544.e1-544.e10		13
1383	Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. <b>2017</b> , 60, 4279-4292		14
1382	Potential medicinal plants for progressive macular hypomelanosis. <b>2017</b> , 111, 346-357		5
1381	Inhibition of Midkine Suppresses Prostate Cancer CD133 Stem Cell Growth and Migration. <b>2017</b> , 354, 299-309		15
1380	Curcumin loading potentiates the chemotherapeutic efficacy of selenium nanoparticles in HCT116 cells and Ehrlich's ascites carcinoma bearing mice. <b>2017</b> , 117, 346-362		38
1379	Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. <b>2017</b> , 19, 1481-1493		23
1378	Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from <i>Candida albicans</i> . <b>2017</b> , 57, 1426-1438		20
1377	Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells. <b>2017</b> , 174, 2427-2443		29

1376	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3834-3845	10.1	58
1375	Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry. <b>2017</b> , 22, 325-337		12
1374	In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. <b>2017</b> , 400, 47-60		27
1373	Tumor Static Concentration Curves in Combination Therapy. <b>2017</b> , 19, 456-467		6
1372	Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells. <b>2017</b> , 795, 50-57		14
1371	Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. <b>2017</b> , 9, 1334-1355		99
1370	Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. <b>2017</b> , 16, 1819-1830		25
1369	Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas. <b>2017</b> , 16, 2083-2093		19
1368	The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. <b>2017</b> , 810, 100-111		44
1367	Nanoformulations for combination or cascade anticancer therapy. <b>2017</b> , 115, 3-22		120
1366	Anti-tumor effect of cisplatin in human oral squamous cell carcinoma was enhanced by andrographolide via upregulation of phospho-p53 in vitro and in vivo. <b>2017</b> , 39, 1010428317705330		12
1365	The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma. <b>2017</b> , 39, 395-401		2
1364	Gemcitabine-camptothecin conjugates: a hybrid prodrug for controlled drug release and synergistic therapeutics. <b>2017</b> , 5, 1889-1897		29
1363	Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. <b>2017</b> , 436, 119-136		22
1362	RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems. <b>2017</b> , 13, 219-227		32
1361	Synergistic interaction of ten essential oils against <i>Haemonchus contortus</i> in vitro. <b>2017</b> , 243, 47-51		38
1360	Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma. <b>2017</b> , 31, 1078-1089		13
1359	Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs. <b>2017</b> , 16, 1555-1565		27

1358	Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines. <b>2017</b> , 90, 1029-1035	14
1357	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. <i>Cancer Research</i> , <b>2017</b> , 77, 3885-3893	10.1 18
1356	Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. <b>2017</b> , 95, 965-975	5
1355	Cytotoxic effects of 15-deoxy- $\Delta^2,14$ -prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma. <b>2017</b> , 13, 2939-2945	5
1354	Efficient Codelivery of Paclitaxel and Curcumin by Novel Bottlebrush Copolymer-based Micelles. <b>2017</b> , 14, 2378-2389	47
1353	Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors. <b>2017</b> , 60, 5599-5612	22
1352	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <b>2017</b> , 109,	7
1351	Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. <b>2017</b> , 10, 112	32
1350	Differences in p53 status significantly influence the cellular response and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in colorectal cancer cells. <b>2017</b> , 56, 2486-2498	20
1349	Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2/P-gp dependent pathway. <b>2017</b> , 803, 57-64	11
1348	A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer. <b>2017</b> , 28, 557-564	15
1347	Synergism of co-delivered nanosized antioxidants displayed enhanced anticancer efficacy in human colon cancer cell lines. <b>2017</b> , 2, 82-95	7
1346	Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs). <b>2017</b> , 134, 97-109	15
1345	The dopamine D receptor antagonists PG01037, NGB2904, SB277011A, and U99194 reverse ABCG2 transporter-mediated drug resistance in cancer cell lines. <b>2017</b> , 396, 167-180	15
1344	Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. <b>2017</b> , 36, 4267-4276	38
1343	Targeted radionuclide therapy for lung cancer with iodine-131-labeled peptide in a nude-mouse model. <b>2017</b> , 28, 480-488	1
1342	A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient. <b>2017</b> , 28, 551-556	8
1341	Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. <b>2017</b> , 28, 569-580	22

1340	Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model. <b>2017</b> , 28, 489-502	1
1339	The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines. <b>2017</b> , 17, 42	9
1338	Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin. <b>2017</b> , 16, 45	9
1337	Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells. <b>2017</b> , 7, 45954	21
1336	Inhibiting the system x/glutathione axis selectively targets cancers with mutant-p53 accumulation. <b>2017</b> , 8, 14844	140
1335	Allosteric cross-talk in chromatin can mediate drug-drug synergy. <b>2017</b> , 8, 14860	54
1334	Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells. <b>2017</b> , 58, 2439-2451	17
1333	Multisite aggregation of p53 and implications for drug rescue. <b>2017</b> , 114, E2634-E2643	40
1332	Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. <b>2017</b> , 7, 44075	24
1331	MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. <b>2017</b> , 11, 628-639	25
1330	Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancer cells. <b>2017</b> , 89, 1142-1151	18
1329	Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E- $\beta$ Catenin Axis. <b>2017</b> , 354, 182-189	8
1328	Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. <b>2017</b> , 35, 412-426	7
1327	Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor. <b>2017</b> , 16, 717-728	12
1326	CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. <b>2017</b> , 102, e17-e21	12
1325	Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells. <b>2017</b> , 1517, 115-126	5
1324	Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. <b>2017</b> , 16, 440-452	49
1323	Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells. <b>2017</b> , 388, 262-268	23

1322	Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. <b>2017</b> , 389, 33-40	8
1321	Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. <b>2017</b> , 55, 729-739	48
1320	AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1 $\beta$ stabilization. <b>2017</b> , 388, 149-157	28
1319	Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. <b>2017</b> , 11, 254-262	242
1318	Subcellular co-delivery of two different site-oriented payloads for tumor therapy. <b>2017</b> , 9, 1547-1558	13
1317	Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach. <b>2017</b> , 120, 532-540	3
1316	Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro. <b>2017</b> , 174, 328-340	19
1315	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. <b>2017</b> , 129, 771-782	49
1314	Differential regulation of baicalin and scutellarin on AMPK and Akt in promoting adipose cell glucose disposal. <b>2017</b> , 1863, 598-606	23
1313	Bioresponsive polymer coated drug nanorods for breast cancer treatment. <b>2017</b> , 28, 045601	14
1312	Dual and Inhibition Demonstrates Synergy against Neuroblastoma. <b>2017</b> , 23, 2856-2868	53
1311	Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status. <b>2017</b> , 28, 1118-1125	5
1310	Pre-clinical evaluation of a thermosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. <b>2017</b> , 268, 176-183	23
1309	Chemotherapeutic efficacies of a clofazimine and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on Babesia bovis. <b>2017</b> , 7, 13888	21
1308	Co-Delivery of Curcumin and Chrysin by Polymeric Nanoparticles Inhibit Synergistically Growth and hTERT Gene Expression in Human Colorectal Cancer Cells. <b>2017</b> , 69, 1290-1299	72
1307	Identification of 7-(4'-Cyanophenyl)indoline-1-benzenesulfonamide as a mitotic inhibitor to induce apoptotic cell death and inhibit autophagy in human colorectal cancer cells. <b>2017</b> , 7, 12406	6
1306	Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade. <b>2017</b> , 5, 950-956	87
1305	Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. <b>2017</b> , 411, 35-43	19

1304	Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. <b>2017</b> , 130, 2073-2083	31
1303	Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma. <b>2017</b> , 16, 2759-2769	33
1302	Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer. <b>2017</b> , 7, 12754	10
1301	Development of a dual drug-loaded hydrogel delivery system for enhanced cancer therapy: in situ formation, degradation and synergistic antitumor efficiency. <b>2017</b> , 5, 8487-8497	28
1300	Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015. <b>2017</b> , 7, 12230	26
1299	Inhibition of Thioredoxin Reductase by Targeted Selenopolymeric Nanocarriers Synergizes the Therapeutic Efficacy of Doxorubicin in MCF7 Human Breast Cancer Cells. <b>2017</b> , 9, 36493-36512	16
1298	In vitro combined effect of Doxorubicin and sulfonated zinc Phthalocyanine-mediated photodynamic therapy on MCF-7 breast cancer cells. <b>2017</b> , 39, 1010428317727278	15
1297	Tretinoin-loaded lipid-core nanocapsules overcome the triple-negative breast cancer cell resistance to tretinoin and show synergistic effect on cytotoxicity induced by doxorubicin and 5-fluororacil. <b>2017</b> , 96, 404-409	13
1296	Programmed Nanococktail Based on pH-Responsive Function Switch for Self-Synergistic Tumor-Targeting Therapy. <b>2017</b> , 9, 39127-39142	25
1295	Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles. <b>2017</b> , 9, 40006-40016	17
1294	Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. <b>2017</b> , 38, 2774-2786	19
1293	Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy. <b>2017</b> , 16, 2422-2431	16
1292	The effect of brassinolide, a plant steroid hormone, on drug resistant small-cell lung carcinoma cells. <b>2017</b> , 493, 783-787	12
1291	A review on engineering polymer drug conjugates to improve combination chemotherapy. <b>2017</b> , 31, 75-85	48
1290	Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. <b>2017</b> , 3, 17058	25
1289	Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines. <b>2017</b> , 410, 228-237	25
1288	Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor. <b>2017</b> , 13, 1164-1171	103
1287	Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras. <b>2017</b> , 493, 213-219	10

1286	Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer. <b>2017</b> , 264, 276-287	4
1285	Reduction-sensitive Paclitaxel Prodrug Self-assembled Nanoparticles with Tetrandrine Effectively Promote Synergistic Therapy Against Drug-sensitive and Multidrug-resistant Breast Cancer. <b>2017</b> , 14, 3628-3635	27
1284	Dihydroartemisinin and Curcumin Synergistically Induce Apoptosis in SKOV3 Cells Via Upregulation of MiR-124 Targeting Midkine. <b>2017</b> , 43, 589-601	28
1283	Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. <b>2017</b> , 7, 8090	19
1282	The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. <b>2017</b> , 19, 772-780	14
1281	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. <b>2017</b> , 19, 750-761	14
1280	Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin. <b>2017</b> , 7, 8419	16
1279	Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. <b>2017</b> , 7, 9842	21
1278	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <b>2017</b> , 102, 2113-2124	13
1277	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <b>2017</b> , 8, 451	72
1276	Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells. <b>2017</b> , 8, e2943	78
1275	The reversion of anti-cancer drug antagonism of tamoxifen and docetaxel by the hyaluronic acid-decorated polymeric nanoparticles. <b>2017</b> , 126, 84-96	24
1274	CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1. <i>Cancer Research</i> , <b>2017</b> , 77, 4823-4834	10.1 24
1273	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <b>2017</b> , 23, 6203-6214	22
1272	In Vitro targeting of colon cancer cells using spiropyrazoline oxindoles. <b>2017</b> , 139, 168-179	15
1271	Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models. <b>2017</b> , 109, 131-143	28
1270	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. <b>2017</b> , 20, 999-1015	45
1269	Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells. <b>2017</b> , 22, 1246-1259	40

1268	Kinetic interpretation of log-logistic dose-time response curves. <b>2017</b> , 7, 2234	13
1267	Intracatinol synergistically enhances the anticancerous activity of cisplatin in human A549 cells via p38 MAPK/p53 signalling. <b>2017</b> , 22, 1273-1286	15
1266	Broad-spectrum non-nucleoside inhibitors for caliciviruses. <b>2017</b> , 146, 65-75	13
1265	In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. <b>2017</b> , 28, 503-513	16
1264	Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells. <b>2017</b> , 92, 164-172	10
1263	MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. <b>2017</b> , 7, 2685	10
1262	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <b>2017</b> , 23, 6602-6615	19
1261	Phytochemistry. <b>2017</b> , 111-140	2
1260	Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <b>2017</b> , 9,	58
1259	Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. <b>2017</b> , 23, 6958-6968	47
1258	The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. <b>2017</b> , 16, 2689-2700	22
1257	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <b>2017</b> , 109,	89
1256	Self-assembled DNA nanowires as quantitative dual-drug nanocarriers for antitumor chemophotodynamic combination therapy. <b>2017</b> , 5, 7529-7537	20
1255	Synergistic Chemopreventive and Therapeutic Effects of Co-drug UA-Met: Implication in Tumor Metastasis. <b>2017</b> , 65, 10973-10983	8
1254	Alcoholic extracts of Epilobium, Urtica dioica and Evernia prunastri with 5-fluorouracil in controlling murine colon carcinoma cell growth in vitro. <b>2017</b> , 17, 325-336	2
1253	A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions. <b>2017</b> , 8, 2129	37
1252	Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. <b>2018</b> , 39, 455-464	13
1251	Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. <b>2017</b> , 9, 1948-1960	15

1250	Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. <b>2017</b> , 24, 1909-1926	99
1249	Hybrid combinations containing natural products and antimicrobial drugs that interfere with bacterial and fungal biofilms. <b>2017</b> , 37, 14-26	26
1248	Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. <b>2017</b> , 26, 112-125	26
1247	Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer. <b>2017</b> , 113, 564-570	7
1246	Plant phenolics and terpenoids as adjuvants of antibacterial and antifungal drugs. <b>2017</b> , 37, 27-48	68
1245	Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia. <b>2018</b> , 46, 1792-1798	8
1244	Tetrandrine and arsenic trioxide synergistically inhibit proliferation of HCC1937 triple negative breast cancer cells. <b>2017</b> , 37, 436-443	7
1243	Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. <b>2017</b> , 7, 4204	19
1242	Ratiometric co-delivery of multiple chemodrugs in a single nanocarrier. <b>2017</b> , 107, 16-23	23
1241	Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression. <b>2017</b> , 38, 1036-1046	128
1240	Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. <b>2017</b> , 406, 105-115	22
1239	Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. <b>2017</b> , 44, 27-35	7
1238	Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. <b>2017</b> , 23, 6215-6226	39
1237	Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. <b>2017</b> , 3, 17	27
1236	Actions of sesquiterpene lactones isolated from <i>Moquiniastrum polymorphum</i> subsp. <i>floccosum</i> in MCF7 cell line and their potentiating action on doxorubicin. <b>2017</b> , 18, 53	2
1235	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. <b>2017</b> , 178, 936-948	28
1234	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <b>2017</b> , 10, 127	20
1233	Salinomycin overcomes acquired tamoxifen resistance through AIB1 and inhibits cancer cell invasion in endocrine resistant breast cancer. <b>2017</b> , 44, 1042-1052	7

1232	Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia. <b>2017</b> , 16, 101-108	5
1231	Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. <i>Cancer Research</i> , <b>2017</b> , 77, 86-99	10.1 43
1230	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. <b>2017</b> , 24, 300-316	13
1229	Oblongifolin C and guttiferone K extracted from <i>Garcinia yunnanensis</i> fruit synergistically induce apoptosis in human colorectal cancer cells in vitro. <b>2017</b> , 38, 252-263	13
1228	Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. <b>2017</b> , 31, 1269-1277	50
1227	SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity. <b>2017</b> , 426, 1-8	15
1226	Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. <b>2017</b> , 385, 243-250	24
1225	Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling. <b>2017</b> , 29, 138-149	4
1224	Synergistic Anticancer Effect of Peptide-Docetaxel Nanoassembly Targeted to Tubulin: Toward Development of Dual Warhead Containing Nanomedicine. <b>2017</b> , 6, 1600718	16
1223	Combined antitumor effect of ßsecretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer. <b>2017</b> , 22, 257-268	10
1222	Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. <b>2017</b> , 140, 109-119	35
1221	Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer. <b>2017</b> , 22, 59-69	23
1220	Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. <b>2017</b> , 125, 760-769	37
1219	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <b>2017</b> , 23, 1862-1874	78
1218	Sorafenib with ASC-J9 synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. <b>2017</b> , 140, 705-717	21
1217	The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. <b>2017</b> , 23, 2027-2037	41
1216	Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer. <b>2017</b> , 27, 106-114	50
1215	Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. <b>2017</b> , 23, 1748-1759	36

1214	Pharmacogenomics and chemical library screens reveal a novel SCF inhibitor that overcomes Bortezomib resistance in multiple myeloma. <b>2017</b> , 31, 645-653	33
1213	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. <b>2017</b> , 23, 1945-1954	27
1212	Physico-Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumor-Targeted Drug Delivery. <b>2017</b> , 17, 1600160	99
1211	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 566-578	10.1 28
1210	Plant flavonoids in cancer chemoprevention: role in genome stability. <b>2017</b> , 45, 1-14	208
1209	Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?. <b>2017</b> , 140, 234-246	56
1208	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. <b>2017</b> , 23, 1552-1563	49
1207	Bundling potent natural toxin cantharidin within platinum (IV) prodrugs for liposome drug delivery and effective malignant neuroblastoma treatment. <b>2017</b> , 13, 287-296	11
1206	Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. <b>2018</b> , 39, 367-375	4
1205	Pharmacological targeting of apelin impairs glioblastoma growth. <b>2017</b> , 140, 2939-2954	46
1204	Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. <b>2018</b> , 52, 337-366	19
1203	Combined cytotoxicity of aflatoxin B1 and deoxynivalenol to hepatoma HepG2/C3A cells. <b>2017</b> , 10, 387-399	4
1202	Combining thioridazine and loratadine for the treatment of gastrointestinal tumor. <b>2017</b> , 14, 4573-4580	12
1201	Torin2 enhances the radiosensitivity of MCF-7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation. <b>2018</b> , 17, 366-373	7
1200	Costunolide enhances doxorubicin-induced apoptosis in prostate cancer cells via activated mitogen-activated protein kinases and generation of reactive oxygen species. <b>2017</b> , 8, 107701-107715	23
1199	An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. <b>2017</b> , 8, 158	102
1198	Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. <b>2017</b> , 51, 369-377	39
1197	Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells. <b>2017</b> , 7, 1914-1927	27

1196	Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF- $\kappa$ B/COX-2 signaling pathways. <b>2017</b> , 10, 5471-5482	29
1195	Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer. <b>2017</b> , 12, 5109-5118	24
1194	Synergistic Effects of Danshen ( <i>Salvia Miltiorrhizae Radix et Rhizoma</i> ) and Sanqi ( <i>Notoginseng Radix et Rhizoma</i> ) Combination in Angiogenesis Behavior in EAhy 926 Cells. <b>2017</b> , 4,	7
1193	The Effects of Selected Sesquiterpenes from <i>Myrica rubra</i> Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines. <b>2017</b> , 22,	17
1192	BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors. <b>2017</b> , 18,	31
1191	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. <b>2017</b> , 8, 631	103
1190	Induction of Early Autophagic Process on by Synergistic Effect of Miltefosine and Innovative Semi-synthetic Thiosemicarbazone. <b>2017</b> , 8, 255	28
1189	Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. <b>2017</b> , 7, 288	6
1188	Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin. <b>2017</b> , 2017,	23
1187	Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. <b>2017</b> , 10, 4869-4883	14
1186	Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. <b>2017</b> , 8, 16220-16232	21
1185	Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. <b>2017</b> , 12, 2081-2108	27
1184	Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway. <b>2017</b> , 11, 3333-3341	17
1183	An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts. <b>2017</b> , 12, e0168960	6
1182	Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia. <b>2017</b> , 12, e0169128	16
1181	Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. <b>2017</b> , 12, e0176139	23
1180	Effects of PPAR $\gamma$ Inhibition in head and neck paraganglioma cells. <b>2017</b> , 12, e0178995	19
1179	Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity. <b>2017</b> , 12, e0182022	12

1178	Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. <b>2017</b> , 12, e0185687	12
1177	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. <b>2017</b> , 12, e0172315	25
1176	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <b>2017</b> , 8, 365	33
1175	Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. <b>2017</b> , 17, 711	37
1174	Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. <b>2017</b> , 10, 544	11
1173	Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. <b>2017</b> , 17, 820	8
1172	Solanum nigrum Unripe fruit fraction attenuates Adriamycin resistance by down-regulating multi-drug resistance protein (Mdr)-1 through Jak-STAT pathway. <b>2017</b> , 17, 370	12
1171	Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients. <b>2017</b> , 38, 1011-1020	13
1170	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). <b>2017</b> , 8, 47305-47316	32
1169	Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. <b>2017</b> , 8, 46145-46162	23
1168	Combination of esomeprazole with chemotherapeutics results in more pronounced cytotoxic effect via apoptosis on A549 nonsmall-cell lung cancer cell line. <b>2017</b> , 41, 231-241	4
1167	Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. <b>2017</b> , 8, 63635-63645	4
1166	Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7. <b>2017</b> , 51, 587-598	27
1165	The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia. <b>2017</b> , 10, 2581-2593	10
1164	Clmbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets. <b>2017</b> , 33, 2410-2412	10
1163	Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. <b>2017</b> , 8, 8854-8866	49
1162	Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. <b>2017</b> , 8, 30742-30755	20
1161	Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases toxicity of PARP inhibition by preventing Rad51 foci formation in wild type high-grade serous ovarian cancer. <b>2017</b> , 8, 111026-111040	48

1160	Folic acid conjugation improves the bioavailability and chemosensitizing efficacy of curcumin-encapsulated PLGA-PEG nanoparticles towards paclitaxel chemotherapy. <b>2017</b> , 8, 107374-107389	28
1159	Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. <b>2017</b> , 8, 80124-80138	21
1158	Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. <b>2017</b> , 8, 51429-51446	22
1157	The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. <b>2017</b> , 7, 53322-53333	1
1156	PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer. <b>2017</b> , 8, 11937-11949	34
1155	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. <b>2017</b> , 8, 12558-12575	70
1154	The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing Expression and Targeting Tumor-Initiating Cells. <i>Cancer Research</i> , <b>2018</b> , 78, 2396-2406	10.1 28
1153	Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. <b>2018</b> , 99, 543-551	34
1152	Interactions of Schiff base compounds and their coordination complexes with the drug cisplatin. <b>2018</b> , 42, 5834-5843	19
1151	Predicting Mixture Toxicity with Models of Additivity. <b>2018</b> , 235-270	4
1150	In vitro and in vivo effects of MK2206 and chloroquine combination therapy on endometriosis: autophagy may be required for regrowth of endometriosis. <b>2018</b> , 175, 1637-1653	14
1149	The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. <b>2018</b> , 474, 57-64	22
1148	Co-inhibition of BET proteins and NF- $\kappa$ B as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. <b>2018</b> , 9, 315	22
1147	Gambogic acid sensitizes breast cancer cells to TRAIL-induced apoptosis by promoting the crosstalk of extrinsic and intrinsic apoptotic signalings. <b>2018</b> , 119, 334-341	10
1146	Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NF $\kappa$ B-mediated apoptosis in hepatocellular carcinoma cell line HepG2. <b>2018</b> , 99, 939-946	39
1145	Synergistic Cytotoxic Effect on Gastric Cancer Cells of an Immunotoxin Cocktail in Which Antibodies Recognize Different Epitopes on CDH17. <b>2018</b> , 37, 1-11	4
1144	In silico screening for human norovirus antivirals reveals a novel non-nucleoside inhibitor of the viral polymerase. <b>2018</b> , 8, 4129	18
1143	Stattic enhances the anti-proliferative effect of docetaxel via the Bax/Bcl-2/cyclin B axis in human cancer cells. <b>2018</b> , 69, 188-196	9

1142	BTK drives ibrutinib resistance via ERK1/2 and protects BTK MYD88-mutated cells by a paracrine mechanism. <b>2018</b> , 131, 2047-2059	48
1141	Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro. <b>2018</b> , 99, 384-390	18
1140	Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. <b>2018</b> , 423, 47-59	32
1139	2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy. <b>2018</b> , 9, 361	12
1138	Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells. <b>2018</b> , 17, 5581-5588	10
1137	Simultaneous elimination of cancer stem cells and bulk cancer cells by cationic-lipid-assisted nanoparticles for cancer therapy. <b>2018</b> , 11, 4183-4198	8
1136	Targeting MDMX and PKC $\delta$ to improve current uveal melanoma therapeutic strategies. <b>2018</b> , 7, 33	10
1135	In Vitro and in Vivo drug combination for the treatment of Trypanosoma cruzi infection: A multivariate approach. <b>2018</b> , 189, 19-27	8
1134	Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF- $\kappa$ B Signaling. <b>2018</b> , 66, 162-169	8
1133	miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. <b>2018</b> , 427, 85-93	15
1132	Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. <b>2018</b> , 65, e12496	25
1131	A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. <b>2018</b> , 23, 918-929	25
1130	Homoharringtonine could induce quick protein synthesis of PSMD11 through activating MEK1/ERK1/2 signaling pathway in pancreatic cancer cells. <b>2018</b> , 119, 6644-6656	13
1129	Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. <b>2018</b> , 119, 6216-6230	9
1128	The role of pollutants in type 2 diabetes mellitus (T2DM) and their prospective impact on phytomedicinal treatment strategies. <b>2018</b> , 190, 262	5
1127	Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. <b>2018</b> , 167, 8-19	56
1126	The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment. <b>2018</b> , 10, 253-269	12
1125	Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-fluorothymidine. <b>2018</b> , 24, 3126-3136	10

1124	HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. <b>2018</b> , 143, 1388-1401		38
1123	Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. <b>2018</b> , 14, 1301-1313		12
1122	-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K. <i>Cancer Research</i> , <b>2018</b> , 78, 2000-2013	10.1	10
1121	combinations of inert phenolato Ti(IV) complexes with clinically employed anticancer chemotherapy: synergy with oxaliplatin on colon cells. <b>2018</b> , 8, 5822-5827		5
1120	Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer. <b>2018</b> , 143, 212-224		6
1119	Enhanced anticancer effects of <i>Scutellaria barbata</i> D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells. <b>2018</b> , 217, 140-151		18
1118	PPARγ agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. <b>2018</b> , 823, 19-26		20
1117	Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle. <b>2018</b> , 151, 71-77		6
1116	Dietary isoflavone daidzein synergizes centchroman action via induction of apoptosis and inhibition of PI3K/Akt pathway in MCF-7/MDA MB-231 human breast cancer cells. <b>2018</b> , 40, 116-124		18
1115	Hyaluronic Acid-Modified Micelles Encapsulating Gem-C and HNK for Glioblastoma Multiforme Chemotherapy. <b>2018</b> , 15, 1203-1214		18
1114	Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. <b>2018</b> , 29, 112-127		46
1113	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 2383-2395	10.1	20
1112	Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. <b>2018</b> , 200, 1727-1736		3
1111	Cytotoxicity of Tanshinone IIA combined with Taxol on drug-resist breast cancer cells MCF-7 through inhibition of Tau. <b>2018</b> , 32, 667-671		9
1110	Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer. <b>2018</b> , 9, 137		14
1109	Enzymatic Self-Assembly Confers Exceptionally Strong Synergism with NF-κB Targeting for Selective Necroptosis of Cancer Cells. <b>2018</b> , 140, 2301-2308		43
1108	Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. <b>2018</b> , 118, 802-812		9
1107	A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers. <b>2018</b> , 24, 1905-1916		8

1106	Intensified Crystallization Processes for 1:1 Drug-Drug Cocrystals of Sulfathiazole-Theophylline, and Sulfathiazole-Sulfanilamide. <b>2018</b> , 18, 1339-1349	15
1105	Amoebicidal activity of curcumin on <i>Entamoeba histolytica</i> trophozoites. <b>2018</b> , 70, 426-433	8
1104	PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia. <b>2018</b> , 10,	29
1103	Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-ALL). <b>2018</b> , 153, 230-241	17
1102	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <b>2018</b> , 32, 1135-1146	68
1101	Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis. <b>2018</b> , 36, 545-560	10
1100	Oxidative stress via inhibition of the mitochondrial electron transport and Nrf-2-mediated anti-oxidative response regulate the cytotoxic activity of plumbagin. <b>2018</b> , 8, 1073	20
1099	Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. <b>2018</b> , 12, 406-420	33
1098	The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. <b>2018</b> , 97, 839-849	6
1097	Synergistic effect of pyrazoles derivatives and doxorubicin in claudin-low breast cancer subtype. <b>2018</b> , 98, 390-398	12
1096	Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex. <b>2018</b> , 36, 160.e1-160.e13	19
1095	Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations. <b>2018</b> , 93, 190-196	3
1094	COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. <b>2018</b> , 17, 474-483	22
1093	Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. <b>2018</b> , 15, 472-485	12
1092	Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group. <b>2018</b> , 81, 427-441	10
1091	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <b>2018</b> , 142, 2139-2152	41
1090	Novel Targeting of Transcription and Metabolism in Glioblastoma. <b>2018</b> , 24, 1124-1137	28
1089	In vitro and in vivo characterization of stem-like cells from canine osteosarcoma and assessment of drug sensitivity. <b>2018</b> , 363, 48-64	20

1088	An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation. <b>2018</b> , 61, 236-242	16
1087	KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop. <i>Cancer Research</i> , <b>2018</b> , 78, 1444-1456	10.1 9
1086	The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer. <b>2018</b> , 7, 408-419	7
1085	Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR. <b>2018</b> , 355, 266-273	16
1084	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <b>2018</b> , 110, 777-786	36
1083	Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma. <b>2018</b> , 475, 531-545	23
1082	Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3. <b>2018</b> , 70, 306-315	15
1081	Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer. <b>2018</b> , 17, 1554-1565	23
1080	Effects of miconazole/clotrimazole and praziquantel combinations against the liver fluke <i>Opisthorchis felinus</i> in vivo and in vitro. <b>2018</b> , 117, 2327-2331	9
1079	The combination index (CI). <b>2018</b> , 7, 49-50	38
1078	Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. <b>2018</b> , 6, 1	23
1077	Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway. <b>2018</b> , 32, 1764-1769	13
1076	Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. <b>2018</b> , 51, 74-82	7
1075	Inhibition of NF- $\kappa$ B results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. <b>2018</b> , 428, 77-89	35
1074	Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. <b>2018</b> , 25, 654-667	37
1073	Calcium carbonate-doxorubicin@silica-indocyanine green nanospheres with photo-triggered drug delivery enhance cell killing in drug-resistant breast cancer cells. <b>2018</b> , 11, 3385-3395	15
1072	Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. <b>2018</b> , 6, 2230-2239	17
1071	Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy. <b>2018</b> , 40, 158-164	6

1070	Artemisinin and AIEgen Conjugate for Mitochondria-Targeted and Image-Guided Chemo- and Photodynamic Cancer Cell Ablation. <b>2018</b> , 10, 11546-11553	66
1069	Discovery of new A- and B-type laxaphycins with synergistic anticancer activity. <b>2018</b> , 26, 2310-2319	20
1068	CISNE: An accurate description of dose-effect and synergism in combination therapies. <b>2018</b> , 8, 4964	19
1067	Blockade of nuclear factor- $\kappa$ B (NF- $\kappa$ B) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells. <b>2018</b> , 99, 1-9	24
1066	Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine. <b>2018</b> , 15, 4641-4648	3
1065	Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer. <b>2018</b> , 44, 56-64	6
1064	AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. <b>2018</b> , 37, 3275-3289	44
1063	Predictive approaches for drug combination discovery in cancer. <b>2018</b> , 19, 263-276	41
1062	Regulating the Master Regulator: Controlling Ubiquitination by Thinking Outside the Active Site. <b>2018</b> , 61, 405-421	9
1061	Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. <b>2018</b> , 7, 1700432	21
1060	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <b>2018</b> , 32, 139-148	17
1059	Nano-encapsulated metformin-curcumin in PLGA/PEG inhibits synergistically growth and hTERT gene expression in human breast cancer cells. <b>2018</b> , 46, 917-925	64
1058	Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. <b>2018</b> , 119, 1193-1203	10
1057	Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. <b>2018</b> , 17, 204-214	9
1056	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <b>2018</b> , 24, 120-129	54
1055	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. <b>2018</b> , 414, 99-106	38
1054	Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. <b>2018</b> , 24, 234-247	24
1053	An improved model for the analysis of combined antimicrobials: a replacement for the Chou-Talalay combination index method. <b>2018</b> , 124, 97-107	1

1052	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <b>2018</b> , 67, 2142-2155	71
1051	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. <b>2018</b> , 16, 352-363	13
1050	Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3 $\beta$ <b>2018</b> , 17, 232-242	28
1049	An in vitro cytotoxic approach to assess the toxicity of heavy metals and their binary mixtures on hippocampal HT-22 cell line. <b>2018</b> , 282, 25-36	25
1048	Additive Damage Models for Cellular Pharmacodynamics of Radiation-Chemotherapy Combinations. <b>2018</b> , 80, 1236-1258	2
1047	CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance. <b>2018</b> , 36, 10-19	13
1046	(-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells. <b>2018</b> , 45, 58-67	13
1045	Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner. <b>2018</b> , 495, 1233-1239	9
1044	Detecting the Potential Pharmacological Synergy of Drug Combination by Viability Assays In Vitro. <b>2018</b> , 1709, 129-137	3
1043	Naringin sensitizes human prostate cancer cells to paclitaxel therapy. <b>2018</b> , 6, 126-135	32
1042	Ganoderma microsporium immunomodulatory protein induces apoptosis and potentiates mitomycin C-induced apoptosis in urinary bladder urothelial carcinoma cells. <b>2018</b> , 119, 4592-4606	11
1041	Synergistic effects and their potential significance for the influence of natural intensities of environmental factors on cell growth. <b>2018</b> , 6, 1-8	2
1040	Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells. <b>2018</b> , 7, 196-207	17
1039	Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF- $\kappa$ B pathways. <b>2018</b> , 47, 186-194	31
1038	Metformin synergistically enhances antitumor activity of cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway. <b>2018</b> , 70, 439-448	16
1037	Pharmacokinetic assessment of the monepantel plus oxfendazole combined administration in dairy cows. <b>2018</b> , 41, 292-300	2
1036	Altered TNF- $\alpha$ response by Aconibal $\alpha$ and methotrexate in a lipopolysaccharide-induced setting of inflammatory conditions: Potential on a synergistic combination. <b>2018</b> , 213, 191-197	7
1035	Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. <b>2018</b> , 32, e22007	11

1034	Doxorubicin synergism and resistance reversal in human neuroblastoma BE(2)C cell lines: An in vitro study with dextran-catechin nanohybrids. <b>2018</b> , 122, 176-185	20
1033	Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. <b>2018</b> , 119, 3417-3428	8
1032	The anticancer effects of pharmacological inhibition of autophagy in acute erythroid leukemia cells. <b>2018</b> , 29, 944-955	4
1031	Identification of cisplatin sensitizers through high-throughput combinatorial screening. <b>2018</b> , 53, 1237-1246	4
1030	Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. <b>2018</b> , 9, 28456-28473	10
1029	Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. <b>2018</b> , 52, 1246-1254	9
1028	Changes in fish assemblages caused by different Neotropical biomes.. <b>2018</b> , 46, 660-672	1
1027	The Hsp70 co-chaperone Ydj1/HDJ2 regulates ribonucleotide reductase activity. <b>2018</b> , 14, e1007462	16
1026	Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells. <b>2018</b> , 29, 1011-1020	8
1025	Employing Synergistic Interactions of Virtual Reality and Psychedelics in Neuropsychopharmacology. <b>2018</b> ,	1
1024	A Wideband Sleeve Monopole Antenna. <b>2018</b> ,	
1023	Novel 'Stereoscopic Response' Strategy Can Be Used in Combination Therapy. <b>2018</b> , 35, 369-390	2
1022	Discovery of synergistic anti-inflammatory compound combination from herbal formula GuGe FengTong Tablet. <b>2018</b> , 16, 683-692	2
1021	Chk1 inhibition as a novel therapeutic strategy in melanoma. <b>2018</b> , 9, 30450-30464	14
1020	Human nasopharyngeal carcinoma can be radiosensitized by trichosanthin via inhibition of the PI3K pathway. <b>2018</b> , 16, 4181-4186	1
1019	Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. <b>2018</b> , 298, 1181-1194	20
1018	Particle-in-Particle Platform for Nanoconfinement-Induced Oncothermia.. <b>2018</b> , 1, 1927-1941	5
1017	Antiproliferative Activity of Combined Biochanin A and Ginsenoside Rh <sub>12</sub> n MDA-MB-231 and MCF-7 Human Breast Cancer Cells. <b>2018</b> , 23,	18

1016	Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine. <b>2018</b> , 8, 16837	23
1015	Taxifolin Resensitizes Multidrug Resistance Cancer Cells via Uncompetitive Inhibition of P-Glycoprotein Function. <b>2018</b> , 23,	20
1014	Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy. <b>2018</b> , 25, 1932-1942	25
1013	Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer. <b>2018</b> ,	7
1012	Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with / and / gene arrangements and potential molecular targeted therapies. <b>2018</b> , 9, 33482-33499	7
1011	Indocyanine Green-Conjugated Magnetic Prussian Blue Nanoparticles for Synchronous Photothermal/Photodynamic Tumor Therapy. <b>2018</b> , 10, 74	48
1010	Clofotol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways. <b>2018</b> , 10, 4817-4829	5
1009	Combined Cytotoxicity of the Phycotoxin Okadaic Acid and Mycotoxins on Intestinal and Neuroblastoma Human Cell Models. <b>2018</b> , 10,	11
1008	Apoptosis Induction via ATM Phosphorylation, Cell Cycle Arrest, and ER Stress by Goniiothalamine and Chemodrugs Combined Effects on Breast Cancer-Derived MDA-MB-231 Cells. <b>2018</b> , 2018, 7049053	11
1007	Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity. <b>2018</b> , 13, 7771-7787	12
1006	Antiproliferative and cytotoxic activities of furocoumarins of Ducrosia anethifolia. <b>2018</b> , 56, 658-664	14
1005	Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells. <b>2018</b> , 11, 8455-8463	15
1004	Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. <b>2018</b> , 8, 17914	34
1003	Ergosterol peroxide from marine fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells. <b>2018</b> , 8, 17956	38
1002	The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. <b>2018</b> , 9, 27104-27116	26
1001	The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. <b>2018</b> , 53, 844-854	13
1000	NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. <b>2018</b> , 362, 1416-1422	132
999	The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells. <b>2018</b> , 9, 4536-4546	12

998	Oxymatrine Synergistically Potentiates the Antitumor Effects of Cisplatin in Human Gastric Cancer Cells. <b>2018</b> , 9, 4527-4535	7
997	Bio-Guided Fractionation of Papaya Leaf Juice for Delineating the Components Responsible for the Selective Anti-proliferative Effects on Prostate Cancer Cells. <b>2018</b> , 9, 1319	5
996	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. <b>2018</b> , 34, 922-938.e7	31
995	Multifunctional pH-Responsive Sprayable Hydrogel Based on Chitosan and Lignin-Based Nanoparticles. <b>2018</b> , 35, 1800145	14
994	Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. <b>2018</b> , 34, 611-625.e7	36
993	mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. <b>2018</b> , 17, 2676-2688	20
992	Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis. <b>2018</b> , 9, 986	13
991	Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier. <b>2018</b> , 49, 2443-2462	4
990	Novel molecular mechanisms for the adaptogenic effects of herbal extracts on isolated brain cells using systems biology. <b>2018</b> , 50, 257-284	47
989	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <b>2018</b> , 37, 236	24
988	Actinomycin-D and dimethylamino-parthenolide synergism in treating human pancreatic cancer cells. <b>2018</b> , 79, 287-294	10
987	Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. <b>2018</b> , 36, 6761-6771	7
986	Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress. <b>2018</b> , 38, 5615-5626	7
985	Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. <b>2018</b> , 119, 873-884	26
984	Zebrafish, a Novel Model System to Study Uremic Toxins: The Case for the Sulfur Amino Acid Lanthionine. <b>2018</b> , 19,	8
983	Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma. <b>2018</b> , 37, 241	19
982	The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2. <b>2018</b> , 96, 1251-1266	11
981	Opposite Regulation of CHOP and GRP78 and Synergistic Apoptosis Induction by Selenium Yeast and Fish Oil via AMPK Activation in Lung Adenocarcinoma Cells. <b>2018</b> , 10,	4

980	Synergy assessments of plant extracts used in the treatment of stress and aging-related disorders. <b>2018</b> , 7, 39-48	9
979	A human cell panel for evaluating safe application of nano-ZrO/polymer composite in water remediation. <b>2018</b> , 166, 474-481	5
978	A Plug-and-Play, Drug-on-Pillar Platform for Combination Drug Screening Implemented by Microfluidic Adaptive Printing. <b>2018</b> , 90, 13969-13977	14
977	Luteolin inhibits Musashi1 binding to RNA and disrupts cancer phenotypes in glioblastoma cells. <b>2018</b> , 15, 1420-1432	18
976	Vitamin D3 assisted chemo-photodynamic therapy of rhabdomyosarcoma cancer cells for effective treatment. <b>2018</b> , 15, 125602	3
975	Synergistic Inhibitory Effects of Acacetin and 11 Other Flavonoids Isolated from Artemisia sacrorum on Lipid Accumulation in 3T3-L1 Cells. <b>2018</b> , 66, 12931-12940	9
974	Intercalation of Bioactive Molecules into Nanosized ZnAl Hydrotalcites for Combined Chemo and Photo Cancer Treatment. <b>2018</b> , 1, 6387-6397	4
973	Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. <b>2018</b> , 213, 149-157	38
972	Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. <b>2018</b> , 10,	13
971	Synergistic effect of combined protopanaxatol and ginsenoside Rh2 on antiproliferative activity in MDA-MB-231 human breast cancer cells in vitro. <b>2018</b> , 29, 953-963	5
970	Combination of baicalein and docetaxel additively inhibits the growth of non-small cell lung cancer in vivo. <b>2018</b> , 01, 213-218	12
969	Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells. <b>2018</b> , 40, 3223-3234	8
968	Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines. <b>2018</b> , 16,	18
967	Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. <b>2018</b> , 37, 251	34
966	MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma. <b>2018</b> , 9, 4541	35
965	Tumor Starvation Induced Spatiotemporal Control over Chemotherapy for Synergistic Therapy. <b>2018</b> , 14, e1803602	51
964	Unique Photochemo-Immuno-Nanoplatform against Orthotopic Xenograft Oral Cancer and Metastatic Syngeneic Breast Cancer. <b>2018</b> , 18, 7092-7103	44
963	Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines. <b>2018</b> , 19,	10

962	Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. <b>2018</b> , 129, 454-462	163
961	The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells. <b>2018</b> , 358, 43-55	18
960	Comparative study of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 3D (spheroids) cell culture models. <b>2018</b> , 551, 76-83	25
959	Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells. <b>2018</b> , 49, 1615-1632	17
958	Virucidal and Synergistic Activity of Polyphenol-Rich Extracts of Seaweeds against Measles Virus. <b>2018</b> , 10,	28
957	Recent advances in combinatorial drug screening and synergy scoring. <b>2018</b> , 42, 102-110	49
956	Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. <b>2018</b> , 9, 3653	108
955	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. <b>2018</b> , 9, 3815	75
954	The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis. <b>2018</b> , 98, 1600-1613	30
953	Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells. <b>2018</b> , 11, 5121-5132	1
952	Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma. <b>2018</b> , 19,	13
951	The In Vitro Anti-Proliferative Interaction of Flavonoid Quercetin and Toxic Metal Cadmium in the 1321N1 Human Astrocytoma Cell Line. <b>2018</b> , 86,	0
950	Effects of dichloroacetate as single agent or in combination with GW6471 and metformin in paraganglioma cells. <b>2018</b> , 8, 13610	18
949	Terpenoids from Euphorbia pedroi as Multidrug-Resistance Reversers. <b>2018</b> , 81, 2032-2040	22
948	PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. <b>2018</b> , 24, 2643-2657	73
947	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph <sup>+</sup> Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , <b>2018</b> , 78, 5793-5807	10.1 9
946	Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. <b>2018</b> , 156, 322-339	14
945	Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. <b>2018</b> , 9, 874	19

944	Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by and activated. <b>2018</b> , 2, 2478-2490	6
943	Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. <b>2018</b> , 24, 954-960	178
942	Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. <b>2018</b> , 47, 680-693	20
941	Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. <i>Cancer Research</i> , <b>2018</b> , 78, 4360-4369	10.1 31
940	Crosstalk of NF- $\kappa$ B/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment. <b>2018</b> , 47, 759-773	18
939	A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. <b>2018</b> , 9, 572	90
938	hDNA2 nuclease/helicase promotes centromeric DNA replication and genome stability. <b>2018</b> , 37,	21
937	Oxyfadichalcone C inhibits melanoma A375 cell proliferation and metastasis via suppressing PI3K/Akt and MAPK/ERK pathways. <b>2018</b> , 206, 35-44	18
936	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. <b>2018</b> , 22, 3887	7
935	Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity. <b>2018</b> , 138, 1-39	1
934	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. <b>2018</b> , 52, 124-128	13
933	The cisplatin-based Pt(IV)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. <b>2018</b> , 47, 8268-8282	25
932	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. <b>2018</b> , 218, 1249-1260	50
931	A combination of astragaloside I, levestilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo. <b>2018</b> , 39, 1483-1492	13
930	Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions. <b>2018</b> , 8, 8412	8
929	Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model. <b>2018</b> , 144, 1475-1485	10
928	Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. <b>2018</b> , 19, 921-933	7
927	Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles. <b>2018</b> , 6, 1869-1881	27

926	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. <b>2018</b> , 24, 4874-4886	35
925	Curcumin loaded selenium nanoparticles synergize the anticancer potential of doxorubicin contained in self-assembled, cell receptor targeted nanoparticles. <b>2018</b> , 130, 185-199	25
924	Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase. <b>2018</b> , 15, 3260-3271	12
923	Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells. <b>2018</b> , 8, 1289-1299	7
922	Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells and in nude mice by attenuating HER3/Akt pathway activation. <b>2018</b> , 16, 326-334	2
921	CBF $\beta$ /BIMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. <b>2018</b> , 174, 172-186.e21	37
920	Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells. <b>2018</b> , 105, 1335-1343	46
919	An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth. <b>2018</b> , 293, 13696-13706	14
918	Unified D- $\alpha$ -Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy. <b>2018</b> , 13, 1285-1301	3
917	The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. <b>2018</b> , 92, 2649-2664	21
916	Harnessing synthetic lethality to predict the response to cancer treatment. <b>2018</b> , 9, 2546	44
915	Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition. <b>2018</b> , 68, 710-716	24
914	In vivo and in vitro studies of Cry5B and nicotinic acetylcholine receptor agonist anthelmintics reveal a powerful and unique combination therapy against intestinal nematode parasites. <b>2018</b> , 12, e0006506	11
913	Synergy between chemical permeation enhancers and drug permeation across the tympanic membrane. <b>2018</b> , 289, 94-101	11
912	MELK Inhibition in Diffuse Intrinsic Pontine Glioma. <b>2018</b> , 24, 5645-5657	17
911	Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. <b>2018</b> , 17, 2144-2155	17
910	Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies. <b>2018</b> , 38, 3977-3984	2
909	Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase $\beta$ inhibitors. <b>2018</b> , 10, 1769-1786	2

- 908 Dichloroacetic acid (DCA) synergizes with the SIRT2 inhibitor Sirtinol and AGK2 to enhance anti-tumor efficacy in non-small cell lung cancer. **2018**, 19, 835-846 19
- 907 Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult. *Cancer Research*, **2018**, 78, 5548-5560 10.1 32
- 906 Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. **2018**, 40, 479-487 19
- 905 Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. **2018**, 156, 22-31 14
- 904 Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. **2018**, 6, 2527-2540 30
- 903 Synergistic antifungal effect of chitosan-stabilized selenium nanoparticles synthesized by pulsed laser ablation in liquids against biofilms. **2018**, 13, 2697-2708 40
- 902 Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment. **2018**, 182, 35-43 18
- 901 Eatenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species. **2018**, 435, 66-79 25
- 900 Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids. **2017**, 8, 949 23
- 899 DeCoST: A New Approach in Drug Repurposing From Control System Theory. **2018**, 9, 583 13
- 898 Scutellarin Enhances Antitumor Effects and Attenuates the Toxicity of Bleomycin in H22 Ascites Tumor-Bearing Mice. **2018**, 9, 615 18
- 897 Application of Feedback System Control Optimization Technique in Combined Use of Dual Antiplatelet Therapy and Herbal Medicines. **2018**, 9, 491 2
- 896 Codelivery of doxorubicin and sodium tanshinone IIA sulfonate using multicompartimentalized vesosomes to enhance synergism and prevent doxorubicin-induced cardiomyocyte apoptosis. **2018**, 6, 5243-5247 8
- 895 Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcoma. **2018**, 215, 2137-2155 43
- 894 SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1 $\alpha$  axis. **2018**, 37, 170 19
- 893 Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. **2018**, 11, 1777-1785 8
- 892 Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. **2018**, 11, 1147-1154 6
- 891 Evaluation of the PEG Density in the PEGylated Chitosan Nanoparticles as a Drug Carrier for Curcumin and Mitoxantrone. **2018**, 8, 16

890	The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro. <b>2018</b> , 38, 1383-1397	2
889	In-Vitro Activity of Silybin and Related Flavonolignans against and. <b>2018</b> , 23,	6
888	Significance of combination therapy between <i>Euclea crispa</i> (Thunb.) (leaf and stem bark) extracts and standard antibiotics against drug resistant bacteria. <b>2018</b> , 118, 203-208	
887	Novel tertiary sulfonamides as potent anti-cancer agents. <b>2018</b> , 26, 4441-4451	16
886	Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis. <b>2018</b> , 9, 822	16
885	Valproic Acid Combined with Zoledronate Enhance $\gamma$ Cell-Mediated Cytotoxicity against Osteosarcoma Cells the Accumulation of Mevalonate Pathway Intermediates. <b>2018</b> , 9, 377	12
884	A broad-spectrum antibiotic, DCAP, reduces uropathogenic <i>Escherichia coli</i> infection and enhances vorinostat anticancer activity by modulating autophagy. <b>2018</b> , 9, 780	3
883	MDM2- and FLT3-inhibitors in the treatment of -ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. <b>2018</b> , 103, 1862-1872	19
882	Assessing the influence of the genetically modified factor on mixture toxicological interactions in <i>Caenorhabditis elegans</i> : Comparison between wild type and a SOD type. <b>2018</b> , 242, 872-879	9
881	Mixture Concentration-Response Modeling Reveals Antagonistic Effects of Estradiol and Genistein in Combination on Brain Aromatase Gene ( <i>cyp19a1b</i> ) in Zebrafish. <b>2018</b> , 19,	8
880	The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation. <b>2018</b> , 19,	51
879	Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway. <b>2018</b> , 19,	25
878	The Maxi-K (BK) Channel Antagonist Penitrem A as a Novel Breast Cancer-Targeted Therapeutic. <b>2018</b> , 16,	14
877	In Silico and In Vitro Study of the Bromelain-Phytochemical Complex Inhibition of Phospholipase A2 (Pla2). <b>2018</b> , 23,	4
876	Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamine is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein. <b>2018</b> , 39, 1399-1410	4
875	Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. <b>2018</b> , 20, 54	41
874	Combination therapy with protein kinase inhibitor H89 and Tetrandrine elicits enhanced synergistic antitumor efficacy. <b>2018</b> , 37, 114	24
873	Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. <b>2018</b> , 92, 2845-2857	16

872	Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. <b>2018</b> , 8, 10438	9
871	Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. <b>2018</b> , 24, 441-452	43
870	Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. <b>2018</b> , 16, 544-553	8
869	Tumor targeting via EPR: Strategies to enhance patient responses. <b>2018</b> , 130, 17-38	618
868	HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. <b>2018</b> , 370, 519-530	23
867	Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF- $\kappa$ B signaling pathway in multiple myeloma. <b>2018</b> , 104, 1105-1115	14
866	Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment. <b>2018</b> , 12, 7750-7760	31
865	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. <b>2018</b> , 8, 92	356
864	The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. <i>Cancer Research</i> , <b>2018</b> , 78, 5084-5093	10.1 18
863	Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. <b>2018</b> , 68, 1726-1740	39
862	Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. <b>2018</b> , 40, 1010428310773652	
861	Synergistic effects of cisplatin-caffeic acid induces apoptosis in human cervical cancer cells via the mitochondrial pathways. <b>2018</b> , 15, 7397-7402	14
860	A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. <b>2018</b> , 37, 12	12
859	Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis. <b>2018</b> , 9, 506	12
858	Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy. <b>2018</b> , 6, 1818-1833	22
857	The p53 activator overcomes resistance to ALK inhibitors by regulating p53-target selectivity in ALK-driven neuroblastomas. <b>2018</b> , 4, 56	10
856	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. <b>2018</b> , 18, 542	12
855	Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor- $\kappa$ B Activation. <b>2018</b> , 366, 184-193	16

854	Heat shock protein 70 and heat shock protein 90 synergistically increase hepatitis B viral capsid assembly. <b>2018</b> , 503, 2892-2898	15
853	Physiological concentrations of phytosterols enhance the apoptotic effects of 5-fluorouracil in colon cancer cells. <b>2018</b> , 49, 52-60	4
852	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. <b>2018</b> , 50, 1240-1246	94
851	Anti-Parasitic Activities of and against and. <b>2018</b> , 5,	12
850	Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2. <b>2018</b> , 9, 14977-14992	13
849	Small benzothiazole molecule induces apoptosis and prevents metastasis through DNA interaction and c-MYC gene supression in diffuse-type gastric adenocarcinoma cell line. <b>2018</b> , 294, 118-127	6
848	BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <b>2018</b> , 24, 2155-2166	20
847	Primary tumor and pre-metastatic niches co-targeting "peptides-lego" hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment. <b>2018</b> , 6, 2591-2604	32
846	Synergistic toxicity of some sulfonamide mixtures on Daphnia magna. <b>2018</b> , 164, 84-91	13
845	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. <b>2018</b> , 17, 2297-2308	27
844	POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells. <b>2018</b> , 131, 162-169	38
843	Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo. <b>2018</b> , 18, 113	22
842	Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer. <b>2018</b> , 53, 1442-1454	5
841	Searching Synergistic Dose Combinations for Anticancer Drugs. <b>2018</b> , 9, 535	16
840	Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. <b>2018</b> , 30, e1802368	100
839	Promising synergistic activity of fluconazole with bioactive Guttiferone-A and derivatives against non-albicans Candida species. <b>2018</b> , 28, 645-650	4
838	High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen. <b>2018</b> , 23, 751-760	1
837	Codelivery of Paclitaxel and Everolimus at the Optimal Synergistic Ratio: A Promising Solution for the Treatment of Breast Cancer. <b>2018</b> , 15, 3672-3681	18

836	Statins enhance efficacy of venetoclax in blood cancers. <b>2018</b> , 10,	39
835	AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. <b>2018</b> , 17, 1833-1845	26
834	ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells. <b>2018</b> , 432, 191-204	16
833	Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. <b>2018</b> , 13, e0190653	9
832	Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. <b>2018</b> , 13, e0190854	27
831	The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. <b>2018</b> , 432, 56-68	28
830	Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells. <b>2018</b> , 103, 1472-1483	39
829	Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatform: A dual cell therapy to regress plaques. <b>2018</b> , 283, 241-260	35
828	Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells. <b>2018</b> , 94, 907-916	7
827	Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells. <b>2018</b> , 41, 1194-1202	16
826	The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance. <b>2018</b> , 17, 2004-2012	52
825	Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells. <b>2018</b> , 38, 3493-3500	15
824	Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. <b>2018</b> , 14, e1006192	14
823	A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells. <b>2018</b> , 57, 1383-1395	15
822	Drug combination studies of curcumin and genistein against rhodesain of. <b>2019</b> , 33, 3577-3581	7
821	Epigallocatechin gallate in combination with eugenol or amarogentin shows synergistic chemotherapeutic potential in cervical cancer cell line. <b>2018</b> , 234, 825-836	22
820	Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model. <b>2019</b> , 37, 431-440	6
819	Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. <b>2019</b> , 47, 1295-1311	37

818	Combination treatment of cancer cells with pan-Akt and pan-mTOR inhibitors: effects on cell cycle distribution, p-Akt expression level and radiolabelled-choline incorporation. <b>2019</b> , 37, 424-430	7
817	Methionine gamma lyase from <i>Clostridium sporogenes</i> increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts. <b>2019</b> , 37, 201-209	6
816	Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. <b>2019</b> , 55, 269-281	36
815	Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells. <b>2019</b> , 55, 23-30	27
814	Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells. <b>2019</b> , 234, 2851-2865	6
813	Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment. <b>2019</b> , 29, 153-162	28
812	IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. <b>2019</b> , 105, 84-91	18
811	Identification of the First Synthetic Allosteric Modulator of the CB Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. <b>2019</b> , 62, 276-287	28
810	PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. <b>2019</b> , 38, 6662-6677	33
809	Redox-Responsive Polymeric Nanocomplex for Delivery of Cytotoxic Protein and Chemotherapeutics. <b>2019</b> , 11, 31638-31648	27
808	A STAT3-based gene signature stratifies glioma patients for targeted therapy. <b>2019</b> , 10, 3601	38
807	CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition. <b>2019</b> , 2019, 6486173	7
806	The synergistic antitumor effect of Huaier combined with 5-Fluorouracil in human cholangiocarcinoma cells. <b>2019</b> , 19, 203	13
805	CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263. <b>2019</b> , 10, 602	23
804	Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib by altering cell bioenergetics. <b>2019</b> , 16, 247-263	12
803	Sesquiterpenes $\beta$ -humulene and $\beta$ -caryophyllene oxide enhance the efficacy of 5-fluorouracil and oxaliplatin in colon cancer cells. <b>2019</b> , 69, 121-128	22
802	Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data. <b>2019</b> , 7, 509	44
801	Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. <b>2019</b> , 10, 3716	11

800	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <b>2019</b> , 36, 194-209.e9	92
799	FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. <b>2019</b> , 38, 6737-6751	19
798	SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC. <b>2019</b> , 9, 586	4
797	Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. <b>2019</b> , 40, 1351-1363	11
796	Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. <b>2019</b> , 63, 109381	10
795	Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. <b>2019</b> , 14, 26	9
794	Boronic-targeted albumin-shell oily-core nanocapsules for synergistic aromatase inhibitor/herbal breast cancer therapy. <b>2019</b> , 105, 110099	14
793	Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma and. <b>2019</b> , 10, 864	8
792	HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. <b>2019</b> , 8, 45	24
791	Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics. <b>2019</b> , 20, 3126-3141	17
790	Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy. <b>2019</b> , 1, vdz004	2
789	Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo. <b>2019</b> , 19, 689	10
788	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. <b>2019</b> , 121, 332-339	11
787	Systems Pharmacology for Investigation of the Mechanisms of Action of Traditional Chinese Medicine in Drug Discovery. <b>2019</b> , 10, 743	61
786	Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. <b>2019</b> , 18, 411-419	10
785	Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. <b>2019</b> , 461, 31-43	5
784	Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. <b>2019</b> , 10, 3068	94
783	Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. <b>2019</b> , 461, 102-111	23

- 782 Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin. **2019**, 63, 153000 15
- 781 Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia. **2019**, 12, 1221-1228 9
- 780 Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death. **2019**, 9, 9632 7
- 779 Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells. **2019**, 58, 1594-1602 3
- 778 Ultrastructural Changes and Antitumor Effects of Doxorubicin/Thymoquinone-Loaded CaCO Nanoparticles on Breast Cancer Cell Line. **2019**, 9, 599 21
- 777 Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme. **2019**, 79, 261-273 23
- 776 Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer. **2019**, 14, 465-477 2
- 775 The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2receptor subtype.
- 774 A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment.
- 773 Synergistic Combination of Sulforaphane and Methylseleninic Acid in Inhibiting the Proliferation of MCF-7 Breast Cancer Cells. **2019**, 16, 35-39
- 772 High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma.
- 771 Targeting the Src pathway enhances the efficacy of selective FGFR inhibitors in cancers with FGFR3 alterations.
- 770 WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
- 769 Genetic and reproductive toxicity of lamivudine, tenofovir disoproxil fumarate, efavirenz and their combination in the bone marrow and testicular cells of male mice. **2020**, 5, 1-10 0
- 768 Hesperetin alleviates doxorubicin-induced migration in 4T1 breast cancer cells. **2020**, 6, 1
- 767 Molecular mechanism of gossypol mediating CCL2 and IL-8 attenuation in triple-negative breast cancer cells. **2020**, 22, 1213-1226 0
- 766 Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the sensitivity of hepatocellular carcinoma cells to oxaliplatin via metabolic reprogramming. **2020**, 57, 733-742 1
- 765 THE INVESTIGATION OF ANTIPROLIFERATIVE EFFECTS OF QUERCETIN, CURCUMIN AND THEIR COMBINATIONS ON BREAST CANCER CELL LINES. 424-436

764	Computer simulation on polymer micelles combined administration of gambogic acid and curcumin as a novel anti-cancer drug carrier.	
763	Curcumin and Radiotherapy Exert Synergistic Anti-Glioma Effect In Vitro. <b>2021</b> , 9,	5
762	ZnL-BPs Integrated Bone Scaffold under Sequential Photothermal Mediation: A Win-Win Strategy Delivering Antibacterial Therapy and Fostering Osteogenesis Thereafter. <b>2021</b> ,	20
761	Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. <b>2021</b> , 12, 1028	12
760	Dietary polyphenol oleuropein and its metabolite hydroxytyrosol are moderate skin permeable elastase and collagenase inhibitors with synergistic cellular antioxidant effects in human skin fibroblasts. <b>2021</b> , 1-11	0
759	LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. <b>2021</b> , 4, 1235	1
758	A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer. <b>2021</b> , 584, 7-14	0
757	Chemical mixtures: toxicologic interactions and risk assessment. <b>2020</b> , 401-414	
756	Trends in Phase II trials for cancer therapies.	
755	Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in -altered Prostate Tumors. <b>2021</b> , 27, 1792-1806	6
754	Repressing MYC by targeting BET synergizes with selective inhibition of PI3K against B cell lymphoma. <b>2022</b> , 524, 206-218	1
753	A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. <b>2021</b> , 15, 101260	0
752	Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance.. <b>2020</b> , 3, 302-333	1
751	Epigenetic regulation of protein translation in KMT2A-rearranged AML.	
750	An ATF peptide-functionalized Elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment. <b>2020</b> , 17, 676-692	4
749	Combination Cancer Chemoprevention by Targeting the Epigenome. <b>2020</b> , 577-612	
748	Evaluation of the Synergism Mechanism of Tamoxifen and Docetaxel by Nanoparticles. <b>2019</b> , 19, 1991-2000	
747	Everolimus improves the efficacy of dasatinib in PDGFR-driven glioma.	

746	Effect of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2. <b>2020</b> , 43, 1491-1502	1
745	Investigating Potential Drug Repurposing for Triple Negative Breast Cancer. <b>2020</b> , 15, 242-252	
744	Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells. <b>2020</b> , 12,	0
743	In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors. <b>2020</b> , 20, 295-305	1
742	Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma. <b>2021</b> , 1	0
741	Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. <b>2021</b> , 526, 180-192	1
740	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma. <b>2021</b> , 1	0
739	MMP9-Sensitive PEG-Shedding Nanoliposomes for Targeted Codelivery of Erlotinib and Doxorubicin to MDA-MB-231 Cells.	0
738	Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma. <b>2021</b> , 12, 1048	0
737	Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. <b>2022</b> , 47,	0
736	Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells. <b>2021</b> , 1	0
735	The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. <b>2021</b> ,	0
734	WSG, a glucose-enriched polysaccharide from Ganoderma lucidum, suppresses tongue cancer cells via inhibition of EGFR-mediated signaling and potentiates cisplatin-induced apoptosis. <b>2021</b> , 193, 1201-1201	1
733	Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines. <b>2021</b> , 22,	1
732	ERK5 Inhibition Induces Autophagy-Mediated Cancer Cell Death by Activating ER Stress. <b>2021</b> , 9, 742049	2
731	Photochemical Internalization of Etoposide Using Dendrimer Nanospheres Loaded with Etoposide and Protoporphyrin IX on a Glioblastoma Cell Line. <b>2021</b> , 13,	0
730	FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells. <b>2021</b> , 10,	1
729	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. <b>2021</b> ,	4

728	Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis. <b>2021</b> , 26, 639-656	2
727	Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress-mediated apoptosis and G2/M phase arrest. <b>2020</b> , 44, 1605-1615	3
726	Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. <b>2020</b> , 57, 939-955	1
725	Inactivation of AKT/NF- $\kappa$ B signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin. <b>2020</b> , 44, 1441-1454	2
724	Dynamic multi-OMICS of glioblastoma reveal sensitivity to neddylation inhibition dependent on nuclear PTEN and DNA replication pathways: Nuclear PTEN mediates MLN4924 sensitivity in GBM.	
723	Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance.	0
722	Vulnerability of ARID1A deficient cancer cells to pyrimidine synthesis blockade.	
721	Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma Using Autophagy Inhibition, MEK blockade and CD40 Agonism.	
720	Reanalysis of in vivo drug synergy validation study rules out synergy in most cases.	
719	Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.	0
718	Design, Synthesis, and Biological Evaluation of 4-amino Substituted 2Hchromen- 2-one Derivatives as an NEDD8 Activating Enzyme Inhibitor in Pancreatic Cancer Cells. <b>2020</b> , 16, 969-983	
717	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. <b>2011</b> , 1, 925-54	20
716	Differential cytotoxicity of triphala and its phenolic constituent gallic acid on human prostate cancer LNCap and normal cells. <b>2011</b> , 31, 3739-45	19
715	Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers. <b>2015</b> , 5, 1337-52	8
714	Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. <b>2010</b> , 30, 4573-8	10
713	Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor. <b>2016</b> , 80, 21-31	7
712	Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. <b>2015</b> , 35, 6419-24	5
711	Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. <b>2016</b> , 6, 97-104	49

710	Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment. <b>2016</b> , 6, 937-56	9
709	Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. <b>2016</b> , 19, 890-898	33
708	Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. <b>2016</b> , 6, 2816-2830	27
707	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. <b>2017</b> , 7, 473-483	22
706	Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. <b>2017</b> , 7, 2503-2514	12
705	Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes. <b>2017</b> , 9, 5631-5642	6
704	[Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells]. <b>2016</b> , 19, 805-812	
703	[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. <b>2012</b> , 15, 127-38	0
702	[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation and Apoptosis of Lung Adenocarcinoma Cell H1975]. <b>2015</b> , 18, 599-609	
701	Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies. <b>2018</b> , 8, 2064-2075	4
700	Synergistic Action of 1,2-Epoxy-3 (3- (3,4-dimethoxyphenyl)- 4H-1-benzopyran-4-on) Propane with Doxorubicin and Cisplatin through Increasing of p53, TIMP-3, and MicroRNA-34a in Cervical Cancer Cell Line (HeLa). <b>2018</b> , 19, 2955-2962	3
699	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. <b>2019</b> , 9, 390-405	7
698	Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma. <b>2019</b> , 81, 93-102	6
697	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. <b>2019</b> , 9, 608-618	12
696	Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma. <b>2019</b> , 9, 546-561	6
695	The potential of brentuximab vedotin, alone or in combination with current clinical therapies, in the treatment of testicular germ cell tumors. <b>2019</b> , 9, 855-871	1
694	Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor. <b>2019</b> , 9, 1282-1292	8
693	Triptolide enhances the sensitivity of pancreatic cancer PANC-1 cells to gemcitabine by inhibiting TLR4/NF- $\kappa$ B signaling. <b>2019</b> , 11, 3750-3760	7

- 692 Stimulatory Effect of Indolic Hormone on AsO Cytotoxicity in Breast Cancer Cells: NF- $\kappa$ B-dependent Mechanism of Action of Melatonin. **2018**, 7, 158-168 1
- 691 Current Methods for Quantifying Drug Synergism. **2019**, 1, 43-48 2
- 690 Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. **2020**, 93, 111-121 12
- 689 Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation. **2020**, 12, 847-856 1
- 688 Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER $\alpha$  expression in high-grade serous ovarian carcinoma. **2020**, 10, 1194-1206 3
- 687 [Effect of CPT combined with melphalan on proliferation of human multiple myeloma cells RPMI8226 and its mechanism]. **2019**, 40, 432-435
- 686 ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia. **2020**, 4, 3154-3168 2
- 685 Smart drug combinations for cervical cancer: dual targeting of Bcl-2 family of proteins and aurora kinases. **2020**, 10, 3406-3414 1
- 684 TAS-102 has a tumoricidal activity in multiple myeloma. **2020**, 10, 3752-3764
- 683 The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition. **2020**, 12, 8084-8098 4
- 682 Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition in human colon cancer cell line LS174T. **2021**, 11, 2252-2263 1
- 681 Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment. **2021**, 2 2
- 680 Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor. **2021**, 228, 114012 3
- 679 BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy. **2021**, 15, 101272 2
- 678 Antioxidant interactions between hydrophilic and lipophilic phytochemicals are influenced by their ratios and total concentrations. **2022**, 45, 101465 1
- 677 (Tryptophan) Amphiphiles Form Ion Conducting Pores and Enhance Antimicrobial Activity against Resistant Bacteria. **2021**, 10, 1
- 676 Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G/M cell cycle arrest and apoptosis. **2022**, 23, 16 3
- 675 Mixtures of Scutellaria baicalensis and Glycyrrhiza L. Extracts as Antibacterial and Antiviral Agents in Active Coatings. **2021**, 11, 1438 4

674	Natural-product-inspired design and synthesis of two series of compounds active against <i>Trypanosoma cruzi</i> : Insights into structure-activity relationship, toxicity, and mechanism of action. <b>2021</b> , 119, 105492	0
673	Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. <b>2021</b> , 195, 114864	0
672	A Combination Approach in Inhibiting Type 2 Diabetes-Related Enzymes Using Fucoidan and Acarbose. <b>2021</b> , 13,	1
671	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.. <b>2021</b> , 2, 1204-1223	8
670	A Patient-Derived Xenograft Model of Dedifferentiated Endometrial Carcinoma: A Proof-of-Concept Study for the Identification of New Molecularly Informed Treatment Approaches. <b>2021</b> , 13,	0
669	Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1.. <b>2021</b> , 24, 103528	0
668	-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC. <b>2021</b> , 26,	2
667	Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. <b>2021</b> , 40, 373	2
666	Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model.. <b>2021</b> , 9,	3
665	Valproic Acid Prodrug Affects Selective Markers, Augments Doxorubicin Anticancer Activity and Attenuates Its Toxicity in a Murine Model of Aggressive Breast Cancer.. <b>2021</b> , 14,	
664	Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs. <b>2021</b> , 21, 1201	1
663	CHK1 inhibition exacerbates replication stress induced by IGF blockade. <b>2021</b> ,	0
662	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <b>2021</b> , 40, 364	3
661	FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis. <b>2021</b> ,	1
660	Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma. <b>2021</b> , 40, 381	2
659	Dissolution of Biofilm Secreted by Three Different Strains of <i>Pseudomonas aeruginosa</i> with Bromelain, N-Acetylcysteine, and Their Combinations. <b>2021</b> , 11, 11388	0
658	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. <b>2021</b> , 144, 112330	0
657	Synergistic Anticancer Effect of a Combination of Chidamide and Etoposide Against NK/T Cell Lymphoma. <b>2021</b> ,	0

656	In vitro anticancer activity and oxidative molecular damage by cannabidiol administered alone and in combination with epirubicin. <b>2021</b> , 35, 1613-1622	0
655	Exploring the potential of site-specific co-delivery of Berberine alongside 5-fluorouracil in oral cancer: Formulation development, in-vitro apoptosis, ex-vivo permeability and in-vivo biocompatibility studies. <b>2022</b> , 68, 103105	0
654	Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells.. <b>2021</b> , 16, 101313	2
653	A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.. <b>2021</b> , 290, 120236	
652	Inhibition of the endosomal recycling pathway downregulates HER2 activation and overcomes resistance to tyrosine kinase inhibitors in HER2-positive breast cancer.. <b>2022</b> , 529, 153-167	1
651	All-in-one hollow nanoformulations enabled imaging-guided Mn-amplified chemophototherapy against hepatocellular carcinoma. <b>2022</b> , 43, 101382	0
650	Synergistic Effects of 5-Fluorouracil in Combination with Diosmetin in Colorectal Cancer Cells. <b>2021</b> , 7, 6	0
649	Prediction of the impact induced by Cd in binary interactions with other divalent metals on wild-type and Cd-resistant strains of <i>Dictyosphaerium chlorelloides</i> . <b>2021</b> ,	0
648	GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.. <b>2022</b> , 14,	0
647	Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy.. <b>2022</b> , 12, 1800-1815	4
646	Identification of ZER6 Isoform p52-ZER6 as an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding Inhibitors.	
645	Isoalantolactone Enhances the Antitumor Activity of Doxorubicin by Inducing Reactive Oxygen Species and DNA Damage.. <b>2022</b> , 12, 813854	
644	Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.. <b>2022</b> , 14,	0
643	Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.. <b>2022</b> , 12,	3
642	SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets.. <b>2022</b> ,	14
641	Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.. <b>2022</b> , 1-14	
640	Enhanced photothermal heating and combination therapy of NIR dye conversion to self-assembled ionic nanomaterials.. <b>2022</b> ,	1
639	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.. <b>2022</b> , 8, 39	1

638	Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC $\delta$ .. <b>2022</b> ,	0
637	Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis.. <b>2022</b> , 19, 233-241	
636	Turning the tide on Alzheimer's disease: modulation of $\beta$ -secretase.. <b>2022</b> , 12, 2	3
635	The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.. <b>2022</b> , 14,	1
634	Independent Drug Action in Combination Therapy: Implications for Precision Oncology.. <b>2022</b> ,	5
633	S-Adenosylmethionine enhances the inhibitory effect of gemcitabine against pancreatic cancer cells via suppression of the EGFR/AKT pathways. 1	
632	The Anti-Proliferative Effect of PI3K/mTOR and ERK Inhibition in Monolayer and Three-Dimensional Ovarian Cancer Cell Models.. <b>2022</b> , 14,	2
631	Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma. <b>2021</b> , 915, 174688	
630	Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.. <b>2022</b> , 29, 342-350	6
629	Triple combination of BET plus PI3K and NF- $\kappa$ B inhibitors exhibit synergistic activity in adult T cell leukemia/lymphoma.. <b>2022</b> ,	1
628	Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes.. <b>2022</b> , 39, 35	1
627	Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.. <b>2022</b> , 15,	0
626	Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma.. <b>2021</b> , 11, 773186	2
625	A comparison of different regression models for the quantitative analysis of the combined effect of P2Y and P2Y receptor antagonists on ADP-induced platelet activation.. <b>2022</b> , 211, 88-97	0
624	Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.. <b>2022</b> , 14,	0
623	Managing GSH elevation and hypoxia to overcome resistance of cancer therapies using functionalized nanocarriers. <b>2022</b> , 67, 103022	0
622	The Effects of Polyphenol, Tannic Acid, or Tannic Acid in Combination with Pamidronate on Human Osteoblast Cell Line Metabolism.. <b>2022</b> , 27,	0
621	PRODeepSyn: predicting anticancer synergistic drug combinations by embedding cell lines with protein-protein interaction network.. <b>2022</b> ,	0

- 620 Caffeic acid phenethyl ester induces radiosensitization via inhibition of DNA damage repair in androgen-independent prostate cancer cells.. **2022**, 0
- 619 Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil.. **2022**, 115887 2
- 618 Piperlongumine induces ROS mediated apoptosis by transcriptional regulation of SMAD4/P21/P53 genes and synergizes with doxorubicin in osteosarcoma cells.. **2022**, 109832 0
- 617 Combination of ruthenium (II) polypyridyl complex [Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.. **2022**, 230, 111749 3
- 616 Cannabis with breast cancer treatment: propitious or pernicious?. **2022**, 12, 54 0
- 615 Oleanolic Acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma.. **2022**, 121479 2
- 614 Nitazoxanide and related thiazolides induce cell death in cancer cells by targeting the 20S proteasome with novel binding modes.. **2022**, 114913 0
- 613 Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma.. **2022**, 147, 112661 0
- 612 Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.. **2022**, 120, 105604 1
- 611 Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.. **2022**, 62, 1-9 0
- 610 Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.. **2022**, 18, 101354 1
- 609 Exploring synergy and its role in antimicrobial peptide biology.. **2022**, 663, 99-130 2
- 608 Biocatalytic and chemical derivatization of fungal meroditerpenoid chevalone E. 0
- 607 Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis.. **2022**, 2022, 2619781 0
- 606 Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.. **2022**, 23, 2
- 605 DNA damage-induced translocation of mitochondrial factor HIGD1A into the nucleus regulates homologous recombination and radio/chemo-sensitivity.. **2022**, 1
- 604 Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals.. **2022**, 103, 0
- 603 Synergistic apoptotic effect of Mcl-1 inhibition and doxorubicin on B-cell precursor acute lymphoblastic leukemia cells.. **2022**, 49, 2025 0

602	Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells. <b>2022,</b>	
601	: phytochemistry and pharmacological potential of a gifted species.. <b>2022,</b> 1-30	0
600	pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Tumorigenesis Breast Cancer.. <b>2022,</b>	4
599	Piperlongumine, a piper alkaloid, enhances the efficacy of doxorubicin in breast cancer: involvement of glucose import, ROS, NF- $\kappa$ B and lncRNAs.. <b>2022,</b> 27, 261	0
598	Effects of the combination of some essential oils with methylparaben and sodium metabisulfite against pathogenic foodborne bacteria.	
597	Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.. <b>2022,</b> 438, 115911	0
596	Blockade of Nuclear Factor- $\kappa$ B (NF- $\kappa$ B) Pathway Using Bay 11-7082 Enhances Arsenic Trioxide-Induced Antiproliferative Activity in U87 Glioblastoma Cells.. <b>2022,</b> 10, 602-613	
595	Borneol and Tetrandrine Modulate the Blood-Brain Barrier and Blood-Tumor Barrier to Improve the Therapeutic Efficacy of 5-Fluorouracil in Brain Metastasis.. <b>2022,</b> 21, 15347354221077682	0
594	Camel Milk plus Atorvastatin Influence Lipid Profile and Body Weight in Hyperlipidemic Rats. <b>2022,</b> 22, 22-32	
593	Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.. <b>2022,</b> 23,	1
592	Honeybee Venom Synergistically Enhances the Cytotoxic Effect of CNS Drugs in HT-29 Colon and MCF-7 Breast Cancer Cell Lines.. <b>2022,</b> 14,	0
591	Polyherbal effect between Phyllanthus urinaria and Curcuma longa as an Anticancer and Antioxidant. <b>2022,</b> 671-678	
590	Diosmetin Exerts Synergistic Effects in Combination with 5-Fluorouracil in Colorectal Cancer Cells.. <b>2022,</b> 10,	1
589	A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer's Disease.. <b>2022,</b> 14, 780602	3
588	Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.. <b>2022,</b>	1
587	Treatment of Human Glioblastoma U251 Cells with Sulforaphane and a Peptide Nucleic Acid (PNA) Targeting miR-15b-5p: Synergistic Effects on Induction of Apoptosis.. <b>2022,</b> 27,	4
586	Inhibitory Effect of Extract and Its Active Components on Cervical Intraepithelial Neoplastic Cells.. <b>2022,</b> 27,	0
585	Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma.. <b>2022,</b> 14,	1

- 584 Combination Effects of Abelmoschus manihot (L.) Medik of N-Hexane extracts and Doxorubicin in Breast cancer 4T1 Cells Line. **2022**, 639-642
- 583 The central role of a two-way positive feedback pathway in molecular targeted therapies-mediated pyroptosis in anaplastic thyroid cancer.. **2022**, 12, e727 ○
- 582 SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.. **2022**, 41, 75 ○
- 581 Interaction Tolerance Detection Test for Understanding the Killing Efficacy of Directional Antibiotic Combinations.. **2022**, e0000422 ○
- 580 Hsp90 inhibition sensitizes DLBCL cells to cisplatin.. **2022**, 89, 431 1
- 579 Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.. **2022**, 1
- 578 Isoprenylcysteine carboxyl methyltransferase is critical for glioblastoma growth and survival by activating Ras/Raf/Mek/Erk.. **2022**, 89, 401
- 577 Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines.. **2022**, 13, 837503 ○
- 576 Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.. **2022**, 89, 469 ○
- 575 A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.. **2022**, 1
- 574 Potential Synthetic Lethality for Breast Cancer: A Selective Sirtuin 2 Inhibitor Combined with a Multiple Kinase Inhibitor Sorafenib.. **2021**, 106050 ○
- 573 RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.. **2022**, 1
- 572 The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.. **2022**, 23,
- 571 Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.. **2022**, 1 1
- 570 SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.. **2022**, 1
- 569 Targeted Codelivery of Prodigiosin and Simvastatin Using Smart BioMOF: Functionalization by Recombinant Anti-VEGFR1 scFv.. **2022**, 10, 866275 ○
- 568 OBIF: an omics-based interaction framework to reveal molecular drivers of synergy.. **2022**, 4, lqac028 ○
- 567 Triterpenes From as Cytotoxic Agents and Chemosensitizers to Overcome Multidrug Resistance of Cancer Cells.. **2022**, ○

566	A machine learning framework for predicting synergistic and antagonistic drug combinatorial efficacy. <b>2022</b> , 60, 752-769	
565	Inhibitory Mechanism of Combined Hydroxychavicol With Epigallocatechin-3-Gallate Against Glioma Cancer Cell Lines: A Transcriptomic Analysis.. <b>2022</b> , 13, 844199	1
564	Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.. <b>2022</b> , 13, 1673	0
563	Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases.. <b>2022</b> , 60, 700-707	0
562	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.. <b>2022</b> , 185, 995-1007.e18	7
561	Identification of Guaifenesin-Andrographolide as a Novel Combinatorial Drug Therapy for Epilepsy Using Network Virtual Screening and Experimental Validation.. <b>2022</b> ,	
560	Ubiquitin-specific protease 1 inhibition sensitizes hepatocellular carcinoma cells to doxorubicin by ubiquitinated proliferating cell nuclear antigen-mediated attenuation of stemness.. <b>2022</b> ,	
559	Next Generation of Cancer Drug Repurposing: Therapeutic Combination of Aspirin and Oseltamivir Phosphate Potentiates Gemcitabine to Disable Key Survival Pathways Critical for Pancreatic Cancer Progression.. <b>2022</b> , 14,	2
558	Metformin and ICG-001 Act Synergistically to Abrogate Cancer Stem Cells-Mediated Chemoresistance in Colorectal Cancer by Promoting Apoptosis and Autophagy.. <b>2022</b> , 14,	1
557	Unique Phenanthrenes from and Their Antiproliferative and Synergistic Effects with the Conventional Anticancer Agent Doxorubicin against Human Cancer Cell Lines.. <b>2022</b> , 14,	1
556	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.. <b>2022</b> , 12, 39	1
555	GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling.. <b>2022</b> ,	0
554	Comparative Study on Synergistic Toxicity of Enrofloxacin Combined with Three Antibiotics on Proliferation of THLE-2 Cell.. <b>2022</b> , 11,	0
553	Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.. <b>2022</b> ,	0
552	Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication.. <b>2022</b> ,	0
551	Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.. <b>2022</b> , 11,	0
550	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication and Decreases Viral Titers and Disease Progression in Syrian Hamsters.. <b>2022</b> , e0370521	1
549	In silico drug repositioning based on integrated drug targets and canonical correlation analysis.. <b>2022</b> , 15, 48	0

- 548 Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.. **2022**, 23, 310-318 0
- 547 Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.. **2022**, 14, eabc7480 1
- 546 All-in-one theranostic nano-platform based on polymer nanoparticles for BRET/FRET-initiated bioluminescence imaging and synergistically anti-inflammatory therapy for ulcerative colitis.. **2022**, 20, 99 2
- 545 Synergistic effect of compounds directed to triosephosphate isomerase, a combination to develop drug against trichomoniasis.. **2022**, e2200046
- 544 Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.. **2022**, 119, e2100670119 1
- 543 Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells.. **2022**, 8, e09103 2
- 542 Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.. **2022**, 440, 115951 0
- 541 Cyclin-dependent kinase inhibitor fadradiclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.. **2022**, 2
- 540 The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.. **2022**, 198, 114948 1
- 539 GANT61 elevates chemosensitivity to cisplatin through regulating the Hedgehog, AMPK and cAMP pathways in ovarian cancer.. **2022**, 14, 479-500 0
- 538 The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects.. **2022**, 2022, 2800488
- 537 Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells.. **2022**, 115989 2
- 536 Metabolomics-based phenotypic screens for evaluation of drug synergy via direct-infusion mass spectrometry.. **2022**, 25, 104221 0
- 535 Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.. **2022**, 116739 1
- 534 Ferroptosis plays an essential role in the antimalarial mechanism of low-dose dihydroartemisinin.. **2022**, 148, 112742 0
- 533 SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.. **2022**, 13, 841308 0
- 532 Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile.. **2022**, 1 0
- 531 Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM and CD90 Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.. **2022**, 14, 1

530	Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance.. <b>2022</b> , 12, 860339	1
529	Identification of serum and glucocorticoid-regulated kinase 1 as a regulator of signal transducer and activator of transcription 3 signaling.. <b>2022</b> , 413, 113079	0
528	Co-administration of tariquidar using functionalized nanostructured lipid carriers overcomes resistance to docetaxel in multidrug resistant MCF7/ADR cells. <b>2022</b> , 103323	1
527	Topical fixed-dose combinations: Current in vitro methodologies for pre-clinical development.. <b>2022</b> , 617, 121621	0
526	Single cell mass spectrometry analysis of drug-resistant cancer cells: Metabolomics studies of synergetic effect of combinational treatment.. <b>2022</b> , 1201, 339621	1
525	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.. <b>2022</b> , 51, 102268	1
524	Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer.. <b>2022</b> , 149, 112844	2
523	Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux.. <b>2022</b> , 115024	0
522	Dual-cell culture system with identical culture environment for comparison of anti-cancer drug toxicity. <b>2022</b> , 253, 117555	0
521	Interactions between liposoluble antioxidants: A critical review.. <b>2022</b> , 155, 111104	0
520	Transcriptomics, molecular docking, and cross-resistance profiling of nobiletin in cancer cells and synergistic interaction with doxorubicin upon SOX5 transfection.. <b>2022</b> , 100, 154064	
519	AR independent anticancer potential of enza against prostate cancer. <b>2022</b> , 642, 128598	
518	Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types.. <b>2022</b> , 215665	1
517	Anti-cancer activity of sustained release capsaicin formulations.. <b>2022</b> , 238, 108177	5
516	Biochemical and Cellular Characterization of New Radio-Resistant Cell Lines Reveals a Role of Natural Flavonoids to Bypass Senescence.. <b>2021</b> , 23,	0
515	ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models.. <b>2021</b> , 14,	0
514	Bixin and fucoxanthin sensitize human lung cancer and cervical cancer cell to cisplatin in vitro.. <b>2021</b> , 14, 454	2
513	Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells.. <b>2022</b> , 60, 100-117	4

512	Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs.. <b>2021</b> , 11,	6
511	Targeting the ER/HER Oncogenic Network in Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy.. <b>2021</b> , 23,	0
510	Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures.. <b>2021</b> , 13, 189	5
509	Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma.	0
508	YAP1 Is a Potential Predictive Molecular Biomarker for Response to SMO Inhibitor in Medulloblastoma Cells.. <b>2021</b> , 13,	
507	Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect. <b>2021</b> , 38, 2091	1
506	Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.. <b>2021</b> , 118,	0
505	Characterization of a recently synthesized microtubule-targeting compound that disrupts mitotic spindle poles in human cells. <b>2021</b> , 11, 23665	2
504	Heat shock factor 1 suppression induces spindle abnormalities and sensitizes cells to antimitotic drugs.. <b>2021</b> , 16, 8	
503	Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking.. <b>2021</b> , 14,	4
502	WSG, a Glucose-Rich Polysaccharide from , Combined with Cisplatin Potentiates Inhibition of Lung Cancer and .. <b>2021</b> , 13,	1
501	The RNA-Binding Protein Musashi1 Regulates a Network of Cell Cycle Genes in Group 4 Medulloblastoma.. <b>2021</b> , 11,	0
500	Reduction of breast tumor drug resistance by 2,3,5,4'-tetrahydroxystilbene for exhibition synergic chemotherapeutic effect. <b>2021</b> , 16, e0260533	
499	Glaucoalyxin B Attenuates Ovarian Cancer Cell Growth and Cisplatin Resistance In Vitro via Activating Oxidative Stress.. <b>2022</b> , 2022, 6324292	1
498	Apoptotic and DNA Damage Effect of 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose in Cisplatin-Resistant Non-Small Lung Cancer Cells via Phosphorylation of HAX, CHK2 and p53.. <b>2022</b> , 11,	0
497	Quantitative Estimation of Synergistic Toxicity of Cu and Zn on Growth of by Isobolographic Method.. <b>2022</b> , 10,	0
496	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.. <b>2022</b> , 89, 683	1
495	SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations.	0

494 Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer.. **2022**, 12, 870636

1

493 Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.. **2022**, 58,

492 Table\_1.DOCX. **2019**,

491 Table\_1.DOCX. **2019**,

490 Data\_Sheet\_1.docx. **2019**,

489 Table\_4.xlsx. **2019**,

488 Image\_1.tif. **2018**,

487 Image\_2.tif. **2018**,

486 Table\_1.xls. **2018**,

485 Data\_Sheet\_1.PDF. **2020**,

484 Data\_Sheet\_1.docx. **2020**,

483 Table\_1.docx. **2020**,

482 Presentation\_1.pptx. **2019**,

481 DataSheet\_1.docx. **2020**,

480 Table\_1.DOCX. **2018**,

479 Image\_1.JPEG. **2019**,

478 Image\_2.jpg. **2019**,

477 Image\_3.jpeg. **2019**,

476 Image\_4.jpeg. **2019**,

475 Image\_1.TIF. **2018**,

474 Image\_2.TIF. **2018**,

473 Image\_3.TIF. **2018**,

472 Table\_1.PDF. **2018**,

471 Table\_2.PDF. **2018**,

470 Table\_3.PDF. **2018**,

469 DataSheet\_1.docx. **2020**,

468 Data\_Sheet\_1.docx. **2020**,

467 Image\_1.TIF. **2020**,

466 Image\_2.TIF. **2020**,

465 Image\_3.TIF. **2020**,

464 Image\_4.TIF. **2020**,

463 Data\_Sheet\_1.DOCX. **2018**,

462 Data\_Sheet\_1.docx. **2018**,

461 Data\_Sheet\_2.docx. **2018**,

460 presentation1.pdf. **2020**,

459 DataSheet\_1.pdf. **2019**,

458 DataSheet\_2.pdf. **2019**,

457 Presentation\_1.PPTX. **2019**,

456 Image\_1.PDF. **2018**,

455 Image\_2.PDF. **2018**,

454 Table\_1.DOCX. **2018**,

453 TNKS inhibitors potentiate proliferative inhibition of BET inhibitors via reducing  $\beta$ Catenin in colorectal cancer cells.. **2022**, 12, 1069-1087

452 Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model.. **2022**, 39, 87

451 Inhibition of mTOR by temsirolimus overcomes radio-resistance in nasopharyngeal carcinoma.. **2022**,

450 Orthogonal Design of Supramolecular Prodrug Vesicles via Water-Soluble Pillar[5]arene and Betulinic Acid Derivative for Dual Chemotherapy.. **2022**,

449 Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines. **2022**, 12, 651

448 The Effect of  $\beta$ Mangostin and Cisplatin on Ovarian Cancer Cells and the Microenvironment. **2022**, 10, 1116

447 Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer. **2022**, 12,

446 Nanoformulation of Polyphenol Curcumin Enhances Cisplatin-Induced Apoptosis in Drug-Resistant MDA-MB-231 Breast Cancer Cells.. **2022**, 27,

445 Magnetic-targeted capacitive heterostructure of polypyrrole for hypoxia-tolerant synergistic photodynamic/photothermal therapy under near infrared excitation.. **2022**, 216, 112557

444 TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC.. **2022**, 13, 450

443  $\beta$ Catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib. **2022**, 24,

442 ST08 Altered NF- $\kappa$ B Pathway in Breast Cancer Cells In Vitro as Revealed by miRNA-mRNA Analysis and Enhanced the Effect of Cisplatin on Tumour Reduction in EAC Mouse Model. **2022**, 12,

441 Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.. **2022**, 29, 32

- 440 Evaluation of synergism in drug combinations and reference models for future orientations in oncology. **2022**, 100110 2
- 439 Dose-dependent interaction of two heavy metals with amiodarone toxicity in .. **2022**, 38, 249-258
- 438 Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy.. **2022**, 0
- 437 Novel Diketopyrrolopyrrole NIR-II Fluorophores and DDR Inhibitors for in vivo Chemo-photodynamic Therapy of Osteosarcoma. **2022**, 136929 5
- 436 Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER- $\beta$ -Axis. **2022**, 12, 0
- 435 Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.. **2022**, 20, 175 0
- 434 A high-throughput screening platform identifies novel combination treatments for Malignant Peripheral Nerve Sheath Tumors.. **2022**, 1
- 433 Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth.. **2022**, 1
- 432 Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.. **2022**, 29, 29 1
- 431 Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. **2022**, 12, 0
- 430 Proton Pump Inhibitors Enhance the Antitumor Effect of Chemotherapy for Esophageal Squamous Cell Carcinoma. **2022**, 14, 2395 0
- 429 A racemosin B derivative, C25, suppresses breast cancer growth via lysosomal membrane permeabilization and inhibition of autophagic flux.. **2022**, 201, 115060
- 428 Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells.. **2022**, 53, 102324 2
- 427 Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer.. **2022**, 174, 106199 2
- 426 Sophorolipids: Anti-cancer activities and mechanisms.. **2022**, 65, 116787 1
- 425 Melatonin as an adjuvant treatment modality with doxorubicin.. **2022**, 200, 1-1 0
- 424 Synergistic Interactions between Tocol and Phenolic Extracts from Different Tree Nut Species against Human Cancer Cell Lines. **2022**, 27, 3154 0
- 423 Prevention of acute graft-vs.-host disease by targeting glycolysis and mTOR pathways in activated T cells. **2022**, 24, 0

422	Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.. <b>2022,</b>	
421	Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions.. <b>2022, 10, 31</b>	0
420	Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.. <b>2022, 12, 8275</b>	0
419	DNA repair proteins as the targets for paroxetine to induce cytotoxicity in gastric cancer cell AGS.. <b>2022, 12, 1465-1483</b>	
418	Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma.	
417	EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity. <b>2022, 20, 854-866</b>	1
416	Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR. <b>2022, 10, 1277</b>	0
415	Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells. 1-13	
414	Inhibition of STAT3 reverses Taxol-resistance in ovarian cancer by down-regulating G6PD expression in vitro. <b>2022,</b>	1
413	Evaluation of disinfection byproducts for their ability to affect mitochondrial function. <b>2022,</b>	
412	Correlation of gemcitabine sensitization by Chk1 inhibition with p53 status. 1-5	0
411	The ERK5/NF- $\kappa$ B signaling pathway targets endometrial cancer proliferation and survival.	
410	Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy.	1
409	A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia.	
408	Metabolic Reprogramming by Dual-targeting Biomimetic Nanoparticles for Enhanced Tumor Chemo-Immunotherapy. <b>2022,</b>	1
407	Paclitaxel and Lapatinib dual loaded chitosan-coated PLGA nanoparticles enhance cytotoxicity by circumventing MDR1-mediated trastuzumab resistance in HER2 positive breast cancers: In-vitro and in-vivo studies. <b>2022, 103445</b>	0
406	Chemosensitization Effect of Seabuckthorn (Hippophae rhamnoides L.) Pulp Oil via Autophagy and Senescence in NSCLC Cells. <b>2022, 11, 1517</b>	1
405	Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine.	2

- 404 Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid. **2022**, 13, 13571-13586
- 403 Therapeutic Potential of Skin Stem Cells and Cells of Skin Origin: Effects of Botanical Drugs Derived from Traditional Medicine.
- 402 Synergistic co-administration of docetaxel and curcumin to chemoresistant cancer cells using PEGylated and RIPL peptide-conjugated nanostructured lipid carriers. **2022**, 13, 1
- 401 siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells. **2022**, 14, 1196 0
- 400 Targeting Mechanisms of the DNA Damage Response (DDR) and DNA Repair by Natural Compounds to Improve cAT-Triggered Tumor Cell Death. **2022**, 27, 3567 0
- 399 Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. **2022**, 104518
- 398 Synergistic Tumor Inhibition via Energy Elimination by Repurposing Penfluridol and 2-Deoxy-D-Glucose in Lung Cancer. **2022**, 14, 2750 0
- 397 Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir. **2022**, 30, 101283
- 396 Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. **2022**, 131, 105939
- 395 The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. 13, 0
- 394 Antifungal effect of triclosan on *Aspergillus fumigatus*: quorum quenching role as a single agent and synergy with liposomal amphotericin-B. **2022**, 38, 0
- 393 The synergistic anticancer effect of salinomycin combined with cabazitaxel in CD44+ prostate cancer cells by downregulating wnt, NF- $\kappa$ B and AKT signaling. 1
- 392 Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. 1
- 391 Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. **2022**, 3, 100541 0
- 390 Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. **2022**, 23, 6568 0
- 389 Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer. **2022**, 22, 2
- 388 CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy. **2022**, 22,
- 387 Synergistic Anti-Inflammatory Activity of Ginger and Turmeric Extracts in Inhibiting Lipopolysaccharide and Interferon- $\gamma$ -Induced Proinflammatory Mediators. **2022**, 27, 3877 1

- 386 Editorial on the Special Issue: Multidrug Combinations **2022**, 12, 812
- 385 Co-encapsulation of flavonoids with anti-cancer drugs: a challenge ahead. **2022**, 121942 1
- 384 Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection. **2022**, 8, 100074
- 383 Quinacrine is active in preclinical models of glioblastoma through suppressing angiogenesis, inducing oxidative stress and activating AMPK. **2022**, 105420 0
- 382 Synergistic anti-inflammatory effects and mechanisms of the combination of resveratrol and curcumin in human vascular endothelial cells and rodent aorta. **2022**, 109083 1
- 381 MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib. **2022**, 14, 2859
- 380 Combined Curcumin and Luteolin Synergistically Inhibit Colon Cancer Associated with Notch1 and TGF- $\beta$  Signaling Pathways in Cultured Cells and Xenograft Mice. **2022**, 14, 3001 1
- 379 Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors. **2022**, 14, 1372 0
- 378 Aggregation-Induced Emission Photosensitizer Synergizes Photodynamic Therapy and the Inhibition of the NF- $\kappa$ B Signaling Pathway to Overcome Hypoxia in Breast Cancer. 1
- 377 Bimodal Treatment of Hepatocellular Carcinoma by Targeted Minimally Interventional Photodynamic/Chemotherapy Using Glyco-Covalent-Organic Frameworks-Guided Porphyrin/Sorafenib. **2022**, 1
- 376 Prediction Model for Synergistic Anti-tumor Multi-compound Combinations from Traditional Chinese Medicine based on Extreme Gradient Boosting, Targets and Gene Expression Data.
- 375 Melatonin as an adjuvant treatment modality with doxorubicin. **2022**,
- 374 Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model. **2022**, 12, 0
- 373 Biomimetically constructing a hypoxia-activated programmable phototheranostics at the molecular level. 0
- 372 Synergistic Effect of Environmental Food Pollutants: Pesticides and Marine Biotoxins.
- 371 Synergy and network pharmacology Establishing the efficacy of herbal medicine. **2022**, 501-510
- 370 Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells. 0
- 369 N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. **2022**, 12, 1

- 368 SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations. **2022**, 12, 904 1
- 367 The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK. **2022**, 20, 418 1
- 366 Bone morphogenetic protein inhibitors and mitochondria targeting agents synergistically induce apoptosis-inducing factor (AIF) caspase-independent cell death in lung cancer cells. **2022**, 20, 0
- 365 Antioxidant interactions among hydrophilic and lipophilic dietary phytochemicals based on inhibition of low-density lipoprotein and DNA damage. 0
- 364 Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain. **2022**, 12, 0
- 363 Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. **2022**, 14, 3374
- 362 Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.
- 361 Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity. **2022**, 23, 7518 1
- 360 Targeting colorectal cancer with small-molecule inhibitors of ALDH1B1. 2
- 359 Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma. 10, 0
- 358 Temozolomide associated to gold nanoparticles promoted a synergic effect and apoptosis when exposed to melanoma cells. **2022**, 24,
- 357 Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis. 12,
- 356 Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells: a computational drug discovery and in vitro insight. 1-15 1
- 355 Pentagalloyl Glucose and Cisplatin Combination Treatment Exhibits a Synergistic Anticancer Effect in 2D and 3D Models of Head and Neck Carcinoma. **2022**, 15, 830
- 354 GANT61/BI-847325 combination: a new hope in lung cancer treatment. **2022**, 39,
- 353 Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. 0
- 352 Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGFR Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. **2022**, 23, 7774
- 351 Dehydroepiandrosterone (DHEA) Sensitizes Irinotecan to Suppress Head and Neck Cancer Stem-Like Cells by Downregulation of WNT Signaling. 12,

- 350 OSU-T315 and doxorubicin synergistically induce apoptosis via mitochondrial pathway in bladder cancer cells.
- 349 Metabolic plasticity in blast crisis-chronic myeloid leukaemia cells under hypoxia reduces the cytotoxic potency of drugs targeting mitochondria. **2022**, 13,
- 348 Exogenous metabolite feeding on altering antibiotic susceptibility in Gram-negative bacteria through metabolic modulation: a review. **2022**, 18, 1
- 347 Novel regimens of phytopolyphenols with cisplatin or memantine and ZnSO<sub>4</sub> for synergistic inhibition of growth and gingipains of the cultured *Porphyromonas gingivalis*. **2022**,
- 346 Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. **2022**, 12, 652 1
- 345 Tangeretin Synergizes with 5-Fluorouracil to Induce Autophagy through MicroRNA-21 in Colorectal Cancer Cells. 1-22 0
- 344 Untargeted LC-MS/MS-Based Multi-Informative Molecular Networking for Targeting the Antiproliferative Ingredients in *Tetradium ruticarpum* Fruit. **2022**, 27, 4462 2
- 343 Cell Metabolomics Study on Synergistic anti-Hepatocellular Carcinoma Effect of Aidi Injection Combined with Doxorubicin.
- 342 Novel Gemcitabine-Re(I) Bisquinoliny Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy. 13,
- 341 Biocompatible Polymeric Nanoparticles for Effective Codelivery of Tamoxifen with Ganoderic Acid A: Systematic Approach for Improved Breast Cancer Therapeutics.
- 340 GDNF regulates lipid metabolism and glioma growth through RET/ERK/HIF-1/SREBP-1. **2022**, 61,
- 339 Adapalene and Doxorubicin Synergistically Promote Apoptosis of TNBC Cells by Hyperactivation of the ERK1/2 Pathway Through ROS Induction. 12, 1
- 338 Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy. 13,
- 337 Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.
- 336 Novel Human-derived EML4-ALK Fusion Cell Lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. **2022**,
- 335 Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence. **2022**, 349, 565-579 1
- 334 Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches. **2022**, 14, 3726
- 333 Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors. 12, 0

- 332 Interactions between Medical Plant-Derived Bioactive Compounds: Focus on Antimicrobial Combination Effects. **2022**, 11, 1014 1
- 331 Pinus mugo Essential Oil Impairs STAT3 Activation through Oxidative Stress and Induces Apoptosis in Prostate Cancer Cells. **2022**, 27, 4834 1
- 330 Benzothiazole Derivatives Endowed with Antiproliferative Activity in Paraganglioma and Pancreatic Cancer Cells: Structure-Activity Relationship Studies and Target Prediction Analysis. **2022**, 15, 937
- 329 Decreased DNA damage and improved p53 specificity of RITA analogs.
- 328 MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975. **2022**, 195, 105-115 0
- 327 Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells. **2022**, 12, 1318 0
- 326 Identification of solamargine as a cisplatin sensitizer through phenotypical screening in cisplatin-resistant NSCLC organoids. 13, 0
- 325 Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition.
- 324 Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy. **2022**, 12, 2672 2
- 323 HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells. **2022**, 23, 8645 0
- 322 Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action. 13, 1
- 321 Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells.
- 320 Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. Publish Ahead of Print,
- 319 Synergistic antifungal effectiveness of essential oils from andean plants combined with commercial drugs. **2022**, 8, 023-031
- 318 Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus. **2022**, 13, 1
- 317 In Silico Deterministic Assessment on TdP Risks of Drug-drug Interactions under CiPA Paradigm.
- 316 Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer. **2022**, 14, 1759
- 315 CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis. **2022**, 13, 0

- 314 Selenium Yeast and Fish Oil Combination Diminishes Cancer Stem Cell Traits and Reverses Cisplatin Resistance in A549 Sphere Cells. **2022**, 14, 3232 0
- 313 Alpha Mangostin and Cisplatin as Modulators of Exosomal Interaction of Ovarian Cancer Cell with Fibroblasts. **2022**, 23, 8913
- 312 New diterpenes from the marine sponge *Spongionella* sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein. **2022**, 12, 1
- 311 Targeted non AR mediated smart delivery of abiraterone to the prostate cancer. **2022**, 17, e0272396 0
- 310 Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH. **2022**, 144, 14758-14768 4
- 309 Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma. **2022**, 119, 0
- 308 Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma. **2022**, 200244
- 307 The combination of in situ photodynamic promotion and ion-interference to improve the efficacy of cancer therapy. **2022**, 1
- 306 Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid receptor-dependent activation of EGFR. **2022**, 22,
- 305 Microfluidized Dextran Microgels Loaded with Cisplatin/SPION Lipid Nanotherapeutics for Local Colon Cancer Treatment via Oral Administration. 2201140 1
- 304 HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. **2022**, 23, 666-681 0
- 303 Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941. 13, 2
- 302 Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. **2022**, 14, 4027
- 301 Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo. **2022**, 119, 1
- 300 Drug Combination Modeling: Methods and Applications in Drug Development.
- 299 Protective effect of the curcumin-baicalein combination against macrovascular changes in diabetic angiopathy. 13, 0
- 298 Pediatric glioblastoma cells are sensitive to drugs that inhibit eIF2 $\alpha$  phosphorylation and its phosphomimetic S51D variant. 12,
- 297 The Occurrence and Co-Occurrence of Regulated, Emerging, and Masked Mycotoxins in Rice Bran and Maize from Southeast Asia. **2022**, 14, 567 2

- 296 Combined Treatment of Bronchial Epithelial Calu-3 Cells with Peptide Nucleic Acids Targeting miR-145-5p and miR-101-3p: Synergistic Enhancement of the Expression of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene. **2022**, 23, 9348 1
- 295 p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors. 0
- 294 Combination of PAKs inhibitors IPA-3 and PF-3758309 effectively suppresses colon carcinoma cell growth by perturbing DNA damage response. 1-15
- 293 Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. 2
- 292 Combined effects of cadmium and ochratoxin A on intestinal barrier dysfunction in human Caco-2 cells and pig small intestinal epithelial cells.
- 291 In vitro chemosensitivity of a canine tumor venereal transmissible cancer cell line. 9,
- 290 Joint Action of Herbicides on Weeds and Their Risk Assessment on Earthworm (*Eisenia fetida* L.).
- 289 Disulfiram increases the efficacy of 5-fluorouracil in organotypic cultures of colorectal carcinoma. **2022**, 153, 113465 0
- 288 Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma. **2022**, 26, 275-288 1
- 287 Metabolic alterations and mitochondrial dysfunction underlie hepatocellular carcinoma cell death induced by a glycogen metabolic inhibitor. **2022**, 203, 115201 0
- 286 Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma. **2022**, 154, 113602 0
- 285 Triterpenes from *Momordica balsamina* (African pumpkin): ABCB1 inhibition and synergistic interaction with doxorubicin in resistant cancer cells. **2022**, 203, 113354 0
- 284 Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha. **2022**, 628, 106-115 1
- 283 The cyclin dependent kinase inhibitor p21Cip1/Waf1 is a therapeutic target in high-risk neuroblastoma. 12, 0
- 282 THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours. **2022**, 20, 0
- 281 Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. 0
- 280 Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo. **2022**, 350, 584-599 0
- 279 Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas. **2022**, 26, 101540 0

278	Measuring Herb-Drug Interaction and Synergy. <b>2022</b> , 5-14	0
277	Discovery of Highly-Functionalized 5-Hydroxy- &lt;i>2H</i>-Pyrrol-2-Ones that Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen.	0
276	Combination of the Natural Product Mensacarcin with Vemurafenib (Zelboraf) Combats BRAF Mutant and Chemo-Resistant Melanoma in Vitro by Affecting Cell Metabolism and Cellular Migration.	0
275	SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning. <b>2022</b> , 11,	1
274	Cytotoxic effect of combining two antisense oligonucleotides against telomerase rna component (hTR and mRNA of centromere protein B (CENP-B) in hepatocellular carcinoma cells. <b>2022</b> , 94,	0
273	Phytochemical Profiles, Antioxidant Activity and Antiproliferative Mechanism of <i>Rhodiola rosea</i> L. Phenolic Extract. <b>2022</b> , 14, 3602	1
272	Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA. 1-8	1
271	Liposomes Embedded with PEGylated iron oxide nanoparticles enabling ferroptosis and combination therapy in cancer.	2
270	Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells.	0
269	ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. <b>2022</b> , 7,	0
268	Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin. <b>2022</b> , 23, 9903	1
267	Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells.	0
266	Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy. <b>2022</b> , 14, 4675	0
265	Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells. <b>2022</b> , 10, 2429	0
264	Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer. <b>2022</b> , 23, 10503	1
263	Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma.	2
262	Combination Treatment of Retinoic Acid Plus Focal Adhesion Kinase Inhibitor Prevents Tumor Growth and Breast Cancer Cell Metastasis. <b>2022</b> , 11, 2988	0
261	Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.	0

- 260 Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism. **2022**, 13, 0
- 259 Luteolin enhances erlotinib cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines. 13, 1
- 258 Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1. **2022**, 20, 0
- 257 The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death. **2022**, 39, 0
- 256 Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma. **2022**, 14, 4357 1
- 255 Amygdalin as a chemoprotective agent in co-treatment with cisplatin. 13, 0
- 254 The ERK5/NF- $\kappa$ B signaling pathway targets endometrial cancer proliferation and survival. **2022**, 79, 1
- 253 Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC. **2022**, 13, 0
- 252 Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells. **2022**, 37, 2710-2724 0
- 251 Bruton Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. **2022**, 14, 1994 0
- 250 Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF7/SC Breast Cancer Cells. **2022**, 23, 11340 0
- 249 Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. 1
- 248 Synergistic Effect of Drug Delivery System Combining DOX and V9302 on Gastric Cancer Cells\*\*. **2022**, 7, 0
- 247 Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. **2022**, 41, 0
- 246 Visible light-induced synergic antimicrobial activity of silver nanoparticles/methylene blue nanohybrids encapsulated in chitosan and pluronic polymers. 0
- 245 Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP. **2022**, 39, 0
- 244 Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. **2022**, 6, 1
- 243 Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1 $\beta$ -EphA2-Laminin-5 $\alpha$  network in human oral cancer. 1

242	Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells. <b>2022</b> , 14, 4626	1
241	5-Arylidenerhodanines as P-gp Modulators: An Interesting Effect of the Carboxyl Group on ABCB1 Function in Multidrug-Resistant Cancer Cells. <b>2022</b> , 23, 10812	1
240	Mixture Effects of Tryptophan Intestinal Microbial Metabolites on Aryl Hydrocarbon Receptor Activity. <b>2022</b> , 23, 10825	1
239	Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. <b>2022</b> , 15, 1199	1
238	Control of cell state transitions. <b>2022</b> , 609, 975-985	2
237	Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion. <b>2022</b> , 8, e10465	0
236	An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. <b>2022</b> , 13,	0
235	Synergistic anticancer effect of flavonoids from Sophora alopecuroides with Sorafenib against hepatocellular carcinoma.	1
234	PD-L1 antibody enhanced Eglucan antitumor effects via blockade of the immune checkpoints in a melanoma model.	0
233	NOTCH signaling limits the response of Low Grade Serous Ovarian Cancers to MEK inhibition.	0
232	Combination of the natural product mensacarcin with vemurafenib (Zelboraf) combats BRAF mutant and chemo-resistant melanoma in vitro by affecting cell metabolism and cellular migration. <b>2022</b> , 100070	0
231	Novel compound C150 inhibits pancreatic cancer through induction of ER stress and proteasome assembly. 12,	0
230	Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. <b>2022</b> , 6,	0
229	Combined phototherapy with metabolic reprogramming-targeted albumin nanoparticles for treating breast cancer.	1
228	Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. <b>2022</b> , 23, 12587	0
227	Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds. <b>2022</b> , 27, 6714	0
226	The synergistic effect and mechanisms of flavonoids and polysaccharides from Houttuynia cordata on H1N1-induced pneumonia in mice. <b>2022</b> , 115761	0
225	Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action. <b>2022</b> , 12, 1490	1

- 224 Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells. **2022**, 23, 12240 ○
- 223 5-FU and the dietary flavonoid carvacrol: a synergistic combination that induces apoptosis in MCF-7 breast cancer cells. **2022**, 39, ○
- 222 Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer. ○
- 221 TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. **2022**, 14, 5240 ○
- 220 Pro-Apoptotic and Anti-Migration Properties of a Thiazoline-Containing Platinum(II) Complex in MDA-MB-231 Breast Cancer Cells: The Role of Melatonin as a Synergistic Agent. **2022**, 11, 1971 ○
- 219 Correspondence on Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase<sup>®</sup>. ○
- 218 Impact of Altering the Ratio of Black Tea Granules and Ocimum gratissimum Leaves in a Binary Infusion on Radical Scavenging Potential Employing Cell Free Models and Ex Vivo Assays. **2022**, 12, 10632 1
- 217 Insecticidal and repellent activities of *Artemisia herba alba* Asso, *Juniperus phoenicea* L and *Rosmarinus officinalis* L essential oils in synergized combinations against adults of *Tribolium castaneum* (Herbst) (Coleoptera: Tenebrionidae). **2022**, 45, 102513 ○
- 216 Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide. **2022**, 23, 11760 2
- 215 Antidepressant Drug Sertraline against Human Cancer Cells. **2022**, 12, 1513 ○
- 214 A technical note on emerging combination approach involved in the onconanotherapeutics. **2022**, 29, 3197-3212 ○
- 213 Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells. **2022**, 44, 4930-4949 ○
- 212 Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy. **2022**, 23, 12919 ○
- 211 Enhancing HIV-1 neutralization by increasing the local concentration of MPER-directed bnAbs. ○
- 210 Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis. **2022**, 13, ○
- 209 Exploiting ligand binding domain dimerization for development of novel androgen receptor inhibitors. 1
- 208 Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen. **2022**, 14, 5174 ○
- 207 Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells. **2022**, 55, 506-511 ○

206	Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.	o
205	Enhanced Cytotoxic Effects of Arenite in Combination with Active Bufadienolide Compounds against Human Glioblastoma Cell Line U-87. <b>2022</b> , 27, 6577	o
204	Nardosinone and aurantio-obtusin, two medicine food homology natural compounds, are anti-influenza agents as indicated by transcriptome signature reversion. <b>2022</b> , 154515	o
203	Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells. <b>2022</b> , 23, 13019	o
202	Correspondence on Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase <sup>®</sup> .	1
201	Curcumin derivative 1,2-bis((3E,5E)-3,5-bis(4-chlorobenzylidene)-4-oxopiperidine-1-yl)ethane-1,2-dione hemihydrate, ST09, regulates miR-197-5p/GPX3 axis in breast cancer cells and abrogates tumor growth in mouse xenograft model.	o
200	An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. <b>2022</b> , 14, 2429	o
199	A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell Leukemia.	o
198	Comparative study of dual delivery of gemcitabine and curcumin using CD44 targeting hyaluronic acid nanoparticles for cancer therapy. <b>2022</b> , 77, 103883	o
197	Dual-drug loaded nanomedicine hydrogel as a therapeutic platform to target both residual glioblastoma and glioma stem cells. <b>2022</b> , 628, 122341	o
196	Hyaluronic acid and cholecalciferol conjugate based nanomicelles: Synthesis, characterization, and cytotoxicity against MCF-7 breast cancer cells. <b>2022</b> , 522, 108706	o
195	SAHmap: Synergistic-antagonistic heatmap to evaluate the combined synergistic effect of mixtures of three pesticides on multiple endpoints of <i>Caenorhabditis elegans</i> . <b>2022</b> , 315, 120378	o
194	Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment. <b>2022</b> , 12, 32534-32551	1
193	Synergistic effect of environmental food pollutants: Pesticides and marine biotoxins. <b>2023</b> , 858, 160111	o
192	Topical delivery of Bruton's tyrosine kinase inhibitor and curcumin-loaded nanostructured lipid carrier gel: Repurposing strategy for the psoriasis management. 1-14	o
191	Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach. <b>2022</b> , 12,	o
190	Synergistic Effect of DIBOA and Verbascoside from <i>Acanthus mollis</i> Leaf on Tyrosinase Inhibition. <b>2022</b> , 23, 13536	o
189	Combined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects. <b>2022</b> , 14, 5481	o

- 188 Synergistic antibacterial effects of 5-fluorouracil or thioridazine in combination with phytopolyphenols on cultured *Porphyromonas gingivalis*. **2022**, ○
- 187 Pharmacotoxicological Assessment of the Combined Cytotoxic Effects of Digoxin and Betulinic Acid in Melanoma Cells. **2022**, 12, 1855 ○
- 186 Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic. 12, 1 ○
- 185 Synergistic combination therapy delivered via layer-by-layer nanoparticles induces solid tumor regression of ovarian cancer. ○
- 184 Evaluating the Potential Anticancer Properties of *Salvia triloba* in Human-Osteosarcoma U2OS Cell Line and Ovarian Adenocarcinoma SKOV3 Cell Line. **2022**, 12, 11545 ○
- 183 Guggulsterone Induces Apoptosis in Multiple Myeloma Cells by Targeting High Mobility Group Box 1 via Janus Activated Kinase/Signal Transducer and Activator of Transcription Pathway. **2022**, 14, 5621 ○
- 182 Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1 $\beta$ /STAT3 Axis. OF1-OF17 ○
- 181 Biodegradable PEG-PCL Nanoparticles for Co-delivery of MUC1 Inhibitor and Doxorubicin for the Confinement of Triple-Negative Breast Cancer. ○
- 180 Arsenic Trioxide Sensitizes Pancreatic Cancer Cells to Gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR Axis.. **2022**, ○
- 179 Zinc Acts Synergistically with Berberine for Enhancing Its Efficacy as an Anti-cancer Agent by Inducing Clusterin-Dependent Apoptosis in HT-29 Colorectal Cancer Cells. ○
- 178 Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. ○
- 177 Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer. **2022**, 14, ○
- 176 Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib. **2022**, 14, 5602 ○
- 175 Silibinin-Loaded Nanostructured Lipid Carriers for Growth Inhibition of Cisplatin-Resistant Ovarian Cancer Cells. ○
- 174 A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. **2022**, 41, ○
- 173 Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. **2022**, 3, 100815 1
- 172 Andrographolide elevates tumor necrosis factor-related apoptosis-inducing ligand lethality through reactive oxygen species accumulation and gasdermin E cleavage in breast cancer cells. **2023**, 40, ○
- 171 Improvement of radiotherapy with an ozone-carried liposome nano-system for synergizing cancer immune checkpoint blockade. **2022**, 47, 101675 ○

- 170 The first marine dual-drug cocrystal of cytarabine with 5-fluorouracil having synergistic antitumor effects shows superior biopharmaceutical peculiarities by oral administration. **2022**, 629, 122386 ○
- 169 The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer. **2022**, 79, ○
- 168 Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma. **2023**, 114, 109521 ○
- 167 Periplocin exerts antitumor activity by regulating Nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells. **2023**, 157, 114039 1
- 166 Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents. ○
- 165 Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam. **2023**, 360, 114286 ○
- 164 Combination synergy between  $\beta$ -carotene and lupeol against breast adenocarcinoma in vitro and in vivo using combination index. **2023**, 3, 100392 ○
- 163 In vitro and in vivo antiviral effect of Fufang Yinhua Jiedu granules (FFYH) combined with oseltamivir against influenza A virus. **2023**, 3, 100386 ○
- 162 Targeting DNA Junctions with Small Molecules for Therapeutic Applications in Oncology. **2022**, 1-24 ○
- 161 Discovery of New Glucose Uptake Inhibitors as Potential Anticancer Agents by Non-Radioactive Cell-Based Assays. **2022**, 27, 8106 1
- 160 Drug Combination Studies of the Dipeptide Nitrile CD24 with Curcumin: A New Strategy to Synergistically Inhibit Rhodesain of *Trypanosoma brucei* rhodesiense. **2022**, 23, 14470 ○
- 159 Sisplatin ve Timokinon Kombinasyonunun MCF-7 Hücrelerindeki Antiproliferatif Etkisinin Değerlendirilmesi. ○
- 158 A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers. ○
- 157 Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. **2022**, 65, 16541-16569 ○
- 156 Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. **2022**, ○
- 155 BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target. 12, 1
- 154 Flavonoid Constituents and Alpha-Glucosidase Inhibition of *Solanum stramonifolium* Jacq. Inflorescence with In Vitro and In Silico Studies. **2022**, 27, 8189 ○
- 153 Deoxyelephantopin, a germacrane-type sesquiterpene lactone from *Elephantopus scaber*, induces mitochondrial apoptosis of hepatocarcinoma cells by targeting Hsp90  $\alpha$  in vitro and in vivo. ○

- 152 Salvage Chemotherapy with Cisplatin, Ifosfamide, and Paclitaxel in Aggressive Variant of Metastatic Castration-Resistant Prostate Cancer. **2022**, 23, 14948 ○
- 151 Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer. **2022**, 14, 5894 ○
- 150 N, N-Disubstituted Benzimidazolium Salts: Synthesis, Characterization, Micromolar Detection of Fe(III) ions in Aqueous system, Biological Evaluation and Molecular Docking Studies. **2022**, 7, ○
- 149 3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. **2022**, 23, 15650 ○
- 148 Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia. ○
- 147 Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches. **2023**, 24, 69 1
- 146 High-throughput Approaches to Uncover Synergistic Drug Combinations in Leukemia. ○
- 145 Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway. ○
- 144 The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. **2023**, 24, 97 1
- 143 MicroRNAs miR-584-5p and miR-425-3p Are Up-Regulated in Plasma of Colorectal Cancer (CRC) Patients: Targeting with Inhibitor Peptide Nucleic Acids Is Associated with Induction of Apoptosis in Colon Cancer Cell Lines. **2023**, 15, 128 ○
- 142 Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer. **2022**, 4, 1830-1846 1
- 141 Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies. ○
- 140 Hyaluronan-based theranostic nanomicelles for breast cancer-targeting and anticancer drug delivery. **2022**, 111551 1
- 139 Anticancer and chemosensitizing activities of stilbenoids from three orchid species. ○
- 138 Synergistic Effect of Cucurbitacin E and Myricetin on Anti-Non-Small Cell Lung Cancer: Molecular Mechanism and Therapeutic Potential. **2022**, 154619 ○
- 137 Carotenoid-Enriched Nanoemulsions and IRays Synergistically Induce Cell Death in a Novel Radioresistant Osteosarcoma Cell Line. **2022**, 23, 15959 ○
- 136 Pharmacoinformatic screening of phytoconstituent and evaluation of its anti-PDAC effect using in vitro studies. 1-15 ○
- 135 Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. ○

134	Screening combinatorial perturbations via a bifurcation-based method.	0
133	Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.	1
132	Antitumor activity of bovine lactoferrin and its derived peptides against HepG2 liver cancer cells and Jurkat leukemia cells.	1
131	Four-armed host-defense peptidomimetics-augmented vanadium carbide MXene-based microneedle array for efficient photo-excited bacteria-killing. <b>2023</b> , 456, 141121	1
130	Fixed Dose Versus Loose Dose: Analgesic Combinations. <b>2023</b> ,	0
129	WEE1 and PARP-1 play critical roles in myelodysplastic syndrome (MDS): A novel approach to targeted MDS therapy.	0
128	Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. <b>2023</b> , 11, 119	0
127	Combination Treatment of a Phytochemical and a Histone Demethylase Inhibitor: A Novel Approach towards Targeting TGF $\beta$ -Induced EMT, Invasion, and Migration in Prostate Cancer. <b>2023</b> , 24, 1860	0
126	Chloroquine Enhances Death in Lung Adenocarcinoma A549 Cells Exposed to Cold Atmospheric Plasma Jet. <b>2023</b> , 12, 290	1
125	Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. <b>2023</b> , 14,	0
124	Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time.	0
123	Proteasome Inhibitors Interact Synergistically with BCL2, HDAC, BET, and JAK Inhibitors Against CTCL Cells. <b>2023</b> ,	0
122	ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.	0
121	The Determination of Cisplatin and Luteolin Synergistic Effect on Colorectal Cancer Cell Apoptosis and Mitochondrial Dysfunction by Fluorescence Labelling.	1
120	Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy. <b>2023</b> , 7,	0
119	Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles. Volume 17, 1-13	0
118	Evaluation of pH-Sensitive Polymeric Micelles Using Citraconic Amide Bonds for the Co-Delivery of Paclitaxel, Etoposide, and Rapamycin. <b>2023</b> , 15, 154	2
117	Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. <b>2023</b> , 12, 399	0

- 116 Inhibition of Colorectal Cancer Cell Proliferation by Treatment with Itadori Leaf Extract. **2023**, ○
- 115 Antiparasitic Activity of *Hippeastrum* Species and Synergistic Interaction between Montanine and Benznidazole against *Trypanosoma cruzi*. **2023**, 11, 144 ○
- 114 Small-molecule inhibitor of Fam20C in combination with paclitaxel suppresses tumor growth by LIF-JAK2/STAT3-modulated apoptosis in triple-negative breast cancer. **2023**, 143, 104673 ○
- 113 PDT-sensitized ROS-responsive dextran nanosystem for maximizing antitumor potency of multi-target drugs. **2023**, 633, 122567 ○
- 112 Gold nanorods-loaded chitosan-based nanomedicine platform enabling an effective tumor regression in vivo. **2023**, 632, 122561 ○
- 111 Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy. **2023**, 354, 155-166 ○
- 110 Injectable hydroethanolic physical gels based on *Codonopsis pilosula* polysaccharide for sustained anticancer drug delivery. **2023**, 230, 123178 ○
- 109 Glucocorticoids and medroxyprogesterone acetate synergize with inflammatory stimuli to selectively upregulate CCL20 transcription. **2023**, 563, 111855 ○
- 108 Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by  $\alpha$ -tocopherol succinate micelles for the treatment of glioblastoma. **2023**, 5, 100147 ○
- 107 Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH. ○
- 106 Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. 1
- 105 Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited. **2023**, 15, 93 1
- 104 Computational analysis of synergism in small networks with different logic. ○
- 103 Estrogen Receptor-positive Breast Cancer Cells are Sensitized by Piperine to Chemo/Radio Therapy through Lowering the expression of a NHEJ repair protein DNA-PK. ○
- 102 Natural Compound Allicin Containing Thiosulfinate Moieties as Transmembrane Protein 16A (TMEM16A) Ion Channel Inhibitor for Food Adjuvant Therapy of Lung Cancer. **2023**, 71, 535-545 ○
- 101 Machine Learning for Analyzing Drug Safety in Electronic Health Records. **2023**, 595-610 ○
- 100 Combinatorial Drug Screening Based on Massive 3D Tumor Cultures Using Micropatterned Array Chips. **2023**, 95, 2504-2512 ○
- 99 Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells. **2023**, 15, 902 ○

- 98 Antitumor Activity of Bioactive Compounds from *Rapana venosa* against Human Breast Cell Lines. **2023**, 16, 181 ○
- 97 CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo. 1-12 ○
- 96 Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis/Apoptosis Therapy of Hepatocellular Carcinoma. 2202663 ○
- 95 AMPK attenuates SHH subgroup medulloblastoma growth and metastasis by inhibiting NF- $\kappa$ B activation. **2023**, 13, ○
- 94 In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part III. **2023**, 24, 2239 1
- 93 Castasterone, a Plant Steroid Hormone, Affects Human Small-Cell Lung Cancer Cells and Reverses Multi-Drug Resistance. **2023**, 16, 170 ○
- 92 Pinostrobin and Tectochrysin Conquer Multidrug-Resistant Cancer Cells via Inhibiting P-Glycoprotein ATPase. **2023**, 16, 205 ○
- 91 Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia. ○
- 90 Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. **2023**, ○
- 89 Lycorine Carbamate Derivatives for Reversing P-glycoprotein-Mediated Multidrug Resistance in Human Colon Adenocarcinoma Cells. **2023**, 24, 2061 ○
- 88 Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. **2023**, 7, ○
- 87 Biochemical reaction network topology defines dose-dependent Drug-Drug interactions. **2023**, 106584 ○
- 86 Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. **2023**, 15, ○
- 85 Network Analysis Identifies Potential Small-Molecule Drugs Sensitizing Triple-Negative Breast Cancer to Tamoxifen. **2022**, ○
- 84 Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways. **2023**, 24, 3418 ○
- 83 Self-Assembled Redox-Sensitive Polymeric Nanostructures Facilitate the Intracellular Delivery of Paclitaxel for Improved Breast Cancer Therapy. **2023**, 20, 1914-1932 ○
- 82 The super elongation complex drives transcriptional addiction in MYCN -amplified neuroblastoma. **2023**, 9, ○
- 81 Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles. **2023**, ○

- 80 Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway. **2023**, 14, ○
- 79 SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Directed at Cell Signaling Networks. ○
- 78 Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. **2023**, 380, 93-101 ○
- 77 A practical preTACS-cytoblot platform accelerates the streamlined development of PROTAC-based protein degraders. **2023**, 251, 115248 ○
- 76 Novel lignans from *Zanthoxylum nitidum* and antiproliferation activity of sesaminone in osimertinib-resistant non-small cell lung cancer cells. **2023**, 134, 106445 ○
- 75 The mycelium of the *Trametes versicolor* synn. *Coriolus versicolor* (Turkey tail mushroom) exhibit anti-melanoma activity in vitro. **2023**, 161, 114424 ○
- 74 Candimine from *Hippeastrum escoipense* (Amaryllidaceae): Anti-*Trypanosoma cruzi* activity and synergistic effect with benznidazole. **2023**, 114, 154788 ○
- 73 Betulinic acid, a major therapeutic triterpene of *Celastrus orbiculatus* Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation. **2023**, 309, 116295 ○
- 72 Bioassay guided isolation of caffeoylquinic acids from the leaves of *Ilex pubescens* Hook. et Arn. and investigation of their anti-influenza mechanism. **2023**, 309, 116322 ○
- 71 Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis. **2023**, 102, 151292 1
- 70 Leaching of herbicides mixtures from pre-exposed agricultural plastics severely impact microalgae. **2023**, 326, 138475 ○
- 69 Peptide functionalized actively targeted MoS<sub>2</sub> nanospheres for fluorescence imaging-guided controllable pH-responsive drug delivery and collaborative chemo/photodynamic therapy. **2023**, 639, 302-313 ○
- 68 Synergistic effect of chrysin and radiotherapy against triple-negative breast cancer (TNBC) cell lines. ○
- 67 Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects. ○
- 66 Artemisinin derivatives induce oxidative stress leading to DNA damage and caspase-mediated apoptosis in *Theileria annulata*-transformed cells. **2023**, 21, ○
- 65 Mechanistic investigation of the differential synergistic neurotoxicity between pesticide metam sodium and copper or zinc. **2023**, 328, 138430 ○
- 64 Quantitative analysis of effects of salvianic acid a combined with hydroxy safflower yellow a on rat endothelial cells after hypoxic injury using the combination index method. 58, ○
- 63 Elevated PAF1-RAD52 axis confers chemoresistance to human cancers. **2023**, 42, 112043 ○

- 62 Mild photothermal therapy boosts nanomedicine antitumor efficacy by disrupting DNA damage repair pathways and modulating tumor mechanics. **2023**, 49, 101767 ○
- 61 Recent Advances in Supramolecular-Macrocyclic-Based Nanomaterials in Cancer Treatment. **2023**, 28, 1241 ○
- 60 Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin lymphoma. ○
- 59 MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers. **2023**, 24, 2782 ○
- 58 Ganetespib with Methotrexate Acts Synergistically to Impede NF- $\kappa$ B/p53 Signaling in Human Lung Cancer A549 Cells. **2023**, 16, 230 ○
- 57 A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation. **2023**, 250, 115198 ○
- 56 Utilizing mixture design response surface methodology to determine effective combinations of plant derived compounds as prostate cancer treatments. **2023**, 6, ○
- 55 Reversal of Multidrug Resistance by Symmetrical Selenoesters in Colon Adenocarcinoma Cells. **2023**, 15, 610 ○
- 54 Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells. ○
- 53 An oxygen-carrying and lysosome-targeting BODIPY derivative for NIR bioimaging and enhanced multimodal therapy against hypoxic tumors. **2023**, 241, 112666 ○
- 52 Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro. **2023**, 24, 3760 ○
- 51 Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease. **2023**, 355, 604-621 ○
- 50 Association of polar fraction of *Ageratum conyzoides* from the Brazilian Amazon with doxycycline against infection of macrophages with *Ehrlichia canis*. **2023**, 155, 90-97 ○
- 49 PX-12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro. ○
- 48 In silico assessment on TdP risks of drug combinations under CiPA paradigm. **2023**, 13, ○
- 47 Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy. **2023**, 235, 123686 ○
- 46 Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance. OF1-OF14 ○
- 45 Design, synthesis and biological evaluation of seco-DSP/DCK derivatives reversing P-glycoprotein-mediated paclitaxel resistance in A2780/T cells. **2023**, 250, 115218 ○

- 44 Combined Radiomodifying Effect of Fucoidan from the Brown Alga *Saccharina cichorioides* and Pacificusoside D from the Starfish *Solaster pacificus* in the Model of 3D Melanoma Cells. **2023**, 13, 419 ○
- 43 Combinatorial effect of diclofenac with piperine and D-limonene on inducing apoptosis and cell cycle arrest of breast cancer cells. **2023**, 13, 80 ○
- 42 MAPK-interacting kinases inhibition by eFT508 overcomes chemoresistance in preclinical model of osteosarcoma. **2023**, 42, 096032712311580 ○
- 41 KPT -330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF- $\kappa$ B signaling. **2023**, 13, 751-762 ○
- 40 Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs. **2023**, 198, 607-621 ○
- 39 Exploiting Vitamin D Receptor and Its Ligands to Target Squamous Cell Carcinomas of the Head and Neck. **2023**, 24, 4675 ○
- 38 Citric Acid Enhances the Activities of Astilbin on Psoriasis via Down-Regulation of P-Glycoprotein. **2023**, 20, 1964-1974 ○
- 37 Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus. **2023**, 12, 625 ○
- 36 cRGD-modified nanoparticles of multi-bioactive agent conjugate with pH-sensitive linkers and PD-L1 antagonist for integrative collaborative treatment of breast cancer. ○
- 35 Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells. **2023**, 24, 5553 ○
- 34 A two-pronged approach against glioblastoma: Drug repurposing and nanoformulation design for in situ-controlled release. ○
- 33 Chloroquine synergizes doxorubicin efficacy in cervical cancer cells through flux impairment and down regulation of proteins involved in the fusion of autophagosomes to lysosomes. **2023**, 656, 131-138 ○
- 32 Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants. **2023**, 14, 747 ○
- 31 Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice. **2023**, 13, ○
- 30 Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA. 1-9 ○
- 29 Tailored Beta-Lapachone Nanomedicines for Cancer-Specific Therapy. ○
- 28 Application of a novel multicomponent nanoemulsion to tumor therapy Based on the theory of Unification of drugs and excipients 1-12 ○
- 27 Synergistic apoptotic effects of ethanolic extracts of ginger and *Ganoderma lucidum* in a colorectal cancer cell line. 1-7 ○

- 26 Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. **2023**, 67, ○
- 25 CDK4/6 Inhibition Induces Senescence and Enhances Radiation Response by Disabling DNA Damage Repair in Oral Cavity Squamous Cell Carcinoma. **2023**, 15, 2005 ○
- 24 Anticancer Activity of Region B Capsaicin Analogs. **2023**, 66, 4294-4323 ○
- 23 Targeted Inhibition of Hsp90 in Combination with Metformin Modulates Programmed Cell Death Pathways in A549 Lung Cancer Cells. ○
- 22 A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells. **2023**, 15, 1148 ○
- 21 Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K inhibitors. **2023**, 8, ○
- 20 STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo. **2023**, 15, 2239 ○
- 19 Improvement of the In Vitro Cytotoxic Effect on HT-29 Colon Cancer Cells by Combining 5-Fluorouacil and Fluphenazine with Green, Red or Brown Propolis. **2023**, 28, 3393 ○
- 18 The neuroprotective effects of the combined extract of mulberry fruit and mulberry leaf against hydrogen peroxide-induced cytotoxicity in SH-SY5Y Cells. **2023**, 23, ○
- 17 Heparin Biofunctionalized Selenium Nanoparticles as Potential Antiangiogenic Chemotherapeutic Agents for Targeted Doxorubicin Delivery. ○
- 16 Naproxen-Derived New Compound Inhibits the NF- $\kappa$ B, MAPK and PI3K/Akt Signaling Pathways Synergistically with Resveratrol in RAW264.7 Cells. **2023**, 28, 3395 ○
- 15 Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug Metabolism, Toxicity, and Multidrug Transporters. **2023**, 28, 3415 ○
- 14 Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases. **2023**, 91, 146-163 ○
- 13 Co-Encapsulation of Hydrophilic and Hydrophobic Drugs into Human H Chain Ferritin Nanocarrier Enhances Antitumor Efficacy. ○
- 12 Styrylquinazoline derivatives as ABL inhibitors selective for different DFG orientations. **2023**, 38, ○
- 11 SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Targeting Cell Signalling Networks. **2023**, 357-381 ○
- 10 Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma. **2023**, ○
- 9 FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. **2023**, 42, ○

- 8 Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR. **2023**, 16, ○
- 7 Construction of Curcumin and Paclitaxel Co-Loaded Lipid Nano Platform and Evaluation of Its Anti-Hepatoma Activity in vitro and Pharmacokinetics in vivo. Volume 18, 2087-2107 ○
- 6 pH-Responsive Nano-transferosomes of Purpurin-18 Sodium Salt and Doxorubicin for Enhanced Anticancer Efficiency by Photodynamic and Chemo Combination Therapy. **2023**, 8, 16479-16490 ○
- 5 Cannabinoid compounds in combination with curcumin and piperine display an anti-tumorigenic effect against colon cancer cells. 14, ○
- 4 Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways. **2023**, 15, 2468 ○
- 3 Photoactivation of Boronic Acid Prodrugs via a Phenyl Radical Mechanism: Iridium(III) Anticancer Complex as an Example. **2023**, 145, 10082-10091 ○
- 2 Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer. Volume 18, 2209-2223 ○
- 1 Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK. **2023**, 116644 ○